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ABSTRACT
A model autocrine cell system was constructed by transfecting the genes for
transforming growth factor alpha (TGFa) and its receptor (epidermal growth factor receptor,
EGFR) into a cell line normally lacking both, mouse B82 fibroblasts. The human TGFa gene
was transfected into both EGFR-positive and EGFR-negative B82s cells using a two-plasmid
tetracycline inducible vector, permitting both autocrine and paracrine cell systems. The full-
length TGFct transmembrane protein was correctly transported to the cell surface and 99% of
the TGFx cleaved and secreted into the extracellular media as the mature 5.5 kDa TGFa
protein. A 100-fold range in TGFx secretion expression is achieved by altering medium's
tetracycline concentrations.
Validation of anchorage-dependent autocrine cell computer modelling was achieved
experimentally for both extracellular bulk ligand concentrations and receptor / ligand complex
levels. High ligand expression rates enabled extracellular ligand accumulations, measured by
TGFca ELISAs, to remain independent of cell density and addition of anti-receptor blocking
antibodies. At lower secretion rates, both cell density and blocking antibody additions were
important parameters in receptor-mediated ligand uptake.
The autocrine model was also validated by development of a novel assay to quantify
receptor ligand complexes. Molecular Devices Cytosensor measurements of cellular metabolic
rates were correlated to receptor complexes via free EGF in 1125 EGF binding experiments and
Cytosensor experiments. Using the Cytosensor enabled precise measurements of TGFoa
induction in autocrine cells, complex levels as a function of TGFx secretion rates and inhibition
of receptor complexes as a function of competing antibodies. It was determined experimentally
and mathematically that blocking antibody inhibited autocrine receptor complex formation
around 1 nM and was a 1000x more effective inhibitor than decoy antibodies. An indication of
intracellular receptor / ligand binding was found in B82R' / secreted mature EGF as addition of
blocking antibodies could not inhibit receptor complex signalling compared to autocrine B82R ÷ /
transmembrane TGFa.
Further investigations using these engineered cell systems should help yield an
improved understanding in regulation of wound healing, tissue regeneration, and cancer
progression facilitated by autocrine factors.
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Title: J. R. Mares Professor of Chemical Engineering
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Chapter 1: Introduction and Background
Cell functions such as proliferation and migration are important in physiological and
pathological situations, including wound healing, cancer, and tissue regeneration. Cellular
interactions in these processes are often regulated by growth factor receptors and their ligands
(Bennett and Schultz 1993; ten Dijke and Iwata 1989; Kumar et al. 1992). When the receptor
and its ligand are produced by the same cell, it is called an autocrine cell. This situation is found
in many different cell lines, such as lymphocytes, fibroblasts, and primary tumors. (Derynck
1992; Morishige et al. 1991; Sporn and Roberts 1992; Sporn and Todaro 1980). Mathematical
analysis of the autocrine network have identified key molecular and cellular parameters
governing the dynamics of receptor / ligand complexes as well as cell signaling. Important
parameters include autocrine ligand secretion rate, cellular density, receptor binding and receptor
trafficking rate constants (Forsten and Lauffenburger 1992a). These parameters can be
systematically altered with cells accessible to the manipulation of the receptor and ligand genes.
The research in this thesis deals with the development and characterization of this sort of model
autocrine system, for the purposes of testing the importance of key parameters and elucidating
control mechanisms governing cell responses to autocrine factors.
1.1 Growth Factors and Cell Functions
Metabolic processes in the cell can be maintained through the uptake of amino acids,
essential vitamins, nutrients and salts in serum free media, however, only upon the addition of
growth factors will quiescent cells begin cell division or mitosis (Bennett and Schultz 1993).
Growth factors are produced and secreted from a variety of cells including platelets,
keratinocytes and fibroblasts. Although a multitude of cells express growth factors (ligands),
the growth factors interact with their high affinity receptors via only four pathways (Figure
1.1). The endocrine and paracrine pathways involve the production and transport of the
secreted ligand to either distant or adjacent cells, respectively. The juxtacrine pathway is similar
to a paracrine system, but the ligand binds adjacent cells while remaining membrane-bound. In
the last pathway, the autocrine system, the ligand is secreted and bound by the same cell. Note
that if a subset of the autocrine cells' receptors become internalized (down-regulated) or are
inhibited from binding the ligand, autocrine cells become paracrine cells.
Upon growth factor / receptor binding, a cascade of events occur leading to the uptake
of Ca2+, phosphorylation of proteins, and eventually, the synthesis of DNA and cell
proliferation (Carraway and Cerione 1993; Gill et al. 1987; Kumar et al. 1992).
Overproduction of the receptor and / or its ligand in an autocrine pathway could lead to over-
stimulation of the cell and runaway cell proliferation. One growth factor, transforming growth
factor alpha (TGFat) and it receptor, epidermal growth factor receptor (EGFR) has been found
over-expressed in several cancers. Over half of the mammary carcinomas and most squamous,
hepatomas, melanomas, glioblastomas and renal carcinomas express this enhanced synthesis
autocrine pathway (Derynck 1992).
Because growth factors are important in cell proliferation and migration, clinical
strategies that modulate growth factor activities have been receiving attention as methods for
promoting wound healing and inhibiting cancer. Treatment of chronic wounds increase health
care costs because it requires extended hospital stays and half of the amputations in the United
States are a result of ulceration (Meyer-Ingold 1993; Roberts 1993). Thus, the use of growth
factors to promote cell proliferation and migration could speed healing, decrease patient's
discomfort, shorten hospital stays and reduce amputations. These growth factors could be
added exogenously or via gene therapy. One particular study used transfected insulin-like
factor-I (IGF-I) keratinocytes, promoting increased epithelium growth in vivo (Eming et al.
1996). While secretion of IGF-I in epithelia is normally paracrine (fibroblast to keratinocytes),
this study created an autocrine growth system to show IGF-I role in epidermal proliferation.
Other autocrine studies utilizing TGFx and TGF3 have been performed in transgenic mice
(Sellheyer et al. 1993; Vassar and Fuchs 1991), showing these cytokines are also important
autocrine mediators of epidermal homeostasis.
At the opposite end are attempts to inhibit cancer cell proliferation. As mentioned, some
cancer cell lines over-express growth factors and / or growth factor receptors. High levels of
human epidermal growth factor receptor or HER1, has been found in a significant fraction of
epidermoid head and neck carcinomas, breast cancer, and epidermal carcinomas (Fabricant et al.
1977; Filmus et al. 1985; Hendler et al. 1985). Some of these carcinomas, A431 and MDA
MB-468, also have been shown to produce TGFa, classifying them as autocrine (Derynck et al.
1987; Ennis et al. 1989). Over-expression of a related receptor, Neu / HER2, is associated with
poor prognosis in breast cancer, ovarian cancer, and lung carcinoma (Kern et al. 1990; Kraus et
al. 1987; Slamon et al. 1987; Slamon et al. 1989; Varley et al. 1987; van der Vijver et al. 1987).
When a growth factor and its receptor are produced by the same cell, at abnormally high levels,
there is the potential for loss of regulation. While, several clinical trials have attempted to affect
wound healing and tumor progression by modulating growth factor activities, their results have
been unclear (Meyer-Ingold 1993; Mulshine et al. 1992). In most of these studies, the protein
(ligand or antibody) was used without an understanding of half-lives, secretion rates, ligand /
receptor dynamics, and effective concentrations at the target site. Experimental studies in this
thesis as well as computer modelling should help increase our understanding of autocrine cell
systems and aid in the design of related clinical treatments.
1.2 Transforming Growth Factor Alpha (TGFa)
Epidermal growth factor (EGF) was first discovered by Stanley Cohen (Cohen 1962)
when studying a nerve growth promoting protein of the mouse submaxillary gland. This
protein promoted precocious eyelid opening and teeth eruption of newborn mice. Later isolation
and characterization of the protein established that EGF is synthesized as a large precursor of
1207 amino acids (160 kD), containing eight EGF-like repeats and one full length EGF
sequence which is cleaved into the secreted 53 amino acid (6 kD) protein (Bell et al. 1986; Scott
et al. 1983). EGF has been shown to be an effective inhibitor of gastric acid and pepsin
secretions with high levels of protein detected in the urine, mammary fluids, saliva, and
prostatic fluids (Carpenter and Wahl 1990).
EGF's sister protein was discovered when analyzing polypeptides from mouse sarcoma
virus-transformed cell medium which induced anchorage independent growth of normal rat
kidney (NRK) cells on soft agar, a characteristic of transformed cells (DeLarco and Todaro
1978; Todaro et al. 1980). Upon further purification of the medium, two proteins were
isolated, transforming growth factor alpha (TGFa) and beta (TGFI). TGFo is able to bind
epidermal growth factor's receptor (EGFR), but can only transform NRK cells in the presence
of TGF3, which cannot bind EGFR (Anzano et al. 1982). Thus, it is the synergistic effect of
these two proteins that leads to the reversible transformation of the NRK cells. Since its
discovery, TGFx has been found in many cancer cells, but also in several "normal" cells like
epithelial and gastric intestinal mucosa cells (Beauchamp et al. 1989; Valverius et al. 1989),
macrophages (Madtes et al. 1988; Rappolee et al. 1988a), in the brain (Wilcox and Derynck
1988b), and in the pituitary (Kobrin et al. 1988).
TGFx is a 50 amino acid protein (5.6 kDa) derived from a 160 amino acid glycosidic
transmembrane precursor (25 kDa) (Carpenter and Wahl 1990; Feild et al. 1992). Shown in
Figure 1.2, the transmembrane precursor consists of a 39 amino acid N-terminal signal
sequence with an Asn24 N-glycosylation site, the mature TGFo protein and a 71 amino acid
carboxyl terminal transmembrane tail. The TGFx protein is a member of the epidermal growth
factor (EGF) family (Figure 1.3) which besides EGF (Cohen 1962), includes heparin - binding
EGF (Higashiyama et al. 1992), amphiregulin (Shoyab et al. 1989), betacellulin (Shing et al.
1993), and heregulin (Holmes et al. 1992; Wen et al. 1992). The EGF family is characterized
by the CX 7CX 4-5CX,0 13CXCXC motif where X is any non-cysteine amino acid. (Carpenter
and Wahl 1990). TGFx shares about 40% homology with EGF, but within its own TGFc
family, there is up to 90% amino acid homology between human and rat TGFct (Carpenter and
Wahl 1990). Nuclear magnetic resonance studies along with homology and site-directed
mutagenesis studies suggest that the TGFc structure is similar to EGF.
A schematic representation of TGFx is shown in Figure 1.4. The mature TGFca protein
is composed of several anti-parallel 3 sheets and a tight turn in the middle of the protein. These
3 sheets and tight turn align the two terminals to opposite sites of the protein and has been
suggested to construe the binding domain for the EGF family (Campbell et al. 1990; Hoeprich
et al. 1989). However, chimeric TGFa/EGF studies with chicken EGF receptor (cEGFR)
indicate that the B-loop 1-sheet is not only a structural motif, but may be a binding site for the
TGFo-cEGFR complex (Richter et al. 1995). Analysis of site-directed mutagenesis on TGFca
and EGF proteins show that the six cysteines along with Gly 19, Va133, Tyr38, and Gly40 are
highly conserved structural amino acids while Phel5, Phel7, Arg42 and Leu48 appear to be
important EGF receptor binding sites (Feild et al. 1992). Site directed mutagenesis with these
amino acids result in a decrease of ligand-receptor affinity, ranging over three orders of
magnitude.
The ligand-receptor affinity is a function of the binding and dissociation rate constants
for ligand binding to its receptor, commonly referred to as Kd (equilibrium dissociation
constant). Human EGF's and TGFa's affinity for the human EGF receptor is 1 nM (Ebner and
Derynck 1991). While, both TGFx and EGF have similar affinities for human EGFR, TGFc
is a 100x fold better agonist for chicken EGFR than EGF ligand (Lax et al. 1988a). This
preference for TGFx is likely due to a bulky hydrophobic amino acid between the fourth and
fifth cysteines (valine 33) at the "hinge" site, compared to EGF's hydrogen bond donor
(asparagine 33). Betacellulin and heparin-binding EGF also have hydrophobic residues
(isoleucine 33) with comparable affinity for chicken EGFR as TGFc, while amphiregulin and
heregulin are more similar to EGF (lysine 33). This suggests a sub-grouping of EGF family
proteins into TGFac and EGF -like sub-classifications (Puddicombe et al. 1996).
A major difference between TGFac and EGF is the presence of five histidine amino acids
in TGFuc and two histidines in EGF making the isoelectric points (pl) 4.6 for EGF versus 5.9
for TGFa. The isoelectric point difference may explain ligand-receptor trafficking dynamic
changes resulting in reduced receptor degradation and constant ligand recycling rate in the
presence of TGFa, especially at lower intercellular complex levels. (Ebner and Derynck 1991;
French et al. 1995). This difference may also explain why TGFo is a more potent agonist for
migration and monolayer formation in keratinocytes (Barrandon and Green 1987), increased
arterial blood flow (Gan et al. 1987), bone resorption (Stern et al. 1985), and hepatocyte
growth (Brenner et al. 1989).
1.3 Epidermal Growth Factor Receptor
Members of EGF-like ligand family discussed earlier all bind to receptors in the EGF
family. These receptors are labeled HER1 (Cohen and Ushiro 1980; Cohen et al. 1982), HER2
(King et al. 1985), HER3 (Kraus et al. 1989), and HER4 (Plowman et al. 1993a) for Human
Epidermal growth factor Receptor. As seen in Figure 1.5, all the ligands except heregulin bind
to HER1 while heregulin binds to HER3 and 4. Over-expression of HER2 is a poor prognosis
of cancer, leading to an intensive search for its ligand. During this search, heregulin was
discovered and originally thought to be HER2's ligand as ligand addition causes HER2
phosphorylation (Holmes et al. 1992; Wen et al. 1992). Later, it was determined that heregulin
initiated heterodimerization between HER3 or 4 with HER2, resulting in HER2 phosphorylation
and activation (Carraway and Cantley 1994; Carraway et al. 1995; Plowman et al. 1993b).
While HER2, 3, and 4 are structurally homologous to HER1, there are subtle
differences between the receptors: i.e. to date, no ligand has been found for HER2; HER3 and
4 have closer extracellular homology (-65%) to each other than to the other receptors (-43%);
HER3 does not have intrinsic kinase activity, but binds several different SH2 proteins which do
not interact with the other three receptors (Carraway and Cantley 1994); and all receptors except
HER1 are endocytosis impaired (Baulida et al. 1996). Also, heregulin-induced mitogenesis will
occur in NIH 3T3 cells transfected with HER3 or HER4. However, heregulin-induced cell
transformation was achieved only upon co-transfection of HERI or HER2 with HER3 or
HER4. This transformation correlated with receptor transphorylation (Zhang et al. 1996).
The EGF receptor, HER1, is a 170 kDa transmembrane glycoprotein with intrinsic
protein tyrosine kinase activity (Carpenter and Wahl 1990). The receptor, shown in Figure 1.6,
is composed of four domains: the extracellular, transmembrane, juxtamembrane and
cytoplasmic domains. The extracellular domain consists of 621 amino acids and has two
dominant structural features: 51 cysteine residues (compared with only nine cysteines in the
cytoplasmic domain) and twelve potential N-linked glycosylation sites. The cysteines are
predominantly located in two regions (134-313, 446-612) (Ullrich et al. 1984) which appear to
cooperate in forming a single high-affinity EGF binding site (Gill et al. 1987). The
transmembrane region of the receptor spans residues 622-644 and may function in transmitting
the ligand binding signal to the cytoplasmic domain (Gill et al. 1987). Controversy exists as to
whether the signal is transmitted intramolecular through the transmembrane or intermolecular
with EGFR dimerization (Yarden and Schlessinger 1987). However, several studies have
shown that EGF / EGFR protein signaling can occur in the absence of EGFR dimerization
(Carraway and Cerione 1993). The juxtamembrane region directly following the
transmembrane region contains thirteen highly basic amino acids and has an important
regulatory site, threonine 654, which upon phosphorylation decreases the receptor's affinity for
its ligand (Davis 1988; Lund et al. 1990).
The 539 amino acid cytoplasmic domain contains the catalytic domain and several
regulatory domains. The tyrosine kinase domain from residues 663 to 957 is similar to several
other receptor tyrosine kinases, Figure 1.7 (Czech et al. 1990; Pawson and Schlessinger 1993).
An important amino acid in this domain is Lysine 721 which is required for ATP binding.
Mutations of this amino acid results in failure to mediate phosphatidyl inositol turnover, Ca 2 +
intake, Na+/H+ exchange, DNA synthesis, EGF-stimulated tyrosine kinase activity, receptor
autophosphorylation and internalization (Czech et al. 1990; Moolenaar et al. 1988; Wiley et al.
1991). Another important amino acid in the kinase domain is residue 743. A single nucleotide
mutation changing the amino acid from valine to glycine diminishes the ability of the EGFR to
phosphorylate itself and other proteins by 5 fold and 90%, respectively (Fowler et al. 1995;
Luetteke et al. 1994). The phenotype of this mutation in mice is very similar to TGFao deficient
mice exhibiting skin and eye abnormalities. The domain which regulates ligand induced
internalization is residues 993-1022. Sequential truncation of amino acids from this region
reduces EGFR internalization down to the basal rate of normal membrane turnover (Chang et al.
1993; Chen et al. 1989). The carboxyl terminal residues 1022-1186 function as the
autoregulatory domain and contains four of the five tyrosine autophosphorylation sites -
residues 1068, 1086, 1148 and 1173 (Chang et al. 1993). The effect of autophosphorylation
on receptor kinase activity is controversial, but site-directed mutations of 1068, 1148, and 1173
had only a minor effect on kinase activity (Bertics and Gill 1985; Downward et al. 1984;
Honegger et al. 1987). The domain containing residues 984-996 is the actin binding domain
which mediates interactions believed to be responsible for high affinity binding (den Hartigh et
al. 1992). Occupancy-induced lysosomal targeting of the EGF receptor has been isolated to the
945-991 region where the sequence YLVI, at residues 954-958, as been previously proposed as
a lysosomal targeting motif (Guamier et al. 1993; Opresko et al. 1995). The EGFR lysosomal
targeting region was recently used in a yeast two-hybrid expression library to find EGFR's
lysosomal sorting protein named sorting nexin-l (SNX1). SNX1 contained a region of
homology to yeast vacuolar sorting protein and its over-expression decreased EGFR surface
concentrations (Kurten et al. 1996).
The importance of EGFR in embryonic development is dramatically demonstrated in
EGFR knockout mice. One group developed two strains of knockout mice. The first strain
died at mid-gestation due to placental defects and the other strain lived to 3 weeks with skin,
kidney, brain, liver, and gastrointestinal tract abnormalities (Threadgill et al. 1995). Also
determined was the important role played by EGFR in trophectoderm development (the first
epithelial layer to form in mammalian embryos), blastocoel formation by the trophectoderm, and
implantation (Wiley et al. 1995). A review of EGF / TGFct and their receptor can also be found
in Boonstra or Carpenter (Boonstra et al. 1995; Carpenter and Wahl 1990).
1.4 Control of Autocrine Systems
As described earlier, the autocrine pathway occurs in many different cell lines ranging
from primary human tumors such as multiple myeloma (Kawano et al. 1988), adult T-cell
leukemia (Niitsu et al. 1988), colon and esophageal carcinomas (Sun et al. 1994; Yoshida et al.
1990) to normal cells such as macrophages, lymphocytes, and fibroblasts (Heldin and
Westermark 1990; Wong and Wahl 1991). Normal autocrine cells transformed by transfection
of SV40 large T antigen remain pathologically similar to parental cells (Tsao et al. 1996). It
required the further mutation / mis-regulation of cell mechanisms by additional transfection of v-
Ha-ras into cells to become highly tumorigenic (Valverius et al. 1989).
With this slight change in cellular regulation, an autocrine cell changes from responding
to wound healing signals to unbridled proliferation. This connection between two extremes is
summarized by two reciprocal quotes (Sporn and Roberts 1992): "'a wound is a tumor that
heals itself' (Haddow 1972) , and 'tumors are wounds that do not heal'" (Dvorak 1986). Thus,
while autocrine factors have been associated with cancer, these growth factors are important in
tissue repair and wound healing to breakdown collagen, fibroblast migration, and formation of
new collagen and vessels (Sporn and Roberts 1986). To quote: "The difference between the
involvement of these peptides in carcinogenesis and tissue repair appears to depend more
strongly on the context and degree of their expression and activity, rather than on their mere
presence or absence. Only when regulation is lost, does pathology result (Sporn and Roberts
1992)."
One method to inhibit the autocrine ligand-receptor signaling pathway and restore
equilibrium to a misregulated autocrine system is addition of antibodies against the EGF
receptor (Gill and Lazar 1981; Modjtahedi et al. 1993a; Modjtahedi et al. 1993b; van de Vijver
et al. 1991). In Figure 1.8a, van de Vijver shows the addition of 20 nM (-3 pg/ml) monoclonal
anti-EGFR 528 or 225 antibodies to A431 cells decreases EGFR tyrosine phosphorylation to
30% +/- 10% basal level. As seen in Figure 1.8b, the receptor mass remains constant, thus the
phosphorylation decrease resulted from blocking TGFox / EGFR binding with antibodies and
not degradation of protein. Note, that the TGFao-EGFR Kd, a measure of ligand-receptor
affinity, is about 1 nM, therefore, they were using a twenty fold excess of antibody.
Modjtahedi's group also showed they could completely inhibit TGFu / EGFR binding in neck
carcinoma and breast carcinoma cells using 100 nM of rat monoclonal anti-EGFR antibodies.
An important finding from van de Vijver's paper, is that exogenously added antibodies can
inhibit the binding of TGFa to its EGFR receptor, suggesting that TGF(c-EGFR binding does
not occur during receptor / ligand biosynthesis, intracellular processing, and vesicular secretion.
In Vijver's paper, addition of anti-receptor antibodies reduced receptor phosphorylation
due to the inhibition of receptor-ligand binding. As prolonged phosphorylation leads to DNA
synthesis and proliferation, the question should be "what is the relationship between receptor
occupancy and mitogenic response?" One group calculated there was a linear relationship
between steady-state EGF receptor occupancy and the mitogenic response in fibroblast cells
(Knauer et al. 1984). Knauer's graph, Figure 1.9, shows low EGF receptor occupancy can
induce a mitogenic response, and in fact, maximum mitogenic response is achieved with less
than 25% of total receptor occupancy. Other researchers have studied the effects of autocrine
cell proliferation upon the addition of anti-receptor blocking and anti-ligand decoy antibodies
(Rodeck et al. 1990; Yamada and Serrero 1988). Some of their key findings are presented in
Figure 1.10. In Figure 1.10a, the proliferation of a series of carcinoma cell lines was
completely inhibited upon addition of 30 nM anti-EGFR monoclonal antibody 425, interrupting
the cell's EGF / TGFx autocrine loop. Figure 1.10b shows the addition of micromolar anti-
ligand decoy antibody concentrations resulted in the decreased cell growth of autocrine insulin-
dependent teratoma cells to sixty percent normal. Although system parameters were not
determined in these experiments, the overall trends in receptor phosphorylation, ligand binding,
and cell proliferation indicate the feasibility of using antibodies to inhibit the formation of
receptor / ligand complexes. Therefore, in order to attain complete inhibition of EGFR
signaling and mitogenic response, an analysis of the parameters affecting ligand-receptor
binding should be performed.
1.5 Mathematical Modelling of Autocrine Systems
Mathematical modeling is an ideal technique to determine which cellular parameters are
important for interrupting the autocrine pathway. An early model analyzed cellular and
environmental parameters', such as inoculum cell density and carrier beads versus culture
dishes, importance on regulating mammalian autocrine cell growth. To obtain similar cell
growth rates with increasing microsphere radius required a linearly proportional increase in
initial number of autocrine cells seeded. A second observation was greater inoculum cell
density / unit area was required to achieve similar growth rates for spherical microcarriers
versus flat tissue culture dishes (Lauffenburger and Cozens 1989). This model was based on
autocrine platelet-derived growth factor (PDGF) cells, modelling ligand production, diffusion,
binding, and cell proliferation. Some differences between this model and current experimental
system is the assumption of infinite bulk medium (therefore, no extracellular bulk ligand
concentration variable) and no competing antibodies. Another disadvantage is the use of cell
proliferation as the dependent variable. Experimentally, cell proliferation must be recorded
periodically over several days and the increasing cell density's effect on other cellular
parameters would be difficult to quantitate.
A second group evaluated the antibody concentration required to neutralize gastrin-
releasing peptide (GRP) autocrine growth factor's effect on small cell lung cancer (Mulshine et
al. 1992). It was determined that 160 mg anti-GRP decoy antibody would reduce receptor
occupancy below 10% for a 1 kg tumor in vivo. Some problems with this model are steady
state calculations (thus, no difference between autocrine cells and receptor cells "bathed" in
ligand), assumption of no proliferation below 10% receptor occupancy (see Knauer et al.,
1984), no difference between local cell environment versus bulk medium and based on in vivo
whole body assay versus in vitro culture dish experiments.
Another model analyzed competition between decoy antibodies and surface receptors
(Goldstein et al. 1989). The experimental system used 2,4-dinitrophenyl (DNP) aminocaproyl-
L-tyrosine (DCT) as the ligand. Monoclonal anti-DNP antibodies were used as a decoy
antibody and a cell receptor by anchoring the antibody to rat basophilic leukemia cell's high
affinity FcE receptor. Experimental data and computer modelling indicated that 2.4 jgM decoy
antibody was required to inhibit DCT rebinding to cells containing 6x105 receptors.
Deficiencies with this model include: not an autocrine system (ligand exogenously added),
quasi-steady state equilibrium assumptions, no internalization and degradation of receptor /
ligand complexes or normal receptor trafficking. They do have an implied screening length,
separating receptor / ligand binding at the cell surface from ligand in the bulk medium. An
advantage with this system is using the same antibody as both decoy and receptor plus the
ability to easily manipulate receptor concentrations by varying amount of anti-DNP antibody
bound to cells.
Computation work based on the interleukin 2 (IL2) system, a well studied autocrine T
lymphocyte system (Duprez et al. 1985; Smith 1990) has been performed by Forsten and
Lauffenburger (Forsten and Lauffenburger 1992a; Forsten and Lauffenburger 1992b; Forsten
and Lauffenburger 1994a). Forsten's papers perform mathematical calculations on autocrine
ligand binding using solution decoys and receptor blocking antibodies as competitors to
receptors / ligand binding. In Kim Forsten's computer model shown in Figure 1.11 (decoy)
and Figure 1.12 (blocker), known IL2 values for the ligand and receptor secretion rates, ligand
and receptor binding kinetics, diffusion rates, and degradation rates were used. By varying the
parameters values for cell density, ligand secretion, diffusion, ligand-receptor affinity and
solution decoys, she was able to analyze their effects on receptor complex numbers.
Computer modelling indicate two inhibition regimes exist when using competing soluble
receptor decoys on autocrine cells (Figure 1.13a). The first stage of inhibition occurs at low
decoy concentrations and is a function of the ligand's diffusion limitations into the bulk
medium. The second plateau of inhibition results from the diffusion limitations of the soluble
receptor decoy into the cell receptor's binding "domain." At this point, the cell receptor and
soluble receptor compete directly for freshly synthesized and receptor-released ligand. The
location of these plateaus with respect to soluble receptor concentration is a function of the cell
density and ligand secretion rates. According to the model, every 10 fold increase in cell
density requires a similar 10 fold increase in soluble decoy receptor concentration to achieve the
same inhibition level of receptor complex numbers. Also, increasing secretion rates means a
similar increase in decoy receptor concentrations to maintain similar receptor complexes levels
(Figure 1.13a and b).
A second method for inhibiting receptor - ligand binding uses blocking antibodies
against the receptor as mentioned in section 1.4. In Figure 1.14a, receptor-ligand complex
levels were predicted as a function of cell density and anti-receptor blocking antibodies
concentrations (Forsten and Lauffenburger 1992b). When comparing this figure against Figure
1.13a, there are a few noticeable differences such as the lack of a second plateau and inhibition
of receptor complexes at different inhibitor concentrations. Interruption of the receptor complex
is preempted in the soluble decoy model compared to the receptor blocking model due to the
depletion of soluble decoys by ligand binding as they diffuse into the proximal secretion layer.
This diffusion and "effective" proximal ligand decoy concentration causes the second plateau
and orders of magnitude increase in antibodies required to achieve complete ligand binding
inhibition when compared to receptor blocking antibodies (Figure 1.14b). A possible problem
with this model besides anchorage-independence and 1L2 versus EGF / TGFuo / EGFR cell
systems is the lack of intercellular receptor / ligand sorting between degradation and recycling
pathways upon internalization of complexes. However, these computer models reflect the need
for an experimental understanding into cellular parameters such as cell density and ligand
secretion rates to prevent unregulated proliferation of cancerous cells.
1.6 Expression System for Autocrine Ligand
DNA expression vectors are utilized to promote the expression of a foreign gene in a
transfected cell under constitutive or inducible control. A review of different enhancers and
promoters controlling / promoting the expression of proteins from expression vectors can be
found in Gene Transfer and Expression - A Laboratory Manual by Michael Kriegler (Kriegler
1990). There are several promoters and enhancers used in expression vectors which
constitutively express the desired gene, some of the more common ones include SV40 and
hCMV. SV40 enhancer was the first enhancing DNA sequence discovered, derived from the
viral DNA SV40 (Banerji et al. 1981; Moreau et al. 1981). However, the SV40 enhancer is
very complex (three functional units) and subject to positional effects and has cell type specific
dependencies on cellular factors. The second enhancer is human cytomegalovirus (hCMV)
which is about 400 base pairs long, has little cell-type or species preference and several fold
more active than SV40 (Boshart et al. 1985).
In contrast to the number of constitutive promoters and enhancers, there are very few
which regulate gene expression. Two of the most common ones are metallothionein (Palmiter et
al. 1982) and mouse mammary tumor virus (Huang et al. 1981; Lee et al. 1981).
Metallothionein promoter is induced by the addition of heavy metals or phorbol esters.
Typically, these vectors have high basal expression in the absence of metal and modest
induction of gene expression upon addition of metal (Palmiter et al. 1982). An adjustment of
the ratio between metal-responsive elements and basal-level elements had a best case 200 fold
induction (McNeall et al. 1989). Mouse mammary tumor virus promoter has glucocorticoid-
responsive elements which are induced by addition of dexamethasone. Utilization of this
promoter resulted in low protein expression (unpublished observation).
To obtain a high and controllable protein expression from cells, a two plasmid
transactivator expression system under tetracycline control was used (Gossen and Bujard
1992). This plasmid system was constructed so that protein expression levels could be
gradually induced from low to high expression with the adjustment of tetracycline
concentrations. The first plasmid (pUHD 15.1), shown in Figure 1.15, contains a gene
sequence which fuses the tet repressor protein to the activating domain of herpes simplex virus
virion protein 16. The fused protein, tetracycline-controlled transactivator (tTA), is
constitutively expressed using the human cytomegalovirus (hCMV) promoter / enhancer
regulatory region. The second plasmid, (pUHD 10.3), shown in Figure 1.16, has a hCMV
minimal promoter created by removing the enhancer region via PCR from the normal hCMV
DNA sequence. In addition, seven inserts of the 19 bp inverted repeat sequence for the tet
operator from Tn10 were added upstream of the hCMV minimal promoter, creating the fused
protein's binding site. The 19 bp repeat sequence is 5'- TCTCTATCACTGATAGGGA-3'.
Following the tet operators and hCMV region is the polylinker and SV40 polyadenylation
regions. A schematic of the two plasmid system is shown in Figure 1.17. The tTA protein
from the first plasmid is sensitive to low tetracycline concentrations and in the presence of
tetracycline can not stimulate mRNA transcription on the second plasmid. However, in the
absence of tetracycline, the tTA protein promotes RNA polymerase binding, leading to RNA
transcription and protein synthesis.
1.7 Cell Microphysiometer Assay for Autocrine Ligand Binding
A method for observing autocrine receptor / ligand complex levels can be achieved by
measuring extracellular acidification rates (ECAR) using Molecular Devices Microphysiometer /
Cytosensor and correlating its data to receptor complex numbers obtained from 1125 EGF
binding experiments. The production of acidic metabolites occurs via glycolysis of glucose to
lactic acid or glucose oxidization to CO2 by respiration. At physiological pH, these weak acids
dissociate, yielding two to six H+ per glucose molecule. Normal cultured fibroblast cells have a
very active glycolysis rate, accounting for about 80% of the secreted protons or around 108
protons per second (McConnell et al. 1992). The Cytosensor can also detect intracellular pH
regulation via the sodium-hydrogen exchange pump independent of glucose pathways.
Chemicals inhibiting this ion exchange pump are choline (increases intracellular proton
concentration) and amiloride (inhibitor of Na+-H + exchange system). The secondary signalling
pathway is another contributor to extracellular pH changes and can be interrupted using
genistein (inhibit tyrosine kinase activity), forskolin and cholera toxin (increase cAMP), or
staurosporine (inhibits protein kinase C). Both the sodium-hydrogen exchange pump and
secondary signalling pathway are regulated by receptor / ligand signalling, thus, changes in
complex levels affect cell metabolic rates in shown in Figure 1.18.
The Cytosensor detects small changes in extracellular hydrogen proton concentration
(rms error < 0.001 pH units) using a light-addressable potentiometric sensor (LAPS) (Owicki et
al. 1990). A schematic of the LAPS is shown in Figure 1.19a. The surface of the silicon
nitride insulator contains silanol and silamine groups which titrate as a function of pH (zero
charge at pH 3.5). Using an amplitude-modulated light-emitting diode (LED), a charge
separation results in a compensatory capacitatively coupled movement at the sensor's insulator
surface which is detected by the ammeter. As increasing potential is applied to the solution, the
depletion layer collapses, inhibiting the photocurrent. Thus, a plot of photocurrent (Ip) versus
applied potential (T) is obtained with a characteristic inflection point (d2Ip / dT 2 = 0) defined as
(YT p). As the sensor's surface potential depends on solution pH, changes in the inflection
point correlates to extracellular pH changes. The instrument's pH response to surface potential
is 61 mV per pH unit at 37 OC, sweeping over 1000 mVs. Shown in Figure 1.19b, medium is
pumped by peristaltic pump through a debubbler-degasser to the sensor chamber. Cells are pre-
attached to a membrane insert and in diffusive contact with the LAPS sensor.
The pH change is ascertained over defined time periods by briefly halting the flow of
medium over cells to generate the Ip - T graph (Figure 1.20a). Measuring 'pip once a second
for 20 seconds when the pump is off creates a Tpip versus time graph from which a linear best
fit line gives the cell's H+ secretion rate (Figure 1.20b). The medium's flow is resumed and the
entire pump cycle repeated every few minutes. A plot of cells' acidification rate over time
shows the response of cells to additives (Figure 1.20c).
Original Cytosensor applications include measuring cellular apoptosis as a function of
chemotherapeutic drugs, metabolic poisons (i.e. carbonylcyanide chlorophenylhydrazone), and
various irritants (i.e. dimethyl sulfoxide, acetone, benzalkomiun Cl) (Parce et al. 1989).
Receptor-mediated responses were measured as a function of growth factor additions and
competing antibodies (Owicki et al. 1990) along with secondary pathway transduction
elucidation via probes for G proteins (i.e. cholera toxins, forskolin, protein kinase C inhibitors
(staurosporine), tyrosine kinase inhibitors (genistein)) (Molecular Devices Corp. 1994). More
recent Cytosensor applications are variations of the same experiments including anti-infective
saponins on fungi and bacteria (Okunji et al. 1996), different agonists on dopamine D2 and D3
receptors (Boyfield et al. 1996), peptide ligands or anti-idiotypic antibody on B-lymphoma cells
(Renschler et al. 1995), or HER2 / HER3 metabolic response upon heregulin additions (Chan et
al. 1995). Hypothesizing that extracellular acidification should correlate directly with receptor /
ligand complex levels, it was believed that Cytosensor utilization could be expanded to studying
receptor complexes quantitatively.
Having described the Cytosensor inner workings and previous applications, predictions
on autocrine cell responses to varying ligand concentrations and inhibitors can be formulated.
Shown in Figure 1.21a, it is predicted that autocrine B82R + / TGFx autocrine cells'
extracellular acidification rates will increase as a function of increasing ligand expression as
receptor / ligand signalling complexes correspondingly increase. Addition of antibodies to cells
stimulated by ligand, exogenously added or endogenously secreted, would decrease cell's
ECAR as shown in Figure 1.21 b. Experiments can be performed on two different types of
autocrine cells, this thesis's autocrine B82R' / TGFox cell system (TGFoc synthesized as
transmembrane precursor and cleaved into a mature protein) and an autocrine B82R' / sEGF
(sEGF is synthesized as a mature protein). B82R' / sEGF's ECAR should be higher than
autocrine TGFcx cells, because TGFct must be cleaved at the surface before it can diffuse and
bind to the EGF receptor, allowing more chances for antibody inhibition, whereas sEGF could
bind before surface expression. Autocrine ligands and receptors are secreted in close proximity,
increasing their effective concentrations, whereas, exogenously added ligands and antibodies
must diffuse through the bulk medium before competing for receptor binding. Thus, both
TGFc and EGF autocrine cell's advantage should result in a higher ECAR versus non-autocrine
cells in the presence of antibody.
As Cytosensor's output is a metabolic rate and experimental values in terms of ligand
concentrations / receptor-ligand complexes / free receptor levels, an experiment relating
Cytosensor's data to these variables must be performed. A calibration between Cytosensor
output and receptor / ligand complexes can be obtained using radioactive ligand equilibrium
binding data. Two experiments would be performed, one with radiolabelled ligand data (bound
ligand versus free ligand) and one with Cytosensor data (extracellular acidification rate versus
free ligand). The Scatchard equation from equilibrium binding data (Scatchard 1949) can be
solved from its more common form (Eq. 2.1) for free ligand concentration as shown in equation
2.2.
C / L = - C / Kd + Rt / Kd Equation 2.1
L = C * Kd / (Rt - C) Equation 2.2
After determining the constants, Kd and Rt, Equation 2.2 can be substituted into an analogous
fit of the Cytosensor's ECAR versus free ligand graph. The combined equation eliminates free
ligand, leaving bound ligand (complexes), metabolic rate and grouped constants.
By combining these techniques, the Cytosensor can be utilized to quantify an antibody's
ability to interrupt an autocrine loop. Autocrine receptor / ligand complex formation may be
inhibited by addition decoy and blocking antibody concentrations. Since ECAR is proportional
to receptor complex levels, Cytosensor's data can be replotted as receptor complex levels versus
antibody concentrations. Cytosensor data would be compared to computer model data depicted
in Figure 1.14b predicting blocking antibody superiority over decoy antibody in receptor /
ligand complex inhibition. Thus, a relationship between Cytosensor data and receptor complex
levels will allow analysis of computer models and experimental results.
1.8 Thesis Overview
Computer modelling has indicated methods for inhibiting the autocrine signalling
pathway; however, only a few uncontrolled experiments have been performed on this system.
Some of the experimental problems are cell systems which make more than one ligand for the
EGF receptor or a single, constitutive, ligand production rate. In order to examine methods for
interrupting the autocrine pathway, I have developed an artificial autocrine and paracrine TGFa
cell system using mouse B82 L cells, which do not have endogenous EGF receptors nor EGF
family ligands.
The transmembrane TGFa gene sequence was spliced into the second plasmid of the
two plasmid tetracycline system and transfected into EGF receptor-positive and -negative cells
via calcium precipitation. TGF( secreting cells were isolated using histidinol selection,
subcloning and ELISAs. With the successful transfection of TGFc into these cells, I obtain
single ligand-receptor dynamics. Figure 1.22 shows how the cells were developed and which
plasmids were utilized to construct an B82 EGF receptor-positive and -negative TGFc
expression system. Nomenclature throughout the thesis will refer to autocrine and paracrine
cells using EGF / TGFa ligands with and without their receptor, EGFR. B82R' / TGFa
autocrine cells refer to the normal, same cell, receptor / ligand expression as defined in Figure
1.1. While a true paracrine cell system has ligand expressing cells and ligand receiving receptor
cells, all further references to a paracrine cell refer only to the ligand expressing cell, B82 EGFR
negative (R) / TGFa.
The two plasmid system enables the regulation of TGFc expression levels before,
during and after experiments. Studies in which tetracycline concentrations were varied
demonstrate the ability to incrementally and precisely adjust TGFx expression. TGFct was
characterized using Sephadex column separation and membrane extraction, showing that the
transfected B82 cells secrete mature TGFa. Having characterized the TGFca expression
system, experiments were performed on the cells to test model predictions on bulk ligand
concentrations as a function of cell density and receptor / ligand complexes as a function of
competing antibodies. Bulk ligand measurement as a function of cell density and ligand
secretion rates indicated the importance of cell density and blocking antibodies when performing
ligand accumulation / secretion experiments to obtain a "true" measurement of ligand secretion
rates. The effect of ligand secreting rates verifies predictions that at high secretion, bulk TGFx
concentrations would be independent of ligand uptake by its receptor, while dependent at lower
secretion rates.
To quantify autocrine receptor / ligand complex accurately, an experimental system was
developed using a modified 1125 binding assay and Molecular Devices Cytosensor. These
measurements validated model predictions indicating blocking antibody's superiority over decoy
antibodies for inhibiting autocrine receptor / ligand complexes. Further experiments between
autocrine cells expressing either transmembrane TGFac or mature EGF indicate the possibility of
intracrine signalling in EGFR / EGF autocrine cells. Finally, the effect of increasing ligand
expression levels in autocrine cells on receptor down-regulation and desensitization were
studied. Thus, the bioengineered, experimental, autocrine cell system enabled a systematic
study of cellular parameters which regulate cell signaling, gaining insights into the mechanisms
of cancerous cell growth.
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Figure 1.1: Ligand secretion pathways. Endocrine secretion: The ligand is secreted from
the source cell and travels via the bloodstream to a target celi. Paracrine secretion: The
source and target cells are in close proximity. Autocrine secretion: The target cells secretes
its own ligand. Juxtacrine secretion: The source cell secretes membrane-bound ligand and
by the adjacent target cell. (Adapted from Forsten and Lauffenburger, 1992a)
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Figure 1.2: TGFo precursor.: The arrows indicate the cleavage sites used to excise
the 50 amino acid mature TGFcx protein from the 160 amino acid precursor. The
mature protein is shown in bold. Glycosylation occurs on the asparagine residue of the
NST triplet. (Adapted from Brackmann et al., 1989)
NH2
KI
/0)
/4 K
NH2
(1)
(1)
(1)
(1)
NSDSECPLSHDGYCLHDGVCMYIEAL
NSYPGCPSSYDGYCLNGGVCMHIESL
VVSHFNDCPDSHTQFCFH GTCRFLVQE
VVSHFWKCPDSHTQYCFH GTCRFLVQE
E) (39) NRKKKNPCNAEFQNFCIH GECKYIEHL
F) (28) LGKKRDPCLRKYKDFCIH GECKYVKEL
G) (31) VKTHFSRCPKQYKHYCIH GRCRFVVDE
DKYACNCVVGYIGERCQYRDLKWWELR
DSYTCNCVIGYSGDRCQTRDLRWWELR
DKPACVCHSGYVGARCEHADLLA
EKPQCVCHSGYVGVRCEHADLLA
EAVTCKCQQEYFGERCEKSMKT
RAPSCICHPGYHGERCHGLSLPV
QTPSCICEKGYFGARCERVDLFY
H) (175) GTSHLVKCAEKEKTFCVNGGECFMVKDLSNPSRYLCKCQPGFTGARCTENVPMK
SI I I
Figure 1.3: Amino acid relationship between members of the EGF family.
Heregulin sequence begins with amino acid 175 of the proHRGx protein, while the other
polypeptide sequences are numbered relative to the mature form's NH 2 terminal. Conserved
sequences between the proteins are denoted in bold highlight. Disulfide bonds are indicated by
solid lines at the bottom. Residue numbering for EGF is shown at the top. Legend numbers in
parentheses indicate percent homology with human TGFoX. (Adapted from Shing et al., 1993;
Carpenter and Wahl, 1990)
Legend:
A: Human EGF(40%) E Human Amphiregulin (26%)
B: Mouse EGF (32%) F: Human Heparin Binding-EGF (32%)
C Human TGFca (-) G Mouse Betacellulin (50%)
ID Rat TGF ax (90%) H: Human Heregulin ax (30%)
50
Figure 1.4: Schematic representation of hTGFo structure. Dot-filled circles
are possible conserved EGF receptor binding sites. Hatch-filled circles are possible
conserved TGFc structural amino acids. Conserved cysteines are shown with bold
circles and linked via disulfide bridges indicated by solid lines. (Adapted from
Feild et al., 1992)
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Figure 1.5: Epidermal growth factor ligands and receptors family.
Where EGF is epidermal growth factor, TGFc is transforming growth factor
alpha, EGFR is epidermal growth factor receptor, HER is human EGFR, and
NDF is neu differentiation factor (heregulin).
Y*
54
'21
'43
Y*
NPVY*
NPEY*
NPDY*
- 958
- 973
992
- 1022
-- 1068
-- 1086
- 1
114
148
173
186
Figure 1.6: EGF receptor domains. Mutation of 721 to methionine abolishes kinase
activity. Mutation of 654 to alanine decreases the affinity of EGFR for its ligands and 743
mutation to glycine results in wav-2 phenotype. Sequential deletion of the fragments 1, 2
and 3 from the COOH terminal results in the loss of endocytic function. NPXY motif is
similiar to the LDL receptor internalization code, where Y* indicates tyrosine
phosphorylation sites. (Adapted from Chang et al., 1993 and Opresko et al., 1995)
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Figure 1.7: Receptor tyrosine kinases. Distinct families of receptor tyrosine kinase
families as classified by Ullrich and Schlessinger, 1990. Identified structures are:
tyrosine kinase domain (dotted boxes), transmembrane domain (solid box), cysteine-rich
domains (stripped box), immunoglobulin-like domains (semi-circles), acid domain (open
box), fibronectin III domain (checkered box). (Adapted from Fantl et al., 1993)
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Figure 1.8: Inhibition of phosphorylation by anti-receptor monoclonal antibodies.
Graph A: A431 cells cultured in P32 for 16 hours with or with antibodies 225 and 528.
Maximum phosphorylation response obtained with the culturing of A431 cells with EGF.
Graph B: 170 kD bands exised from graph A and resolved on two-dimensional gel.
Graph C: A431 cells cultured in P32 or S35 with or without antibody 528 for 16 hours.
(Adapted from Van Der Vijver et al., 1991)
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Figure 1.9: Relationship between EGF receptor occupancy and
mitogenic response. Dependence of maximum DNA synthesis rate on the number
of total occupied receptors. (Adapted from Knauer et al., 1994)
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Figure 1.10: Experimental data on ligand decoys' and receptor blocker's affect on autocrine
cell stimulation. Graph A: Inhibition of autocrine EGF/TGFR carcinoma cell proliferation in the
presence of increasing receptor blocker antibody concentrations. Graph B: Inhibition of autocrine
insulin-related factor teratoma cell proliferation in the presence of increasing ligand decoy
antibodies. (Adapted from Rodeck et al., 1990 and Yamada et al., 1988)
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Figure 1.11: Autocrine cell model schematic - decoy antibody.
(Adapted from Forsten and Lauffenburger, 1992a)
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Figure 1.12: Autocrine cell model schematic - blocker model.
(Adapted from Forsten and Lauffenburger, 1992b)
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R = Receptor B = Free Blocker Antibody
L = Ligand Y = Bound Blocker Antibody
D = Diffusion C = Bound Receptor
a = Cell radius 6 = Secretion layer
k = Rate constant -Q = Ligand Synthesis
V = Volume Vr = Receptor Synthesis
Y2 = Receptor / Antibody / Receptor Complex
~f
`\7
\ \
V-7 P
A. 012
al
Qos
C/R
o
Q06
Q04
ao
0
-17 -13 -9 -3 -1
Log (St) M
P U
Qal
C/Ro
06
o
Secretion "
Rate i
i- U
-17 -13 -9 -3 -1
Log (St) M
Figure 1.13: Decoy receptor effects on cell receptor complex levels. Graph A: Effect of
varying cell density on receptor - ligand complex levels. Graph B: Effect of varying ligand
secretion on receptor - ligand complex levels. (Adapted from Forsten and Lauffenburger,
1992a)
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Figure 1.14: Receptor antibody effects on cell receptor complex levels. Graph A: Effect
of varying cell density on receptor - ligand complex levels in the presence of receptor
antibodies. Graph B: Comparison of receptor antibodies versus soluble decoy receptors at a
cell density of 105 cells/ml. (Adapted from Forsten and Lauffenburger, 1992b)
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Figure 1.15: pUHD15.1. First plasmid of the tetracycline controlled two plasmid system.
(Adapted from Gossen and Bujard, 1992)
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Figure 1.16: pUHD10.3. Second plasmid of the tetracycline controlled two plasmid
system. (Adapted from Gossen and Bujard, 1992)
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Figure 1.17: Two plasmid schematic. The removal of tetracycline allows the fused
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Figure 1.18: Schematic of Ligand / Receptor signalling detection by Molecular
Devices Cytosensor.
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Figure 1.19: Schematic drawing of Cytosensor. Graph A) Schematic of light-
addressable potentiometric sensor (LAPS) Graph B) Operational schematic of Cytosensor
with peristalitic pump, degasser, sensor chamber and cells. (Adapted from McConnell,
1992).
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Figure 1.20: Representation of Cytosensor measurement and output. Graph A)
Cytosensor's measurement of photocurrent resulting from applied potential. Graph B) Plot of
Typip from Graph A as a function of time. Graph C) Rate data from Graph B determined by
linear best fit line plotted versus time. (Adapted from Owicki, 1994).
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Figure 1.21: Predicted metabolic response of paracrine and autocrine cells.
Response rates are measured using Molecular Devices' Cytosensor. A) Effect of
metabolic rate on autocrine cells upon addition of antibody. B) Metabolic response of
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Figure 1.22: Artificially engineered B82 TGFo family. A schematic
of plasmids required to create a paracrine and autocrine TGFao cell system.
Legend:Q pUHD15.lneo(lstPlasmid) * pXER (EGFR)
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Chapter 2: Modelling Autocrine Cell Receptor / Ligand / Antibody Interactions
2.1 Revising Anchorage-Independent to -Dependent Model
Described in chapter 1.5 was mathematical modeling work applied previously to IL-2
autocrine system for T-lymphocytes, which are anchorage-independent cells growing in
suspension (Forsten and Lauffenburger 1992a; Forsten and Lauffenburger 1992b; Forsten and
Lauffenburger 1994a). However, the B82R' / TGFox autocrine system is anchorage-
dependent. Therefore, the existing model was modified from an anchorage-independent to -
dependent cell situation. Figure 2.1 is a schematic illustration of the suspended autocrine cell
with anti-receptor blocking antibodies (Forsten and Lauffenburger 1992b) while indicating
important variables and parameters. Figure 2.1b is a schematic converting the anchorage-
independent autocrine cell model to an anchorage-dependent cell situation with its additional
relevant parameters indicated. The model equations for anchorage-dependent autocrine cells are
listed in Table 4.1 (blocking antibody), Table 4.2 (decoy antibody), Table 4.3 (nomenclature).
The anchorage-dependent LSODE programs are listed in Appendix C and D for blocking and
decoy antibodies, respectively. Both models' parameter values were changed from IL-2
receptor system to EGF receptor system.
The secretion layer was determined to be the distance at which ligand flux becomes
radial (Berg 1983), remains the same between suspension and anchored models. However,
anchored cells have an advantage over suspended cells in that they are closer together in a 2D
environment versus 3D environment. This close proximity of cells and cell-cell interactions
suggests an intermediate boundary layer between the anchorage substratum and the bulk
medium, represented by an intermediate volume parameter, V,. Computer simulations with
varying volume heights shows little effect on ligand concentrations and selected to be 25 jim
(Forsten and Lauffenburger 1992a). Thus, bulk volume, V,, is the total volume minus cell,
secretion, and intermediate layer volumes. As all calculations are based on volume per cell, the
bulk volume and intermediate volumes need to be determined on a cell basis. T, cell area (cm 2 /
cell), is a parameter based on assuming an evenly dispersed cell population on a defined surface
area. V, is calculated as intermediate boundary height times T, minus cell and secretion layer
volumes. VB is equal to T times the difference in medium height and intermediate boundary
layer height in a culture dish. Extra diffusion terms are required for ligand and antibody
trafficking between the intermediate boundary layer, secretion layer and bulk volumes. Thus,
the following terms must be included in Equations 6, 7, 5, and 3 in Table 2.1 and similar
substitution in Table 2.2:
-A L ( LB - Li) { la} -A ( B B - B) { lb}
AL(Li-L ) {lc} AB(Bi-B ) {ld}
where:
AiL = (1 DL TP2) / 6, t {2a} AiB = (H DB Y2) / 8,t {2b}
AL = 2 H DL (a + 8) {2c } AB = 2 H DB (a + 8) {2d}
2.2 Computer Modelling Predictions
There are several different venues when analyzing B82R' / ligand autocrine cell
signalling models; however, in this thesis, two directions were chosen: receptor / ligand
complex levels and extracellular bulk ligand concentrations. The first is receptor / ligand
complex levels. Figure 2.2 shows model predictions of cell receptor / ligand complex numbers
as a function of anti-receptor blocking antibody concentration and ligand secretion rates for
plated cells. Note that the receptor-ligand complex level are low compared to the total number
of receptors available. However, only a small proportion of the total steady state receptors are
required to initiate a mitogenic response (Knauer et al. 1984), at least in fibroblasts, as
discussed in chapter 1.4 and shown in Figure 1.7. As seen and intuitively predicted, receptor /
ligand complex levels increase with increasing ligand secretion rates, i.e. more ligand available
allows formation of more complexes. Another important aspect of this graph is at what
blocking antibody concentration completely inhibits receptor / ligand complexes. The model
predicts a concentration of 1 nM blocking antibody will inhibit cell surface receptor / ligand
complexes to essentially zero.
Figure 2.3 illustrates modelling predictions on the effect of anti-ligand decoy and anti-
receptor blocking antibody additions to plated B82R' / ligand autocrine cells. As discussed in
chapter 1.5 and Figure 1.11, blocking antibodies are predicted to be a superior inhibitor of
receptor / ligand complexes compared to decoy antibody. Here again, it requires nearly 1,000
times more decoy antibody to completely inhibit receptor / ligand complexes. Changing the
model from IL-2 to EGF also prominently affects decoy antibody's curve as to what level of
inhibition will occur. In IL-2's curve, decoy antibodies started to inhibit complex as soon as
blocking antibodies did, but had a second plateau over a large change in decoy antibody
concentrations. In EGF autocrine cell model predictions, there was an offset in complex
inhibition compared to blocking antibodies before complexes rapidly drop with a slope similar
to blocking antibody's curve to zero. This difference in the curves is a result of ligand / receptor
affinity and diffusion. IL-2's equilibrium dissociation constant, Kd , is 0.031 nM (Wang and
Smith 1987), while EGF's Kd is 1 nM. Both ligands have a kon rate constant, 0.1 tM-' sec';
however, kff varies between the two by 1,000 fold. Thus, the antibodies are able to inhibit
receptor / ligand complexes at an earlier concentration and mask the diffusion plateau when
comparing differences between EGF and IL-2 receptor systems.
The next venue for modelling analysis is extracellular bulk ligand concentrations or the
amount of ligand that escapes cell receptor binding and accumulates in the extracellular bulk
medium. Extracellular bulk ligand concentration predictions on a per cell basis are plotted as a
function of cell density in Figure 2.4a, for ligand synthesis rates of 30 and 6200 molecules /
cell-minute and other parameter values given in the figure legend. These ligand secretion rates
correspond to experimental data to be discuss in Chapter 4.7. One prediction is, at low cell
densities, per-cell ligand levels should be similar regardless of blocking antibodies, but as cell
density increases, per-cell ligand levels will decrease in the absence of antibody. This
"clearance" is due to endocytic degradation mediated by binding to cell receptors (Will et al.
1995). Upon addition of blocking antibodies (at a concentration of 20 p.g / ml, or
approximately 100 nM), ligand levels increase compared to cells without antibody. In the
presence of blocking antibody, receptor-mediated ligand uptake is inhibited and extracellular
bulk ligand concentrations remain constant regardless of cell density.
A second observation is a predicted difference in ligand clearance between low and high
synthesis rates. At a low synthesis rate, ligand is rapidly lost from the medium at high cell
densities. At a high ligand synthesis rate, ligand levels begin to decrease at the same cell density
in the absence of antibody, but significantly less loss occurs at higher cell densities when
compared to the low ligand secreting cells. This difference is due to competing ligand synthesis
and receptor-mediated ligand degradation rates. At the higher ligand secretion rates, autocrine
cells are simply creating more ligand than they can bind and degrade, becoming "pseudo-
paracrine" cells (Will et al. 1995).
A common method of analyzing bulk ligand concentrations is to plot total ligand
concentration per plate as shown in Figure 2.4b. Using this analysis, ligand accumulation
increases linearly with increasing cell population in both the presence and absence of blocking
antibodies at high ligand secretion rates. At lower secretion rates, ligand accumulation is also
linear in the presence of antibody, due to the prevention of receptor-mediated ligand uptake and
reaches an equilibrium between ligand uptake and secretion in the absence of blocking antibody.
Both methods are valid, allowing the experimenter to analyze and interpret the data via two
different methods.
These results underscore the necessity for measuring bulk ligand concentrations at
defined (preferable low) cell densities and in the presence of sufficient blocking antibody in
order to reliably determine the ligand synthesis rate. Otherwise, one would obtain an incorrect
ligand synthesis rate, underestimating the fraction of ligand taken up by cell receptors. This
suggestion is consistent with the one previous examination of this topic, for the IL-2 T-
lymphocyte system (Claret et al. 1992). In that work, it was found that 25-50 nM of anti-IL-2R
blocking antibody was required to permit 1L-2 to escape from secreting cells at maximal levels.
The IL-2 synthesis rate can be estimated under these conditions to be approximately 300
molecules/cell-minute. These findings compare favorably with model predictions (Figure 2.2)
that roughly 10-100 nM of an anti-receptor blocking antibody (possessing affinity on the order
of 1 nM for the receptor) would be required, blocking a sufficient fraction of cell surface
receptors and permitting a substantial amount of synthesized ligand to escape into the bulk
extracellular medium. We note that this estimate depends on the cell density used by Claret et
al. -- which was not reported in their study -- being sufficiently great (see Figure 2.4) that cell
uptake of synthesize ligand in the absence of blocking antibody is indeed significant. Such an
uncertainty reiterates the need to quantify key system parameters in order to properly interpret
experimental findings.
This sort of mathematical modeling approach yields important insights concerning which
molecular and cellular variables and parameters govern autocrine loop behavior. With an
experimentally validated model, further detailed questions can be asked regarding regulation of
autocrine signaling and consequent cell responses, not only allowing more rational design of
therapeutic interventions but also deeper insight into fundamental biological mechanisms. A
particularly intriguing issue, for instance, is the relationship between the level of autocrine
ligand found in the extracellular environment and the functional significance of an autocrine
loop. More precisely, it is typically considered that autocrine signaling is most important when
a large concentration of autocrine ligand is found in the bulk medium, because this condition
represents a "community" effect signal representing cell density (Alberts et al. 1994).
However, it is alternatively conceivable that the most physiologically effective autocrine
regulation occurs when very little ligand escapes into the extracellular medium. In this case,
instead of reflecting information merely about cell density, the autocrine loop serves to give the
secreting cell data about the molecular components present in its very local neighborhood; this
can be termed a "sonar" effect. Thus, it will be crucial to be able to relate measurements of
extracellular autocrine ligand concentration to other key parameters of the autocrine loop in order
to properly understand the role of an autocrine loop in cell and tissue regulation.
Table 2.1: Autocrine model equations - Blocker antibody
dR / dt = -kR + Vr - kon L*R + koffC - 2kB onB*R + kB,ffY - (kc/sa)RY + 2kcoffY 2
dC / dt = kon L*R - koffC - keC
V* dB* / dt = -2kB onB*R + kB ffY + A*B(B , - B)
dY / dt = 2kaonB *R - kBoffY - k Y + 2kcoffY 2 - (kc / sa) R Y
V* dL* / dt = -konL*R + kBffC + A*L(L, - L*) + Q
V, dL, / dt = -A'L(LB - Li)
V, dB, / dt = -NB(B, - Bi)
V, dL, / dt = -A*L(L , - L*) + A'L(L - L,)
V, dB,I /dt = -A*B(B , - B*) + A'B(BB - Bi)
dY 2 / dt = (kc/ sa)R Y - 2kcofY 2 - k2Y 2
where:
A*L = 2HDL(a + 6)
A'L = RDLI'2 i 61nt
Initial Conditions:
R/Ro= 1.0
C / Ro = 0.0
B* / B, = 1.0
Y / Ro =0.0
L* / Kd = 0.0
L, / Kd = 0.0
BB /B,= 1.0
L,/Kd = 0.0
B,/ B = 1.0
Y, / Ro = 0.0
A * = 2HDB(a + 6)
A'B = 7rDBTY 2 / lnt
Surface Receptors:
Surface Complexes:
Secretion Layer Antibody:
Bound Receptor / Antibody:
Secretion Layer Ligand:
Bulk Media Ligand:
Bulk Media Antibody:
Intermediate Media Ligand:
Intermediate Media Antibody:
Receptor/Antibody/Receptor
All receptor initially unbound
No complexes
homogeneously distributed blocker concentration
No initial binding
secretion has not begun
secretion has not begun
homogeneously distributed blocker concentration
secretion has not begun
homogeneously distributed blocker concentration
No initial binding
where Kd is equilibrium dissociation constant and Bt is receptor blocker concentration
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
Table 2.2 Autocrine model Equations - Decoy antibody
dR / dt = - konLR + koffC - ktR + V
dC / dt = konL*R 
- koffC - keC
V* dL* / dt = - k L*R + krC + 2ks,,X*V* - 2ks ,L*S*V *- V*kS,,L*Y* + V*ksoffY*
+ A*L (L, - L) + Q
4. V* dS* / dt = -2V*kSonL*S* + V*kSoffY* + A*s (S,- S*)
5. V*dY* / dt = 2ksonS*L*V* - kSoffY*V* - kSonY*L*V* + 2kSoffXV * + A*s(Y , - Y*)
6. V* dX* / dt = V*ksonL*Y* - 2V*ksoffX* + A*s(X, - X)
7. V dLB / dt = -2VBksonLBSB + VksoffY, + 2koffXBV, - ksonYLV, - A'L(LB - L i)
8. V, dS, / dt = -2VksonLBSB + VBksoffYB - A' s (SB - S,)
9. V, dYB / dt = 2 ksonSLVB - ksffYVB - ksonYLBVB + 2ksoffXBVB - A's(YB - Yi)
10. Vi dL, / dt = 2ksoffX,V, - 2konL,S,V, - ViksoL,Yi + VksoffY, - A*L(L , - L*) + A'L(LB - L,)
11. Vi dS, / dt = -2konL,SiV, + ksoffY,V, - As*(S
, - S) + A's(SB - S,)
12. V, dY, / dt = 2konL,SiVi - ksoffY,V, - ksonY,L,Vi + 2ksoffXi V , - A s (Yi - Y) +  s(Y, - Y,)
13. V, dX, / dt = V,konL,Y, - 2V,kSoffX, -A s (X,- X) + A's(XB - Xi)
14. X, = [S, (V* + V, + VB) - (S* + Y* + X*)V* - Vi(S, + X, +Y,) - VB(SB + Y,)] / VB
where:
A*L = 2IrDL(a + 8)
AL = 7tDL 2 / 6nt
Initial Conditions:
R /R o =1.0
C / Ro = 0.0
L* /Kd = 0.0
S' / S = 1.0
Y* / S, = 0.0
X*/ S = 0.0
LB / Kd = 0.0
S, / S, 1.0
YB / S, = 0.0
L, /Kd = 0.0
S,/ St = 0.0
Y, / St = 0.0
X, / St = 0.0
XB / S, = 0.0
A*s = 2·tDs(a + 6)
's = 0Ds 2/2 ,nt
Surface Receptors:
Surface Complexes:
Secretion Layer Ligand:
Secretion Layer Antibody:
Secretion Layer Bound L / Ab:
Secretion Layer Bound L / Ab / L:
Bulk Media Ligand:
Bulk Media Antibody:
Bulk Media Bound L / Ab:
Intermediate Media Ligand:
Intermediate Media Antibody:
Intermediate Media L / Ab:
Intermediate Media L / Ab / L:
Bulk Media Bound L / Ab / L:
All receptor initially unbound
No complexes
secretion has not begun
homogeneously distributed decoy conc.
secretion has not begun
secretion has not begun
secretion has not begun
homogeneously distributed decoy conc.
secretion has not begun
secretion has not begun
homogeneously distributed decoy conc.
secretion has not begun
secretion has not begun
secretion has not begun
where Kd is equilibrium dissociation constant and S, is ligand decoy concentration
Table 2.3 Autocrine model nomenclature and parameter values
Starbuck etal., 1990
Kd = 4.7 nM
kon = 0.34 min. -'
kon = 1.2e-13 cm 3 / site-min.
kon S,B = kon
kon S,B = kon
Ro = 100,000 # / cell
kt = 0.03 min. -'
ke = 0.3 min.-'
Forsten etal., 1992a,b
k, = k,
k 2 = ke
8 = 2e-5 cm
8,,, = 25e-4 cm
a = 5e-4 cm
DL = 9e-5 cm 2 / min.
Ds,B = 2e-5 cm 2 / min.
kc = 480e-10 cm 2 / min-molecule
kcoff = 60 min-'
Experimental Conditions
parea = 28.3 cm 2
plvol = 5 cm3
xheight = plvol / parea
T = parea / cell density, cm 2 - cell
VB= P * (xheight 
- ,n)
Vcell =5e-10 cm3 / cell
V* = 6.5e-11 cm / cell
V I= Int - Vcell- V*
Q = 30 - 6,000 # / cell - min.
Vr= Ro* kt
sa = 7.85e-7 cm
Receptor / Ligand Equilibrium Dissoc. constant
Receptor / Ligand Dissociation rate constant
Receptor / Ligand Association rate constant
Antibody - Antigen Dissociation rate constant
Antibody - Antigen Association rate constant
Initial receptor number
Constitutive internalization rate constant
Ligand-induced internalization rate constant
Internalization rate const., Antibody / Receptor
Induced internalization rate constant, Ab / Receptor / Ab
Secretion layer thickness
Intermediate layer thickness
Cell radius
Ligand diffusion constant
Antibody diffusion constant
Antibody / Receptor cell diffusion
Receptor / Antibody / Receptor dissociation
60 mm dish plate area
Media volume
Height of media in plate
Distance between cells - Homogeneously spread
Bulk volume
Cell volume
Secretion layer volume
Intermediate layer volume
Ligand secretion rate
Receptor secretion rate
Cell surface area
A.
V
VLB /
/
/
/4
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V LL-
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Figure 2.1: Autocrine computer model with blocker antibodies. Converting
an autocrine suspension model (A) to a plated anchorage dependent model (B) with
important variable indicated.
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Figure 2.2: Modelling predictions - Varying ligand secretion rates. Effect of
varying ligand secretion rate on receptor / ligand complex levels in the presence of
anti-receptor blocking antibodies. Cell density is le6 cells / 60 mm plate. Ligand
secretion rates: 30 (squares), 300 (triangles), 2000 (circles), and 6200 (diamonds)
molecules / cell - minute.
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Figure 2.3:
Comparison of
Modelling predictions - Blocker versus Decoy antibodies.
receptor antibodies (squares) versus ligand decoy antibodies (circles)
at a ligand secretion rate of 6,000 molecules / min. Cell density is 107 cells / plate.
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Figure 2.4: Modelling predictions - Bulk ligand concentrations. Anchorage
dependent autocrine cell model predictions of extracellular ligand concentrations as a
function of cell density, ligand secretion rates, and blocking antibody concentrations.
Ligand secretion rates are 30 (squares) and 6200 (circles) molecules / cell - minute. A.
Bulk ligand concentrations as molecules / cell. B. Bulk ligand concentrations as
molecules / plate. Antibody concentrations are 0 {-17 log} (solid) and 20 {-6.7} (open)
gig / ml. Parameter values listed in Table 2.3.
Chapter 3: Experimental Methods - Ligand Characterization
3.1 Materials
pUHD 15.1 and pUHD 10.3, shown in Figure 1.15 and 1.16, respectively, were made
by Manfred Gossen and Hermann Bujard (University of Heidelberg, Heidelberg, Germany)
and used with permission. pMTE4 (transmembrane TGFx cleavable protein), shown in Figure
3.1, was kindly provided by Dr. Rik Derynck (University of California-San Francisco, San
Francisco, CA). The EGF receptor plasmid (pXER) in Figure 3.2 and B82 mouse fibroblast
cells containing pXER were made and kindly provided by Dr. Gordon Gill (University of San
Diego, San Diego, CA). The B82 EGF receptor and receptor minus cells containing
pUHD15.1 (1st plasmid) was made and kindly provided by Dr. Birgit Will-Simmons
(University of Utah, Salt Lake City, UT). The Bluescript II KS+ plasmid, Figure 3.3, was
obtained from Strategene. pREP8 in Figure 3.4 was purchased from Invitrogen and modified
into pR8 by Dr. Birgit Will-Simmons with the removal of the EBNA-1 and OriP (epstein barr
virus origin of replication) segments to prevent episomal replication and allow for incorporation
into chromosomal DNA.
The restriction enzymes and DNA modifying enzymes were purchased from Gibco
BRL, New England Biolabs and Boehringer Mannheim. Bovine calf serum was purchased
from Hyclone. Dulbecco-Volt Modified Eagle Media was purchased from Gibco BRL.
Methotrexate, geneticin sulfate (G418) and histidinol were purchased from Sigma. The
monoclonal antibodies 225 and 528 were produced and purified from hybridomas in Steve
Wiley's lab. TriReagent (used fro RNA isolation) was purchased from Molecular Research
Center, Inc.
PBS/EDTA solution is 2.7 mM KCL, 1.5 mM KH 2PO 4, 137 mM NaCl, 8.1 mM
Na 2HPO4, 0.6 mM EDTA, 17 mg/liter phenol red. PBS/EDTA/trypsin is 90% PBS/EDTA and
10% of 0.5% trypsin solution in Ca/Mg free PBS.
B82 cells containing pUHD15.1 were selected and cultured in Dulbecco-Volt Modified
Eagle Media with 10% bovine calf serum, 1 mM glutamine, 100 units/ml penicillin and 2.5
gtg/ml streptomycin. Selection was achieved and maintained with 600 gtg/ml G418. Medium
for the B82 cells containing pXER (B82R') used dialyzed bovine calf serum (6-8000 MWCO in
PBS) and 1 pM methotrexate to maintain selection on pXER.
B82 cells containing pUHD 15.1, pUHD10.3 / TGFu and pR8 were selected and
cultured in a specially made medium containing a subset of amino acids (except histidine), salts,
vitamins, 10% bovine calf serum, 1 mM glutamine, 100 units/ml penicillin and 2.5 gg/ml
streptomycin. See Appendix A for detailed listing of components and concentrations. Selection
was achieved and maintained with 600 gg/ml G418, and 800 gM histidinol. Suppression of
TGFuc secretion was achieved with 1-2 gg/ml of tetracycline. Medium for cells with pXER also
contained dialyzed bovine calf serum and 1 pM methotrexate to maintain selection.
3.2 Making pUHD10.3 / TGFx
The 2nd plasmid, pUHD 10.3, contains pBR322 ColEl and f3-lactamase antibiotic
resistance segments, a regulatory region with tetracycline operators, multiple cloning sites, and
a SV40 polyadenylation sequence.
The TGFc plasmid, pMTE4, contains the signal sequence, mature TGFo protein
sequence and TGFc cleavable transmembrane sequence. The plasmid uses the SV40/DHFR
resistance segment for selection and a early SV40 promoter for constitutive TGFu expression.
The entire TGFc sequence was removed from pMTE4 with a HindIII digest. The 800 bp
fragment was placed into an unique HindIII site in Strategene's Bluescript II KS+ plasmid in
the T7 to T3 orientation as shown in Figure 3.5.
The entire TGFot wild type sequence was cut from the Bluescript KS+ II/TGFx plasmid
with XhoI and EcoRI. Before digesting the plasmid with EcoRI, the linear plasmid (cut with
XhoI) was blunted with a Klenow enzyme fragment. The Klenow was disabled by heating at
75 0 C for 10 minutes before adding EcoRI restriction enzyme to remove the TGFou insert.
pUHD10.3 was prepared by digesting the plasmid with BamHI, blunting with Klenow enzyme
and finally digesting with EcoRI to provide a sticky end for the TGFac insert. The DNA
fragments were isolated by running a 1% agarose gel, isolating the correct DNA segments and
purified by Millipore filters. The concentration and molecular weight of the DNA was measured
by running a 1% agarose gel. The DNA concentrations were determined to be 50 ng/pl for the
800 bp TGFc insert and 15 ng/pl for the 3 kbp pUHD10.3. One hundred ngs of the two DNA
pieces were ligated together in a 6:1 molar ratio overnight at 16 o C with 1 unit of T4 ligase.
The following morning, all of the ligated DNA was added to 100 pls of competent
DH5 bacteria and stored on ice for 30 minutes in a 10 ml Falcon tube. The bacteria / DNA
mixture was heat shocked for 90 seconds at 42 oC before returning to ice for 2 minutes. Eight
hundred pls of SOC media (2% bactotryptone, 0.5% yeast extract, 10 mM NaCI, 2.5 mM KC1,
10 mM MgCl 2, 10 mM MgSO 4, 20 mM glucose in ddH20) was added to the bacteria and
incubated for 45 minutes at 37 oC before streaking the bacteria onto LB/ ampicillin (100 gg/ml)
plates to grow overnight at 37 oC. Three ml LB / ampicillin minipreps of individual bacteria
colonies were grown overnight and the plasmid isolated using Promega's Wizard Miniprep.
The purified plasmid was checked for the presence of the TGFX insert using PstI enzyme as the
TGFc insert contains two sites, 50 bp apart, while pUHD10.3 does not contain a PstI
restriction site. A 1% agarose gel of the cut DNA showed that four of the twelve minipreps had
the TGFuc insert due to the less mobile linear plasmid running slower than the uncut supercoiled
pUHD 10.3 without the TGFca insert. The bacteria from miniprep #3 was grown in 200 mls LB
/ ampicillin and pUHD 10.3 / TGFx (Figure 3.6) purified using Promega's Wizard Maxiprep.
3.3 Transfection of DNA into B82 Cells
The transfection of the B82 cells were accomplished using a CaPO4 / DNA precipitate
solution placed on a sparse cell population (Kriegler 1990; Wigler et al. 1979).
The day before DNA transfection, approximately one million B82R+ / pUHD15.1 and
B82R' / pUHD15.1 cells are plated into separate 60 mm Coming dishes containing normal
medium. The next day, 30 gg of pUHD 10.3 / TGFx and 10 gg of pR8 were mixed into 250
•ls of nanopure water. The DNA was sterilized with 250 gl chloroform, mixed and then
centrifuged at 10,000x g for 2 minutes. The top aqueous / DNA layer was combined with 500
gls of 2x HBS (HEPES Buffered Saline: 10 mM KC1, 11 mM Glucose, 1.4 mM Na2HPO 4,
171 mM NaCl, and 42 mM HEPES), 200 gls of nanopure (sterile) water and 50 ptls of 2.5 M
CaCl2. After mixing and standing at room temperature for 30 minutes, 500 Rls of the CaP0 4 /
DNA precipitate solution was added to the B82R' / pUHD15.1 and B82R- / pUHD 15.1 cells in
normal medium.
After 24 hours, the CaP04 medium was removed and the cells rinsed with PBS/EDTA.
Nonselective medium was added to the plates for 24 hours to allow the transfected cells to
become histidinol resistant. On the second day, the medium was removed, the cells were rinsed
with PBS/EDTA and trypsinized. All the cells from each transfection were passed at a 1:4
dilution into 60 mm Coming dishes containing selective medium (histidinol, G418, tetracycline
and no histidine (His- media)). On the third day, the selective medium was removed and the
cells washed with PBS/EDTA to remove dead cells before adding fresh selective medium to the
plate. The selective medium was replaced about every three days until colonies appear
(approximately 200-1000 cells per colony). The colonies were isolated using Bellco 8 x 8 mm
glass cloning cylinders and transferred into an individual well of a Falcon 24 well plate
containing selective medium. Cells found to produce secreted TGFc were maintained and
cultured in the presence of selective medium.
3.4 Selection of TGFc Secreting Clones
The cells were grown from the Falcon 24 well plates into 3 wells of a 12 well Falcon
plate - uninduced, induced and founder cells. Upon cell confluence, TGFa expression was
induced by the removal of tetracycline-containing medium and replaced with tetracycline-free
medium. The following day, induced and uninduced cell medium was replaced, respectively,
with fresh tetracycline-free medium and tetracycline medium, beginning the 24 hour secretion
period. The tetracycline-free medium was added a day early to remove the tetracycline
suppression, thus enabling the measurement of steady-state TGFao production. The B82R' /
pUHD15.1 / pUHD10.3 - TGFo medium additionally contained 10 jgg/ml of anti-EGFR
monoclonal antibody 528 to prevent receptor-mediated TGFX uptake.
At the end of the 24 hour period, one ml of medium was saved and the remaining
volume recorded. The saved media was placed into a 1.6 ml centrifuge tube and spun at
17,000x g for 10 minutes to remove cell debris. The medium supematant was stored at -70 o C.
Cell number was determined using a Coulter Counter Model ZBIO10 with a 0.5 ml counting
volume and threshold setting at 1 to 15 gm.
3.5 Detection of TGFx
The detection of TGFc in the medium was performed using an Oncogene Science (OS)
TGFao ELISA kit. The ELISA kit uses a sandwich enzyme immunoassay specific to TGFa,
using pre-coated polyclonal goat anti-TGFx wells and goat anti-TGFa secondary biotinylated
antibody. The binding of streptavidin-horseradish peroxidase to the secondary antibody
allowed for the detection of TGFao by catalyzing the conversion of o-phenylenediamine
dihydrochloride from a colorless chromophore to an amber chromophore. The 490 nm
absorbance was measured using Molecular Devices spectrophotometer Model 250 and
Biometallics, Inc ASoft 1.8 Vmax software. Quantification of TGFo present was obtained
using the six TGFo concentration standards in the ELISA kit.
Medium samples were removed from -70 o C and thawed on ice before removing a 55 gtl
aliquot and adding it to a 55 itl aliquot of the 1:20 diluted OS secondary antibody. The OS
ELISA wells were rinsed with 200 pls of lx OS rinse buffer before adding 100 gls of the
medium sample / antibody mixture. After a 3 hour room temperature incubation, the wells were
washed three times with lx OS wash buffer and rinsed twice with lx OS rinse buffer. A 100
gls 1:100 dilution of streptavidin-horseradish peroxidase was added to each well and incubated
for 30 minutes at room temperature. The wells were washed and rinsed again (as above) before
adding 100 gtls of the o-phenylenediamine solution. The reaction was incubated in the dark for
45 minutes before stopping with 100 jtls of 4 N sulfuric acid and solution absorbance measured
at 490 nm.
Medium samples, antibody, and streptavidin-horseradish peroxidase were diluted in
assay buffer provided by Oncogene Science. The OS TGFao standards were diluted in
unconditioned medium. The o-phenylenediamine tablet was diluted in substrate buffer provided
by Oncogene Science. Concentration and composition of buffers was not provided in the OS
ELISA kit. The TGFc standards were 0, 50, 250, 500, 750 and 1000 pg/ml.
3.6 Determining Cellular Processing of TGFx Protein
Twelve 100 mm Coming dishes were plated at a cell density of 1:10 with paracrine cells
in tetracycline-free medium. After 24 hours, the medium was removed, cells washed with lx
PBS/EDTA and 5 mls of serum-free tetracycline-free medium added to each dish. After 6 days,
all of the medium was collected and placed on ice. The medium was concentrated using an
Amicon concentrator with a YM 3000 MWCO (molecular weight cut off) membrane filter. The
medium was further concentrated in several 2 ml capacity Amicon centricons with 3000 MWCO
by spinning at 7,000x g for four 2 hour periods. Both methods were performed on ice or at 4
TC. The medium volume was concentrated from 60 mls down to 1 ml using these two methods.
The final concentration of TGFc was determined to be 160 ng/ml by Oncogene Science TGFo
ELISA.
The molecular weight of the TGFt was determined using a meter G-50 fine Sephadex
column, calibrated with the appropriate standards. 622 gls (100 ngs) of the concentrated TGFo
was added to the mixture of protein standards in Table 2.1 and 59 gls of pure glycerol for a total
volume of 1181 ptls.
The protein/glycerol solution was added to a small PBS buffer head on top of the G-50
column. The protein was eluted into the beads before a larger buffer head was added. The
column ran at 40 mls per hour with the effluent running through a spectrophotometer/chart
recorder and into a fraction collector. The spectrophotometer/chart recorder was set at 280 nm
absorbance, 6 cm/hr chart speed with a 0.5 absorbance range. The fractions were collected in 5
minute aliquots over 9 hours. Immediately after running the column, the fractions were assayed
for TGFkx protein using the Oncogene Science TGFac ELISA kit.
Cellular processing of the TGFc protein was also confirmed by determining the
concentration of TGFz in the medium and cell membrane. Two Coming 60 mm dishes
containing either autocrine or paracrine TGFx B82 cells were grown to 50% confluence before
washing the cells with PBS/EDTA. Tetracycline-free medium was added to the cells and grown
for 24 hours at 37 oC. The cells' medium was replaced with fresh tetracycline-free medium
after washing the cells with PBS/EDTA to begin the 24 hour secretion period. As always,
medium for the autocrine cells contained 10 gg/ml of anti-EGFR monoclonal antibody 528 to
prevent the uptake of TGFo by the EGFR receptor. At the end of the 24 hour secretion period,
one ml of medium was saved from each cell type and the remaining volumes recorded. The
saved medium was placed into a 1.6 ml microcentrifuge tube and spun at 17,000x g for 10
minutes to remove cell debris. The medium supernatant was stored at -70 o C.
The membrane TGFo was extracted as follows. An extraction buffer was made with
800 jils 25 mM CHAPS, 10 gls of 400 mM sodium iodoacetate, 10 kls each of pepstatin,
leupeptin, chymostatin, and aprotinin (all at 10 mg/ml) and diluted to 1 ml with ddHO. The
cells were rinsed three times with PBS / EDTA before adding 250 gls of extraction buffer to
each plate. The cells were scraped off the dish and placed in a 1.6 ml microcentrifuge tube on
ice. The dish was rinsed with 250 gls of extraction buffer and added to the microcentrifuge
tube. After incubating for 15 minutes on ice, the samples were spun at 17,000x g for 15
minutes to remove debris. The supernatant was transferred to a new tube and stored at -70 oC.
Cell number was determined by counting a similarly plated cell dish using a Coulter
Counter Model ZBIO10 with a 0.5 ml counting volume and threshold setting at 1 to 15 jim. The
0.5 mls of trypsinized cells were diluted in 1.5 mls of medium to inhibit further cell
trypsinization and degradation before adding 18 mls of PBS to count the cells.
3.7 TGFa Secretion Time Course from Paracrine Cells
Cells from three confluent 60 mm Coming dishes were plated into thirty 60 mm Coming
dishes at a cell density of 1:10 in tetracycline-containing medium. The cells were allowed to
settle and grow in the dishes for 24 hours before removing the medium and washing the cells
with lx PBS/EDTA. Five mls of tetracycline-free medium was added to all thirty plates to
begin the time course experiment at time equal zero hours. A "pseudo" pulse/chase experiment
was also performed by adding tetracycline-containing medium to half of the dishes after the cells
were in tetracycline-free medium for 12 hours to induce the expression of TGFo.
At each time point, one dish was used for medium sampling and extracting RNA, while
another dish were used to determine cell density. At the correct time, one ml of medium was
collected from a dish, spun at 17,000x g for 10 minutes at 4 oC before storing the supernatant at
-20 oC. One ml of TriReagent was added to the dish and cells lyzed for 10 minutes before
collecting the TriReagent/cell extract in a 1.6 microcentrifuge tube and storing at -20 oC. Upon
completion of time course experiment, the TriReagent and medium samples were transferred to -
70 oC storage. Cell number was determined as described before using the Coulter Counter
Model ZBIO10. The time points for this experiment are shown in Table 2.2. Conditioned
medium's TGFc concentration was determined later by Oncogene Science TGFa ELISA
The asterisk symbol (*) and bold print denotes when fresh medium was added to cells
for the next 24 hour period. The 24 hour replacement of fresh medium was done to maintain
cells in a constant, non-depleting environment of nutrients, growth factors, etc. and were
applicable in a constant concentration of tetracycline.
3.8 Tetracycline Concentration Effect on TGFa Secretion
The uninduced autocrine B82R' / TGFo and paracrine B82R" / TGFac cells were plated
into a 6 well Falcon plate. The following day, cell medium were replaced with a tetracycline
containing gradient to begin the induction of TGFa. 24 hours later, cell medium was replaced
with fresh medium containing the same tetracycline gradient to start the 24 hour secretion
experiment. The tetracycline gradient was 500 gg/ml, 100 ng/ml, 10 ng/ml, 2 ng/ml, 1 ng/ml,
200 pg/ml. Normal suppression of TGFox secretion was achieved using 1 gg/ml, therefore,
these concentrations represent a 500/1, 1/10, 1/100, 1/500, 1/1000, 1/5000 gradient,
respectively. Medium for autocrine cells also contained 10 gg/ml of anti-EGFR monoclonal
antibody 528 to prevent TGFa uptake by the EGF receptor.
At the end of the 24 hour period, one ml of medium was saved and the remaining
volume recorded. The saved medium was placed into a 1.6 ml centrifuge tube and spun at
17,000x g for 10 minutes to remove cell debris. The medium supernatant was stored at -70 o C.
Conditioned medium's TGFx concentration was determined by Oncogene Science TGFo
ELISA
Due to the low number of cells present, cell density was determined using a
hemocytometer. The resuspended trypsinized cell solution was placed in the hemocytometer
and cell number per 4-9 squares counted depending on cell concentration. The average number
of cells per square multiplied by 10,000 gives cell concentration as number / ml.
This experiment was repeated by plating 250,000 autocrine B82R+ / TGF(o clone #1
cells into eighteen 60 mm Coming dish giving a 3 plate replicate with six different tetracycline
concentrations. 24 h later, TGFu expression was pre-induced by addition of a tetracycline
gradient to the cells. The tetracycline gradient was 10, 1, 0.1, 0.01, 0.001, and 0 gg / ml. The
next day, the 24 hour experiment was begun by replacing cell medium with fresh medium
containing the tetracycline gradient and 10 tg / ml blocking anti-EGFR antibody 225. At the
end of the 24 hour period, one ml of medium was saved and the remaining volume recorded.
The saved medium was placed into a 1.6 ml centrifuge tube and spun at 17,000x g for 10
minutes to remove cell debris. The medium supernatant was stored at -70 o C. Conditioned
medium's TGFx concentration was determined by Oncogene Science TGFc ELISA. Cell
number was determined using a Coulter Counter Model S/STD IIA and Multisizer II with a 0.5
ml counting volume and threshold setting at 9.3 jim to out. Trypsinized cells were diluted in
medium to inhibit further cell trypsinization and degradation before adding Isoton II solution to
count cell number.
3.9 Cell Density Effect on TGFa Secretion
B82R' (pXER) / pUHD15.1 / pUHD 10.3 - TGFa / pR8 (autocrine clone #1) cells were
serially diluted (two fold dilutions per point) into sixty 60 mm Coming dishes from 0.02-1 x
106 cells / dish as four sets (15 dishes / set). Triplicate cell density replicate points are done at
5e5, 6e4, and 8e3 cells / dish. On the next day, two sets were induced for the expression of
TGFax by removal of tetracycline from the medium. Following an additional 24 h incubation,
fresh medium containing tetracycline or tetracycline free medium was added to the cells with or
without 20 jtg / ml monoclonal anti-receptor 225 as appropriate, giving the following
experimental conditions: induced cells with mAb225, induced cells without mAb225,
uninduced cells with mAb225 and uninduced cells without mAb225. The amount of antibody
added was constant and not adjusted for cell density or receptor number.
24 hours later, one ml of conditioned medium was removed, spun at 17,000x for 10
minutes to remove cell debris and stored at -20 oC. Conditioned medium's TGFa concentration
was determined by Oncogene Science TGFac ELISA
Cell number was determined using a Coulter Counter Model S/STD IIA and Multisizer
II with a 0.5 ml counting volume and threshold setting at 9.3 gm to out. Trypsinized cells were
diluted in medium to inhibit further cell trypsinization and degradation before adding Isoton II
solution to count cell number. Varying amounts of medium and Isoton II solution was used to
dilute cell numbers at high cell density and maximize cell number at low cell densities during cell
counting for counting on the Coulter Counter.
3.10 Creation of sEGF clones
Creation of B82R' wild type / sEGF and B82R / sEGF clones was performed by Dr.
Birgit Will-Simmons (Will et al. 1995). Normal EGF is synthesized as a transmembrane
protein (170 kDa) and the mature protein (6 kDa) is enzymatically cleaved into the medium upon
surface expression. The EGF gene sequence used by Dr. Will-Simmons is the mature protein
or secreted EGF, hence the term sEGF. The gene sequence was constructed by Niyogi's lab
(Engler et al. 1988) for expression in E. Coli. To obtain mammalian expression, Dr. Will-
Simmons switched EGF's bacteria signal sequence with EGFR's mammalian signal sequence.
The new EGF construct was then placed into pUHDO1.3, 2nd plasmid of the tetracycline
controlled expression system, creating pUHD10.3 / sEGF. The plasmid was co-transfected
with pR8 (histidinol resistance) into B82 EGFR positive and negative cells previously
transfected with pUHD15.1neo, the first plasmid of the tetracycline controlled expression
system.
During this thesis work, pUHD10.3 / sEGF was transfected into several B82 cells
containing mutated EGF receptors (A654, M721, M721A654, A647) (Lund et al. 1990; Wiley
et al. 1991). These mutated EGFR B82 cells were previously transfected with pUHD 15.1 neo,
allowing control of sEGF expression. All transfections done by Birgit and myself with
pUHD10.3 / sEGF and pUHD15.lneo into B82 cells used the method of Wigler as described
earlier in section 3.3
Detection of EGF was achieved by sandwich ELISA similar to TGFot's. Monoclonal
anti-EGF antibody HA (gift from Katsuzo Nishikawa, Kanazawa Medical University, Japan) in
PBS / 0.02% sodium azide (PBSN) at 5-10 gg / ml was used to coat the 96 well ELISA wells.
ELISA wells were rinsed with 0.05% Tween-20 in PBSN after every addition. ELISA wells
were blocked with 10% horse sera in PBSN (blocking buffer). A rabbit polyclonal sera
directed against EGF was used as a secondary antibody diluted 1:100 in blocking buffer.
Alkaline phosphatase-conjugated goat anti-rabbit antibody (Sigma) was used as the tertiary
antibody at a dilution of 1:6000. Detection was achieved by using 1 mg / ml dinitrophenol
(Sigma) in 10 mM diethanolamine and 0.5 mM MgCl 2, pH 9.5. The reaction was quenched
with 0.1 M EDTA after 4-10 minutes. Solution absorbance was read at 405 nm using
Molecular Devices spectrophotometer Model 250 and Biometallics, Inc ASoft 1.8 Vmax
software. All solution volumes were 50 uls except 200 uls of blocking buffer was used to
block ELISA plate. The ELISA plate was incubated overnight at room temperature to coat
ELISA with monoclonal antibody HA and overnight again to block ELISA plate with 10%
horse sera. The medium samples and antibody incubations were 2 hours at room temperature.
Table 3.1: Molecular weight standards used for G-50 fine column.
Protein MW Size Amount Volume
(kDa) (mgs) (gls)
Albumin 66 2.5 100
Carbonic Anhydrase 29 1 100
Cytochrome C 12.4 1 100
Aprotinin 6.5 3 200
Time course points for TGFao secretion from paracrine B82 cells.
The asterisk symbol (*) and bold print denotes when fresh media was added to the cells for
the next 24 hour period.
No Tetracycline Pulse/Chase (Tetracycline added)
0 hour
4 hours
8 hours
12 hours 0 hour (Addition of Tetr. Media)
18 hours 6 hours
24 hours * 12 hours
1 8 hours
36 hours 24 hours *
48 hours * 36 hours
60 hours 48 hours *
60 hours
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Figure 3.6: pUHD10.3 / TGFa. The prepro transmembrane TGF(x inserted in the 2nd
plasmid of the tetracycline controlled two plasmid system.
Chapter 4: Results - Ligand Characterization
4.1 Overview of Experiments
The objective of this chapter was to develop an autocrine and paracrine TGFa - EGFR
cell system. In order to achieve this goal, several sequential short term obstacles had to be
overcome. These obstacles included placing the TGFx gene under the control of an inducible
high expression, plasmid system, transfecting the plasmid into a TGF(o negative cell line and
characterizing the expression of the recombinant TGFx. The TGFca gene was obtained from
Rik Derynck (University of California-San Francisco) and placed into the two plasmid
tetracycline controlled expression system obtained from Gossen (University of Heidelberg).
The two plasmid system was then transfected into mouse B82 L cells which do not have
endogenous EGF receptors or TGFa. Transfection of the EGF receptor into B82 L cells by
Gordon Gill (University of San Diego) enables the development of both an autocrine and
paracrine cell system. TGFc expressed from these two cell systems were characterized by
analyzing protein's molecular weight size, location, and secretion levels. A time course
experiment tested the kinetics of TGFa expression from the two plasmid system. The
utilization of these cells for testing theoretical models was determined by measuring the affect of
tetracycline concentrations and cell densities on TGFx secretion levels.
4.2 Making pUHD10.3 / TGFx
As stated in chapter 3.2, Bluescript II KS+ / TGFx wt was cut with XhoI, blunted with
Klenow and the TGFx wt insert excised with EcoRI. pUHD10.3 was cut with BamHI,
blunted with Klenow and cut with EcoRI to match the TGFac insert ends. The DNA pieces
were gel isolated and ligated together to create pUHD10.3 / TGFo wt (Figure 3.6). After
transforming bacteria, minipreps of individual colonies were grown up and the DNA isolated.
The presence of the TGFct insert in the second plasmid was done by digesting the DNA with
PstI. The PstI restriction site is not in the second plasmid while in the TGFx insert there are
two sites, 50 bp apart. Therefore, a comparison between supercoiled and linear DNA can be
made to determine the insert's presence.
Four bacteria colonies were determined to have the UHD10.3 / TGFa wt plasmid.
Miniprep #3 was used to inoculate 200 mls of LB / ampicillin and the plasmid purified using
Promega's Wizard Maxiprep. The DNA was checked to insure the insert's presence. A EcoRI,
PstI, NcoI and SmaI digest compares a circular pUHD 10.3 to a linearized pUHD 10.3 / TGFo.
A HindIII cut linearizes pUHD10.3 and removes the TGFu insert from pUHD10.3 / TGFa.
Multiple RsaI sites in the TGFc insert and pUHD10.3 indicate the insert presence by comparing
size differences of the small DNA fragments. The 1% agarose gel is shown in Figure 4.1. It
appears that not enough NcoI enzyme was added to the DNA to insure cutting, however, the
remaining enzymes (EcoRI, HindIII, PstI and SmaI) gave the expected band sizes. A
comparison of linearized DNA size by EcoRI and SmaI demonstrates that the second plasmid
contains the insert. PstI and RsaI cut inside TGFx insert sequences and shows that the insert is
TGFax. Excision of the TGFot insert using HindIII indicates that the TGFx fragment is the
correct size.
4.3 Selection of TGFa Secreting Clones
After passing cells transfected with pUHD10.3 / TGFa and pR8 into selective histidine
minus / histidinol medium, the cells were allowed to grow / die for several days with regular
changing of selective medium. The surviving cells grew into colonies from an individual cell
and were isolated using cloning rings. Seventy-two possible autocrine and paracrine clones
were isolated by cloning rings and placed into 24 well plates. From these 72 clones, 28
paracrine clones and 12 autocrine clones continued to grow. Three paracrine clones were also
isolated and grown up from a second pUHD10.3 TGFox / pR8 DNA transfection. The forty
three successful clones were tested for expression of TGFa and determined that 9 clones were
positive (5 autocrine and 4 paracrine).
The induction range of clones expressing TGFa was determined by measuring TGFo
secretion rates at similar cell densities. Cells were grown in either the presence (repressed) or
absence (induced) of tetracycline. B82R' / TGFac autocrine cell media also contained 20 gg/ml
anti-EGFR antibody 225 to prevent TGFcx uptake by the EGF receptor. As shown in Figure
4.2, the autocrine clones displayed both high TGFao expression levels as well as a wide,
dynamic, induction range. For example, the secretion rate of autocrine clone #9 increased from
0.14 to 41 ng/106 cells per 24 h (- 10-3000 molecules/cell-minute) upon removal of tetracycline,
roughly a 300-fold increase. The second highest expressor, autocrine clone #1, displayed a
roughly 25-fold induction (from 1.5 to 36 ng/10 6 cells per 24 h (-100-2700 molecules/cell-
minute)). The paracrine clones displayed a lower level of induced TGFot secretion
(approximately 8 ng/10 6 cells per 24 h, or 600 molecules/cell-minute) and with only a 5-fold
induction range. Shown in Table 4.1 is several other different cell lines expressing autocrine
EGFR / TGFa ranging from 0.4 to 50 ng / million cells - day. Thus, not only does the newly
created autocrine EGFR / TGFuc cell system expresses TGFot within the range of other common
autocrine cells, its expression of TGFox is regulated by tetracycline.
4.4 Determining Cellular Processing of TGFa Protein
Figure 4.3 shows the results of running paracrine's concentrated medium over a G-50
fine column with molecular weight standards. TGFc concentration in the fractions was
determined by Oncogene Science TGFc ELISA. Elutions of the molecular weight standards
monitored at 280 nm is re-plotted from the strip chart recorder data. The figure shows two
TGFc peaks (6 kDa and 31 kDa) eluting off the column. The predicted molecular weight size
for correctly processed, mature, secreted TGFt is 5.6 kDa. Therefore, within the resolution of
this column, TGFa is correctly processed from the 25 kDa transmembrane TGF(o into the
mature protein. The 31 kDa TGFct peak could be derived from two different sources. This
peak could be some secreted transmembrane TGFx which had not been cleaved or an
aggregation of mature TGFo from the Amicon concentrating steps. A resolution between these
two possibilities has not been pursued, but could be resolved by running a denaturing SDS
polyacrylamide gel and protein detection by Western. If the peak was an aggregate, proteins
would denature and run at 6 kDa. If the protein was transmembrane TGFo, the protein would
run at 31 kDa. This avenue of experiments was not pursued as a clear majority of the protein
was the correct molecular weight size, showing that TGFc was correctly processed.
After determined TGFo was correctly processed into its extracellular medium, it was
questioned how much TGFa was secreted into the medium versus retained in the cell membrane
after 24 hours. Samples from the cell membrane and media were analyzed for TGFx
concentration using the Oncogene Science TGFx ELISA kit. As shown in Table 4.2, over 99%
of TGFot is cleaved from the membrane and secreted into the medium. This secretion indicates
that cleavage of TGFa from its membrane bound precursor is neither inhibited nor a rate
limiting step in B82 cells. There could be another reason for low TGFa protein detection in
membrane samples. The miscelle / TGFox sample would be sterically hindering one of the two
anti-TGFuc ELISA antibodies from binding, thus no TGFt would be detected. Western SDS-
Page gels would refute or confirm this possibility. However, as this result was not central to
the thesis, it was not pursued.
4.5 TGFa Secretion Time Course from Paracrine Cells
A time course experiment was performed to gain an understanding of TGFc secretion
kinetics from paracrine cell lines. Figure 4.4 shows the secretion of TGFR from an induced
paracrine cell line compared to a "pulse / chase" experiment from paracrine cells induced for 12
hours and then maintained in tetracycline medium for another 60 hours. There are two clear and
interesting results from this experiment. The first result is the induction of paracrine cells. The
cells quickly responded to removal of tetracycline, producing significant quantities of TGFo
within 4 hours. Over the 60 hour period, the accumulative amount of TGF( in the medium was
fairly constant with respect to time.
The second interesting result from this experiment was that TGFx production rate in the
pulse / chase induced cells did not start to decrease when compared to fully induced cells until
48 hours after the re-introduction of tetracycline. This result would seem to indicate that TGFc
mRNA might be fairly stable, allowing the production of TGFc protein long after new TGFc
mRNA translation was inhibited by the addition of tetracycline. To check this explanation,
would require running mRNA samples from each time point in a ribonuclease protection assay
(RPA) and to determine if the TGFa mRNA remained constant after the addition of tetracycline
for 48 hours. However, to ensure all future experiments with uninduced autocrine B82R' /
TGF( cells are truly uninduced for the expression of TGFa, cells will be continuously cultured
in tetracycline containing medium.
4.6 Tetracycline Concentration Effects on TGFo Secretion
As described in chapter 3.8, the cells were plated into individual wells of a 6 well plate.
The cells were induced for a day before beginning the 24 hour secretion experiment. As
always, autocrine cell medium contained 10 jgg/ml of monoclonal anti-EGFR 528 antibody for
the 24 hour secretion period. The cell density was determined by Coulter Counter. TGFa
concentrations were determined using a TGFx ELISA and stated on a per cell basis. The effect
of tetracycline concentration on TGFa secretion for paracrine and autocrine cells is shown in
Figure 4.5. The figure shows that the cells' TGFa secretion levels can be controlled by
adjusting tetracycline concentrations in the medium. Also, it appears that the autocrine cell has a
tighter "off' control, however, the autocrine cell density might have an affect as the autocrine's
density is about an order of magnitude less than the paracrine's density. TGFx expression in
the paracrine and autocrine cells ranged from 10 to 40 ng / million - 24 hours (500 to 3,200
molecules / cell-minute) and from 0.01 to 1.2 jtg / million - 24 hours (700 to 79,000 molecules /
cell-minute), a 4 fold and 110 fold increase, respectively. This induction should give an
experimenter an excellent range to measure what effect ligand secretion has on receptor
downregulation and receptor-ligand complex levels with respect to cell density, ligand decoy
and receptor blocking.
A review of secretion rates during this experiment and others, one realizes that TGFoc
expression is an order of magnitude higher than other experiments. This tetracycline experiment
was performed in a 6 well Falcon plate with very few cells (autocrine cells contained around
10,000 cells / 35 mm dish - 1,000 cells / cm 2) versus other experiments at 1,000,000+ cells / 60
mm dish (35,000 cells / cm 2 ). The importance of cell density will be discussed in the next
section; however, another problem occurs when dividing TGFa concentration in the medium by
a small cell numbers with possible large errors (counted by hemacytometer) to give a false,
high, absolute number. Thus, while tetracycline can regulate TGFc expression, the absolute
TGFct expression may be suspect.
The experiment was repeated at a later date with replicates to test tetracycline's regulation
of TGFa expression and is shown in Figure 4.6. The experiment was performed as before on
B82R' / TGFc autocrine clone #1 cells. Tetracycline concentration was varied from 10 to
0.001 and 0 pg / ml in medium containing 10 gg / ml blocking antibody 225. TGFc
expression was inhibited down to 0.01 gg / ml tetracycline. Expression began between 0.01
and 0.001 ug / ml tetracycline, increasing 12 fold. The total expression range between
uninduced to induced autocrine clone #1 cells was 70 fold. Also this time, the expression rate
was in the "normal" regime of 100 to 6000 molecules / cell-minute versus the previous
experiment. The error in the last experiment was most likely due to multiplying TGFa
concentration by a low and inaccurate cell density.
4.7 Cell Density Effects on TGFo Secretion
Confirmation of theoretical predictions from chapter 2 is found in the experimental data
shown in Figure 4.7a and b. Induced and uninduced TGFx expression was measured in
autocrine clone #1 as a function of competing antibodies and cell density. As described in
chapter 3.9, B82R' / TGFct autocrine clone #1 cells were serially diluted from 0.02-1 x 106
cells / 60 mm Coming dishes into four sets of 15 plates (9 dilutions with triplicates at 500,000,
62,500, and 7,812 cells / dish dilutions). The induction range in this experiment was 200 fold
changing from 30 to 6200 molecules / cell-minute upon removal of tetracycline. At each cell
density, half of the dishes received 20 gg/ml anti-EGFR blocking antibody 225 to determine
whether the inhibition of TGFuo uptake would vary as a function of cell density.
As shown in Figure 4.7a, at a high ligand synthesis rate of -6200 molecules/cell-
minute, TGFc levels were not increased upon addition of blocking antibodies. This data
contrasts with data obtained at the low ligand synthesis rate of -30 molecules/cell-minute in
uninduced cells. At lower ligand secretion rate, TGFc levels drop sharply to background levels
in the absence of blocking antibody. Upon addition of EGFR blocking antibody, TGFc uptake
is reduced and maintained a fairly constant level until higher cell density.
Figure 4.7b is plotted as total bulk ligand concentrations. As in Figure 2.5, ligand
accumulation increases with increasing cell populations in the presence of antibody at the higher
secretion rate. Upon removal of the antibody at the lower secretion rate, ligand accumulation
does not occur, similar to Figure 2.5. Thus, experimental findings are both qualitatively and
quantitatively consistent with model predictions that the effectiveness of receptor-blocking
antibodies is strongly dependent on both cell density and ligand synthesis rate.
4.8 Creation of B82R ÷ / sEGF Clones and Mutant Receptors
As described earlier in Chapter 3.10 and Will et al., 1995, Dr. Will-Simmons
constructed a mature, secreted, form of EGF - termed sEGF. sEGF's expression plasmid is
pUHD10.3 / sEGF in the two plasmid tetracycline-controlled expression system. She
transfected the plasmid into B82 cells which already contained pUHD15.1 neo and were EGFR
wild type positive or negative, creating B82R' wild type / sEGF and B82R- / sEGF. Dr.
Gordon Gill has also constructed several mutated EGFR plasmids and transfected them into
B82R cells (Chen et al. 1989). These receptor have different affinity and trafficking properties
as shown in Table 4.3 (Lund et al. 1990; Wiley et al. 1991).
During the course of the thesis, there was an interest in looking at how these receptor
affinity and trafficking changes would affect autocrine ligand / receptor interactions. Thus,
pUHD15.1 neo and pUHD10.3 / sEGF was transfected into several mutant EGFR cell lines.
These mutated EGFR cell lines were A654, M721, A654M721, and A647. Shown in Table 4.4
is a compilation of all existing TGFa and sEGF expression systems in normal / mutated EGFR
positive and negative B82 cells. The clones have a variety of TGFo and sEGF expression
levels, however, ligand expression are all similar with nanogram expression. Also, the
detection of ligand was not performed at similar cell density, but represents values obtained
during clonal selections. Thus, a multiple of expression systems exist, allowing an unlimited
number of hypotheses to be experimentally tested.
Comparison of Autocrine TGFx / EGFR cells
Secretion Rate
nL / million cells - day
Autocrine clone #1
A431
MDA468
MCF-7
Ishikawa
MDCK / TGFx 1-16
1-40
10 *'
50
5.2
2.4
0.4 *2
Rheiss et al., 1991
Hamburger and Pinnamaneni, 1992
Fontana et al., 1992
Gong et al., 1992
Dempsey and Coffey, 1994
Note: Referenced cells (except Dempsey and Coffey) did not use blocking antibodies to prevent
ligand uptake by the receptor.
*1 TGFo concentration given as ng/ml, assumed a 10 ml volume.
*2 Assuming cell doubling every day from initial cell density given.
Cell Type Reference
Table 4.1
Detection of secreted and membrane bound TGFao
Cell Type Source pg/million cells % Membrane/Media
Autocrine #1 Membrane 120
Media 25400 0.47
Paracrine #22 Membrane 3
Media 9160 0.04
Table 4.2:
Mutant B82 EGFR trafficking and affinity parameters
Cell 
TVpe
Control +PMA
Wt
A654
M721
A654M721
C' 1022
C'1022A654
I-Int., H-Aff.
I-Int., H-Aff.
L-Int., H-Aff.
L-Int., H-Aff.
I-Int., H-Aff.
I-Int., H-Aff.
L-Int., L-Aff.A647
L-Int., L-Aff.
I-Int., L-Aff.
L-Int., L-Aff.
L-Int., L-Aff.
L-Int., H-Aff.
L-Int., H-Aff.
L-Int., L-Aff.
where:
I-Int. - High ligand induced receptor internalization
L-Int. - Low constitutive membrane turnover receptor internalization
H-Aff. - High receptor / ligand binding affinity
L-Aff. - Low receptor / ligand binding affinity
Source:
Lund et al., 1990; Wiley et al., 1991
ell Tvne- ---- ---
Table 4.3:
Artificially engineered cell systems
Cell Type
EGFR+/TGFo
EGFR-/TGFcx
EGFR /sEGF
EGFR-/sEGF
EGFR' Mutations
A654/sEGF
M721/sEGF
M721A654/sEGF
A647/sEGF
salP mids
pXER/pUHD 15. 1/pUHD 10.3-TGFa/pR9
pUHD 15.1 I/pUHD 10.3-TGFa/pR9
pXER/pUHD 15.1 /pUHD 10.3-EGF/pR9
pUHD 15.1 /pUHD 10.3-EGF/pR9
pXER/pUHD 15. 1/pUHD 10.3-EGF/pHyg.
pXER/pUHD 15. 1/pUHD 10.3-EGF/pHyg.
pXER/pUHD 15. 1/pUHD 10.3-EGF/pR9
pXER/pUHD 15.1/pUHD 10.3-EGF/pHyg.
# of 
Clones
Induced
5 1 -40
4 .5-10
2 5 - 200)
2 2-40 •
6 (2)
12 (2)
15 (2)
1
5 -8
1 - 10
1 - 140
150
Induction is reported as ng/million cells/24 hours.
Will et al., 1995
Not all clones tested at this time
(1)
(2)
Plasmids
Table 4.4
Legend:
Lane 1: MW Standards
Lane 2: Uncut pUHD10.3/TGFu
Lane 3: Blank
Lane 4: pUHD10.3 w/Ncol
Lane 5: pUHD10.3/TGFt w/ NcoI
Lane 6: pUHD10.3 w/EcoRI
Lane 7: pUHD10.3/TGFu w/EcoRI
Lane 8: pUHDIO.3 w/RsaI
Lane
Lane
Lane
Lane
Lane
Lane
Lane
Lane
9:
10:
11:
12:
13:
14:
15:
16:
pUHD 10.3/TGFa w/RsaI
MW Standards
pUHD10.3 w/HindIII
pUHD I0.3/TGFao w/HindIII
pUHD10.3 w/PstI
pUHD 10.3/TGFcx w/PstI
pUHD10.3 w/SmaI
pUHD IO.3ITGFox w/SmaI
Figure 4.1: pUHD10.3 / TGFu Digest. Characterization of the TGFot 2nd plasmid using
several restriction digest enzymes.
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Figure 4.2: EGFR / TGFu expression at similar cell density. Induced TGFu
expression by removal of tetracycline shown as shaded. Uninduced TGFx expression
repressed by continuous tetracycline in cell medium shown as solid. Half of the plated
cells were pre-induced for TGFt expression by removal of tetracycline from the medium.
24 hours later, tetracycline-containing and tetracycline-free media was added to the
appropriate wells and TGFo concentrations were allowed to accumulate for 24 hours. In
addition, autocrine medium contained 10 ptg / ml mAb 528 to prevent ligand uptake by
EGFR. Cell density averaged 900,000 cells / 60 mm dish.
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Figure 4.3: TGFao Molecular Weight. Determination of TGFa's molecular weight
in conditioned medium using a G-50 Sephadex column. Conditioned medium from
B82R- / TGF( cells were concentrated using Amicon filters before adding to a 100x G-
50 Sephadex column. Appropriate molecular standards were run simultaneously with the
conditioned medium. Fractions were collected every 5 minutes and measured via A280
nm for total protein and TGFox ELISA.
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Figure 4.4: TGFa time course. Uninduced B82R- / TGFx clone #22 cells were
plated and allowed to attach for 24 hours. TGFo expression was induced by
replacing all of the cell plates' medium with tetracycline free medium (squares).
Conditioned medium was removed at times indicated and cell number determined.
Half of the cell plates medium were switched back to tetracycline containing media
at 16 hours (diamonds)
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Figure 4.5: Tetracycline controlled TGFcx expression. Plated cells were pre-
induced for TGFu expression by addition of fresh medium containing the tetracycline
gradient for 24 h. The next day, fresh medium containing the tetracycline gradient was
placed on the cells and TGFu concentration allowed to accumulate for 24 h. 10 pgg / ml
monoclonal antibody 528 was added to each well to prevent ligand uptake by EGFR.
Autocrine cell density was -10,000 cells / 35 mm dish. Paracrine cell density was
-120,000 cells / 35 mm dish.
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Figure 4.7: Experimental bulk ligand concentrations. B82R+ / TGFa clone #1
induced (circles) and uninduced (squares) ligand concentrations were tested as a
function of cell density and ligand epxression levels. TGFcx expression occurred with
20 ýtg / ml anti-EGFR monoclonal antibody 225 (open) and without antibody (solid).
A. Bulk ligand concentration as molecules/cell. B. Bulk ligand concentration as
molecules/plate.
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Chapter 5: Methods for Ligand-Receptor Complex Characterization
The last two chapters characterized and examined B82R÷ / TGFa autocrine cells in terms
of ligand expression. However, ligand expression is only half of the story. Binding of ligand
to its receptor is an important cellular initiator and regulator of cell proliferation and migration as
mentioned in chapter one. It has also been observed large fractions of carcinomas have an over-
expressed autocrine loop. In these carcinomas, one or both of the ligand and receptor pair is
over-expressed. How this over-expression affects cellular signalling and proliferation is not
clearly understood. Does increased ligand and receptor lead to increased signalling? or does the
cell regulatory machinery adjust to a new threshold? Previous research in the group analyzed
several important parameters' affect on receptor / ligand complex inhibition as a function of
blocking and decoy antibodies in a mathematical autocrine model. Having developed autocrine
receptor/ ligand expression cell lines, model predictions can be validated and new hypotheses
tested. Autocrine cell parameters which may be varied experimentally are: ligand secretion rate
(controlled by tetracycline concentrations), ligand secretion trafficking (synthesizing
transmembrane precursors or mature protein), receptor trafficking rate (mutant EGFR receptor
cells), receptor / ligand affinity (different ligands / mutated ligands). In these next two chapters,
methods and results from Cytosensor experiments analyzing the first two parameters will be
addressed as a function of blocking antibody and / or decoy antibody concentrations.
First, a method for measuring and quantifying ligand - receptor levels needed to be
developed. Molecular Devices Cytosensor determines cells' metabolic rate by measuring
changes in extracellular pH. The cells' metabolic rate can be increased by adding ligand to a
cells' medium. Upon ligand binding to its receptor, signalling is initiated through the secondary
pathway to increase cellular metabolic activities such as glycolysis and respiration. The ligand /
receptor complex signal is amplified at each step in the secondary pathway, creating a large
signal from a small initial source of complexes. For this detection method to work, the receptor
/ ligand binding step must be the rate-limiting step which would appear on a graph of metabolic
rate vs. EGF as a dose dependent response to EGF concentrations.
5.1 General Protocol for Testing Cells on the Cytosensor
Since B82 mouse fibroblast cells are an anchorage dependent cell line, the cells must be
plated one day prior to running an experiment on the Cytosensor to allow for attachment of the
cells to the transwell membrane. Quarter of a million (250,000) cells are seeded into each
transwell (Coming Transwell #3402 - 3 gm pore size, 12 mm diameter) in normal growth
medium (See Chapter 2 for each cell type's appropriate media). Plating cells in serum free
conditions using D/H/B (Dulbecco-Volt Modified Eagle Media, 25 mM HEPES and 1 mg / ml
BSA, all from Sigma) resulted in dead cells with little or no metabolic activity. One day after
plating cells (experiment day), cell transwells are prepared for placement on the Cytosensor.
First, a spacer (50 gtm high, 6 mm inner diameter, #R7026B - Molecular Devices) is placed in
the transwell's medium directly over the cells. On top of the spacer is placed a transwell insert
(3 Itm pore size, looks like a mini-transwell, fitting flush inside the original transwell, #R7025 -
Molecular Devices). One ml running buffer to each insert cup completes assembly, creating a
self-contained cell chamber of 1.4 gls. Cell / transwell assembly is placed in Cytosensor silicon
sensor chambers and equilibrated for 2-3 hours in DV/cyto buffer (Dulbecco-Volt Modified
Eagle Media with 2.59 gram / liter sodium chloride and 0.1 mg / ml BSA, no sodium
bicarbonate) at a 100 gls / minute flowrate. Pump cycle with all experiments are 30 seconds on
and 30 seconds off. ECAR is measured during the "pump off' period for 20 seconds, starting
8 seconds into the "pump off" period.
All protein samples are diluted in DV/cyto buffer to proper concentration before placing
samples on the Cytosensor. Use of BSA in buffer prevents sample protein from sticking to the
tubing's wall and loss of signal. Signal aberrations resulting from concentrated protein
solutions and their buffers (high antibody concentrations at 100 ýtg / ml) are eliminated by
dialyzing protein in DV/s (DV/cyto without BSA) buffer for 24 hours. Protein concentration is
re-measured using Sigma's BCA protein concentration determination assay (Procedure TPRO-
562 using B9642 Bicinchoninic Acid and C2284 Copper (II) Sulfate Pentahydrate).
Once cell metabolic activity or extracellular acidification rate (ECAR) achieve a steady
state baseline, the experiment is begun. Cells are exposed to EGF or TGFa additions until
achieving maximal ECAR (about 10 minutes) after which the ligand is removed and cells
allowed to acquire a new steady state baseline. In experiments with antibodies, cells are
allowed to re-establish steady state ECAR before exposing them to a 30 minute challenge with
competing antibodies.
5.2 B82R' ECAR Response as a Function of mAb225 and mEGF
B82R' cells were seeded into transwells following the normal protocol and allowed to
grow overnight. Cells were equilibrated in DV/cyto buffer on the Cytosensor before beginning
the experiment as normal. Once cells reached steady state ECAR, each cell lane was re-
equilibrated in the presence of 0, 0.01, 0.1 or 1 pgg/ml anti-receptor blocking antibody mAb225.
Next, a stepwise gradient of mEGF was added to each lane with antibody and maximal ECAR
peaks recorded. The mEGF gradient was 0.1, 1, 10, and 100 ng/ml. After each EGF addition,
cells were allowed to re-equilibrate their ECAR while in the continuous presence of anti-EGFR
blocking antibody 225.
5.3 Correlating Cytosensor's ECAR to Receptor / Ligand Complex Levels
5.3a. 1125 Binding - Receptor / Ligand Complexes
B82R / 1st plasmid or B82R+/ TGFa cells were seeded at approximately 100,000 cells
/ 35 mm Coming tissue culture dishes (#25000) in normal growth medium. Day 2, if induced
B82R+ / TGFc autocrine cells were required, induction was achieved by removal of
tetracycline-containing medium and replacing it with tetracycline-free medium. Day 3, cell
medium was switched from normal growth medium to D/H/B buffer 3 hours before beginning
the experiment. The experiment was begun by removing D/H/B buffer and replacing it with 1125
EGF diluted in D/H/B buffer. Cells were placed in a 37 'C water bath incubator for 10 minutes
to allow binding of 1125 EGF to EGFR. After 10 minutes, cells were placed on ice and 1125 EGF
medium immediately removed. One half ml of cell medium was saved and counted in a Packard
Bell (Cobra Model) Gamma Counter to determine free 1125 EGF concentration. Cells were then
washed three times with lx WHIPS (1 mg / ml PVP, 130 mM NaC1, 5 mM KC1, 0.5 mM
MgC12-6H 20, 1 mM CaCl 2-2H 20, 20 mM HEPES) to remove excess free ligand. Bound
ligand concentrations were determined by lyszing cells with IM NaOH for 10 minutes and
determining radioactive counts of cell lysates plus a Ix WHIPS rinse in the Gamma Counter.
The data was plotted as bound ligand (complexes, # / cell) versus free ligand (ng / ml).
5.3b. Cytosensor ECAR Output
B82R' / 1st plasmid or B82R' / TGFa cells were seeded at 250,000 cells per transwell
in normal growth medium as usual. When measuring induced B82R' / TGFuo autocrine cells,
cells were plated into the transwell in tetracycline-free growth medium for overnight expression.
Cells were equilibrated to steady state ECAR on the Cytosensor in DV/cyto buffer containing 1
gg / ml tetracycline for uninduced autocrine cells and without tetracycline for induced autocrine
cells. Equilibrated cells were exposed to a mEGF concentration gradient of 0.1, 0.3, 0.6, 1.2,
2.5, 5, 10, 25, 50 ng / ml. A method was devised to alternate EGF additions to a particular cell
lane so that each lane "saw" a large increase in EGF concentrations to minimize receptor
downregulation. Thus, additions were performed as follows:
Lane A: 0.1, 1.2, 10 ng / ml EGF
Lane B: 0.3, 2.5, 25 ng / ml EGF
Lane C: 0.6, 5, 50 ng / ml EGF
Lane D: Blank - Background / Baseline
After each EGF addition, cells were allowed to re-equilibrate their ECAR to steady state
before the next ligand addition. Exposure to EGF was minimized by immediate removal of
EGF from cells as soon as peak ECAR was reached - determined by the "leveling" off of
ECAR. Cytosensor data was plotted as peak ECAR (%) versus free ligand (ng / ml).
5.3c. Relating ECAR to Receptor / Ligand Complexes
A best fit line was determined for each curve (1125 EGF and Cytosensor) using
KaleidaGraphTM 3.0 and Scatchard equation (Equation 5.1) (Scatchard 1949). Rearranging the
equation and solving for 1125 EGF (L) in terms of complexes (C) and two parameters (affinity
constant, Kd , and total receptor number, R,) gave Equation 5.2.
C / L = - C / Kd + R,/ Kd Equation 5.1
L = C * Kd / (Rt - C) Equation 5.2
After determining the constants, Kd and Rt, Equation 5.2 was utilized for an analogous
fit of the Cytosensor's ECAR versus free ligand graph, substituting L0.5 for Kd and ECARm
for Rt. A relationship between ECAR and complexes was derived via two methods. The first
method involved using discrete free ligand concentrations and calculating predicted ECAR and
complex numbers from the best fit data. Plotting the two predicted variables together and using
equation 5.2 for a best fit line (replacing R, with ml, grouped variable 1, and Kd with m2,
grouped variable 2) resulted in the desired correlation between ECAR and complexes. The
second method involved mathematically solving equation 5.2, ECAR vs. free EGF and
complexes vs. free EGF equations, for free EGF. Substituting one equation in the another and
solving for ECAR vs. complexes, gave:
ECAR = [C * ECARmax * Kd / (Kd - L0 5)] / [ Lo05 * Rt / (Kd - L0 5) + C] Equation 5.3
5.4 Measuring B82R'/TGFx Induction
Uninduced B82R' / TGFa autocrine cells were seeded as normal at 250,000 cells per
transwell in normal growth medium with 1 jgg / ml tetracycline and allowed to grow overnight.
On Day 2, cells were equilibrated as normal on the Cytosensor in DV/cyto running buffer with 1
jgg / ml tetracycline medium. Upon obtaining steady-state ECAR baseline, the following
conditions are imposed - one condition per lane:
a. No tetracycline and no antibody 225 (Induced - Antibody)
b. No tetracycline and 1 gg / ml antibody 225 (Induced + Antibody)
c. 1 •tg / ml tetracycline and no antibody (Uninduced - Antibody)
d. 1 gg / ml tetracycline and 1 gg / ml antibody 225 (Uninduced + Antibody)
The experiment was run with these conditions for at least 7 hours, allowing TGFot to be
synthesized, expressed, and captured by EGFR.
5.5 Tetracycline Gradient on Autocrine B82R'/TGFu Cells
Uninduced B82R÷ / TGFao autocrine cells were seeded at 250,000 cells per transwell in
normal tetracycline-free growth medium and allowed to grow overnight and induce TGFca
expression. TGFoa expression was repressed in two transwells by addition of 1 plg / ml
tetracycline. TGFa expression was partially inhibited in the third well by addition of 5 ng / ml
tetracycline (0.5% of fully uninduced cells). The fourth well remained tetracycline free,
allowing full induction of TGFx expression. On Day 2, the same tetracycline concentration
was continued in DV/cyto running buffer and cells allowed to reach a steady-state ECAR as
normal. Upon obtaining steady-state, 10 ng / ml mEGF was added to one of the two uninduced
cells, semi-induced cells, and fully induced cells lanes (lanes B, C, and D). The other
uninduced cell lane (A) was used as background / baseline. Upon reaching maximal ECAR,
mEGF was removed and cells allowed to re-equilibrate their ECAR before adding 10 gg / ml
blocking Ab225 to lanes B, C, and D while lane A remained baseline ECAR. The antibody was
left on the cells for a minimum of 30 minutes to ensure obtaining steady state ECAR.
5.6 Antibody Inhibition of Receptor / Ligand Complex on B82R' / TGF(
Uninduced B82R' / TGFao autocrine cells were seeded at 250,000 cells per transwell in
normal growth medium and allowed to grow overnight. TGFo expression was induced during
passage by plating the cells in tetracycline-free medium. On Day 2, cells were equilibrated as
normal in DV/cyto running buffer without tetracycline on the Cytosensor before beginning the
experiment. After reaching steady state ECAR, cells were exposed to 10 ng / ml mEGF in
DV/cyto until maximum ECAR was reached, usually in 10 minutes. This EGF addition was to
insure all cells responded similarly. After measuring peak ECAR, cell ECAR was re-
equilibrated to steady state before adding an antibody gradient and ECAR decline recorded.
Antibody / cell incubation proceeded for at least 30 minutes to insure reaching a new steady-
state ECAR. Three antibody concentrations were tested at a time while the fourth lane received
no antibody and served as the background / baseline lane.
5.7 Blocking Antibody Inhibition of Receptor Complexes on B82R' / sEGF
The same procedure performed in section 5.6 were used with autocrine B82R÷ / sEGF
cells constructed by Dr. Birgit Will-Simmons (Will et al. 1995). Again the procedure is:
Uninduced B82R' / sEGF autocrine cells were seeded at 250,000 cells per transwell in
normal growth medium and allowed to grow overnight. sEGF expression was induced during
passage by plating the cells in tetracycline-free medium. On Day 2, cells were equilibrated as
normal in DV/cyto running buffer without tetracycline on the Cytosensor before beginning the
experiment. After reaching steady state ECAR, cells were exposed to 10 ng / ml mEGF in
DV/cyto until maximum ECAR is reached, usually in 10 minutes. This EGF addition was to
insure all cells responded similarly. After measuring peak ECAR, cell ECAR was re-
equilibrated to steady state before adding an antibody gradient and ECAR decline recorded.
Antibody / cell incubation proceeded for at least 30 minutes to insure reaching a new steady-
state ECAR. Three antibody concentrations were tested at a time while the fourth lane received
no antibody and served as the background / baseline lane.
Chapter 6: Results - Ligand / Receptor Complex Characterization
6.1 Overview of Experiments
Having described methods for receptor - ligand complex detection and quantification in
the previous chapter, the results of these experiments are discussed here. Cytosensor ECAR
readings were shown to be EGF concentration-dependent, allowing a correlation between
cellular metabolic rate as detected by the Cytosensor and receptor - ligand complexes as
measured by 1125 EGF binding studies. The successful correlation between ECAR and ligand /
receptor complex and high signal to noise ratio on the Cytosensor is important because earlier
work using anti-phosphotyrosine Westerns and ELISA incurred low signal to noise ratios,
making complex level quantification difficult (data not shown). Having to perform cell lysates
and multi-day preparations is another disadvantage with Westerns and ELISA, whereas
Cytosensor data is real-time with living cells.
Using the Cytosensor, uninduced autocrine B82R' / TGFcX were placed on the machine
and its ECAR increased upon induction of TGFx expression over a seven hour period. This
ECAR signal was reduced if cells were in the presence of competing anti-receptor blocking
antibody. Finally, both autocrine B82R' / TGFao and B82R* / sEGF cells were exposed to
various antibody concentrations and antigen specificity to determine the proteins' affect on cell
ECAR. These studies prove the superiority of blocking antibodies over decoy antibodies on
B82R÷ / TGFo cells, achieving receptor / ligand inhibition at 1,000 fold less concentration.
However, anti-receptor antibodies were unable to inhibit autocrine B82R' / sEGF cells'
signalling complexes as these cells express an intracrine signalling pathway.
6.2 General Cytosensor Runs
The Molecular Devices Cytosensor measures the cells' extracellular pH every second
during the experiment as described in section 1.7. Briefly, silanol and silamine groups on the
surface of the silicon chip develop a surface potential as a function of pH. By applying an
increasing external potential to the media, an amplitude-modulated light-emitting diode induced
depletion layer collapses, inhibiting photocurrent electron flow in the silicon chip. A plot of
current versus applied potential gives an inflection point characteristic of the solution's pH.
Two regimes of extracellular pH detection and measuring occur in a Cytosensor experiment.
When running buffer is continuously flowing over cells, changes in extracellular pH remains
constant because the buffer's resonance time (1.7 seconds) is too short for cells to significantly
acidify their buffer. However, once the buffer flow is stopped, cell acidification of extracellular
buffer is detectable. The extracellular buffer acidification is measured over several seconds,
typically 20, before resuming buffer's flow. This on / off flow cycle is repeated every minute.
By measuring the slope of pH reading versus time when the buffer is not flowing gives cell
metabolic rate or extracellular acidification rate (ECAR). An example of the raw data measuring
pH as a function of time is shown in Figure 6.1 a.
Side products such as lactic acid and HCO3- are produced during cell breakdown of
glucose to energy in glycolysis and energy utilization during respiration. At physiological pH,
both lactic acid and HCO 3- dissociate, yielding two to six H' per glucose molecule. A cell's
metabolic rate can be increased (addition of growth factors or phorbol esters) or decreased
(addition of competing antibodies or chemicals inhibiting tyrosine kinase and protein kinase C
activity). Figure 6.lb shows a typical response of B82 EGF receptor positive cells to an
growth factor addition (EGF). The curve is normalized to extracellular acidification rates before
addition of EGF and expressed as a percent change in baseline. Normalizing ECAR data is
done because each cell lane has different absolute metabolic rates, but relative changes in
normalized ECAR are similar.
After about 6 to 10 minutes, cells' metabolic rate peaks and starts dropping off. During
the experiments, cells are switched off growth factors after reaching peak ECAR back to normal
running buffer, minimizing receptor exposure to growth factors and allowing multiple growth
factor exposure cycles. The data is analyzed by recording maximal ECAR per EGF addition
and plotting ECAR as a function of EGF (Figure 6.2). This graph reveals that B82R' cell
ECAR response has a dose dependent response to EGF. At low EGF concentrations, the slope
of ECAR to EGF additions is fairly linear, however, at higher EGF concentrations, the ECAR
response is saturating. The curve also indicates that EGF binding to its receptor is the rate
limiting step and that the secondary signalling pathway is not rate limiting due to the dose
dependent response to EGF. A further test proving the secondary signalling pathway was not
rate limit was the addition of PMA (phorbol ester - activating protein kinase C). Cells' ECAR
response was 6 times greater to 1 gM PMA compared to 20 ng / ml EGF (data not shown).
6.3 B82R' ECAR Response as a Function of mAb225 and mEGF
Presented in Figure 6.3 is B82 EGF receptor positive cells challenged with EGF and
anti-receptor blocking antibody mAb225. Addition of monoclonal antibody 225 does not
initiate receptor signalling (discussed later), but does compete for the same binding site on
EGFR as EGF and TGFa. B82R' cells were equilibrated on the Cytosensor in the presence of
varying blocking antibody concentrations until steady state ECAR. Next, varying
concentrations of EGF were added until obtaining peak ECAR, upon which EGF was removed
and cellular ECAR allowed to re-stabilize before adding a new EGF concentration. All buffers
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and samples added to the cells contained blocking antibody, thus maintaining its concentration
throughout the experiment.
The EGF response curve in the absence of antibody shows the dose dependent response
of B82 EGFR positive cells to EGF as previously discussed. However, addition of blocking
antibody inhibited EGF - EGFR binding and signalling, shifting the B82R ÷ ECAR response
curve rightward. The graph can also be analyzed by observing cellular response with 1 ng / ml
EGF and as a function of increasing blocking antibody concentrations. B82R' cell response is
near maximal without antibody, however, is inhibited upon addition of antibody. A hundred
fold increase in antibody concentration, at a thousand fold greater concentration than EGF,
completely inhibits EGF from binding to EGFR. Thus, the Cytosensor provides a method for
measuring receptor / ligand complex inhibition as a function of antibody concentrations.
6.4 Correlating Cytosensor's ECAR to Receptor / Ligand Complex Levels
In the previous experiments, changes in receptor / ligand levels were detected as a
function of ligand and antibody concentrations. However, Cytosensor output is in terms of
extracellular acidification rate or ECAR. Computer models and predictions are in terms of
receptor / ligand complexes. Thus, a correlation between ECAR and complexes was required.
Published data indicated feasibility of measuring ligand dose-dependent responses on the
Cytosensor (Pitchford et al. 1995) and recognizing that the same dose-dependent result occurs
in 1125 EGF equilibrium binding experiments, it was hypothesized a correlation between ECAR
and complex could be obtained. A compilation of data discussed in sections 6.4a, b, and c for
B82R* / 1st plasmid, uninduced and induced autocrine B82R' / TGFa cells is presented in
Figures 6.4, 6.5, and 6.6. The immediate observation is the dose dependent, saturating
response to EGF in both Cytosensor and I125 EGF data. With I"25 EGF, the only event
measured is ligand binding to its receptor. In Cytosensor data, a multitude of events occur,
affecting metabolic rates and Cytosensor output. These events include ligand binding to its
receptor and a cascade of kinases interactions and signalling. A dose dependent EGF response
on the Cytosensor indicates downstream secondary messenger signalling is not rate-limiting and
solely dependent on complex numbers.
6.4a. 1125 Binding - Receptor / Ligand Complexes
Presented in Figures 6.7, 6.8, and 6.9 are the results from 1125 EGF binding
experiments. Originally, I125 EGF binding experiments were performed at 4 oC and free ligand
allowed to incubate on the cells for 3 hours. To match Cytosensor experiments, the binding
experiment was performed at 37 'C and allowed to incubate for 10 minutes. Cells were then
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transferred immediately to ice and its medium removed. After washing cells multiple times with
lx WHIPS, they were lysed and total complexes measured. Cells were lysed because
Cytosensor ECAR output represents both surface and internal signalling complexes. After
converting 1125 binding data from radioactive counts (cpm) to complexes (molecules / cell) and
free ligand (ng / ml), the data was plotted and a best - fit line determined using equation 6.1.
C = L * Rt / (Kd + L) Equation 6.1
Two parameters were determined using this equation, receptor / ligand equilibrium
constant, Kd, and total receptor number, R,. The receptor number between cell lines were fairly
similar, within 40,000 receptors, since B82R+ / 1st plasmid are the parental strain of autocrine
B82R' / TGFa cells. Thus, an abnormal clone, in receptor number, was not selected during
TGFu plasmid transfection into B82R+ / 1st plasmid cells. The gradual reduction in receptor
number going from B82 R+ / 1st plasmid cells to induced autocrine B82R+ / TGFx cells may be
indicative of increased ligand levels down-regulating receptor numbers. The difference between
B82 R / I1st plasmid and autocrine cells could be a clonal effect, but not between uninduced and
induced autocrine cells as they are the same cell clone - only a difference of induction states.
The second parameter was Kd. This value was 10.5 ± 0.7, 11.4 + 1.1, 11.5 + 1 ng / ml
for B82 R+ / 1st plasmid, uninduced autocrine and induced B82 R' / TGFo autocrine cells,
respectively, or similar within experimental error. An average of 11.1 ng / ml equates to 1.84
nM binding affinity constant, within published EGF / EGFR Kd of 1-2 nM (Ebner and Derynck
1991).
6.4b. Cytosensor ECAR Output
The second part to correlating complex number and ECAR is obtaining ECAR versus
free ligand concentrations. This was accomplished by measuring changes in cell's ECAR as a
function of free ligand concentrations. When working with induced autocrine cell, its medium
was tetracycline-free overnight to induce TGFu expression. After equilibrating the cells to
steady state ECAR on the Cytosensor, a gradient of EGF (similar range as performed with 1125
EGF) was added to each Cytosensor lane. Immediately after obtaining a peak ECAR or after 10
minutes of EGF exposure, the EGF was removed and cells allowed to return to baseline
metabolic rates before beginning another EGF addition. Since EGF was sequentially added to
cells, relatively large jumps in EGF concentrations were performed to minimize effects of
previous EGF on later additions. Thus, cells saw a 10 fold increase in EGF versus doubling
ligand concentrations at each measurement. The concentration jumps were accomplished by
exposing a Cytosensor / cell lane to every third EGF concentration in the gradient profile.
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Maximum ECAR was recorded at each EGF addition and plotted as ECAR versus EGF. The
data was curve fit to equation 6.1 replacing R, with ECARmax and Kd with L05.
Results from Cytosensor experiments are shown in Figures 6.10, 6.11, and 6.12. The
data points are far more random compared to 1125 EGF data. This variance is likely due to
measuring a result through multiple secondary pathway signals, inaccuracies in ligand
concentrations, and comparing experiments over several months. Cytosensor ligand
concentrations were diluted down to predicted values. Whereas in 1125 EGF experiments, EGF
concentrations were measured and calculated based on radioactive counts. The worst fit data
was with B82R' / 1st plasmid, however, it was caused mostly by one experimental series. If
that series is removed, the fit improves from R2 = 0.59 to 0.75. The uninduced and induced
curves were a fairly good fit with R2 = 0.85 and 0.79, respectively.
In this experiment, both parameters vary in interesting patterns. There is a large, 50%,
drop in grouped ECARm upon TGFox expression induction. It is difficult to infer the
decrease's significance. ECARm can be considered a function of receptor number or total
signalling complexes similar to parameter R, in 1125 EGF data. It would be expected that R+ / 1st
plasmid cells, having no ligand expression, would have a similar ECARm value as low
expressing, uninduced autocrine B82R' / TGFx cells. However, B82R' / 1st plasmid's
ECARm is significantly different and smaller than uninduced autocrine cells. Eliminating the
three high outliers in both R' / 1st plasmid and induced autocrine data shifts ECARm to 42 and
25, respectively (data not shown), thus, removal of the outliers only magnifies the differences
between uninduced and R' / 1st plasmid cells.
The second parameter is ligand concentration at half maximally ECAR, or L0 5. This
parameter increases with increasing ligand expression. Since receptor / ligand affinity, K d, was
the same between cell lines (Section 6.3a), the increase in L05 could be a result of receptor
desensitization. Therefore, higher concentrations of exogenous ligand are required to obtain
similar signalling / metabolic responses with increasing ligand secretion rates. Removal of
outliers discussed in the previous paragraph does not change this observed L 05 differential. The
numbers change from 10.8 + 3.6 to 9.4 ± 2.9 in the induced autocrine data and doesn't change
in R' / 1st plasmid data (2.1 ± 1 to 2.1 ± .81) while uninduced autocrine cells L0 5 remains 4.5
± 1 (data not shown).
6.4c. Relating ECAR to Receptor / Ligand Complexes
After performing the 1125 EGF and Cytosensor experiments and obtaining best fit
equations, the equations were linked via variable free EGF to derive a correlation between
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ECAR and complex numbers. This correlation can be derived by two methods as described in
section 5.3c.
A best fit line using equation 5.3 was plotted for all three cell types in Figures 6.13,
6.14, and 6.15 with experimental data. To plot experimental data, free ligand concentrations
from each experiment were converted into predicted ECAR or complexes via the corresponding
graph's best fit equation. Thus, experimental free EGF concentrations from 1125 EGF
experiments (experimental free EGF and experimental complexes) were converted to predicted
ECAR using the equation from Cytosensor ECAR vs. free EGF data and plotted as predicted
ECAR vs. experimental complexes.
The ECAR versus complexes graphs' curves become linear with increasing TGFot
expression. This observation goes back to the Cytosensor data described in section 6.4b when
receptor desensitization occurs with increasing TGFcc expression. Thus, in a cell line which
has not seen ligand, i.e. B82R4 / 1st plasmid cells, short ligand exposure times to cells results in
receptor / ligand signal saturation at high ligand concentrations. Compared to cells continuously
in the presence of TGFcx (i.e. autocrine), receptor desensitization has already occurred and
apparently allows a linear signal response thereafter. One argument could be that exogenously
added EGF concentrations is significantly smaller than autocrine TGFx secretion rates, masking
the effect of EGF. However, 0.1 ng / ml exogenously added EGF corresponds to
approximately 7,000 molecules per cell - minute. Induced autocrine TGFa cells express
approximately 3,000 - 7,000 molecules per cell - minute. Calculations and Cytosensor chamber
sizing parameters are in Appendix B.
Finally, an experimental system has been created to accurately, quantitatively, in real
time, measure hard-to-detect receptor / ligand complexes. Also, Cytosensor output in terms of
ECAR can be successfully correlated back to receptor / ligand complexes using correlation
experiments with free ligand on both Cytosensor and 1125 binding experiments.
6.5 Measuring B82R+/ TGFu Induction
The previous experiments discussed in Chapter 6 measured B82 EGFR cell responses to
addition of blocking antibodies and / or EGF, however, the goal of this thesis was to measure
receptor / ligand interactions in autocrine cells as a function of competing antibodies. Therefore,
the following experiment was performed with autocrine B82R+ / TGFc cells to demonstrate
how well the Cytosensor could differentiate between varying TGFo secretion rates. Briefly,
uninduced autocrine B82 R+ / TGFa cells (medium containing 1 jig/ml tetracycline) were plated
onto transwells and allowed to attach overnight. The uninduced autocrine cells were placed on
the Cytosensor and allowed to equilibrate their metabolic rates in normal DV / cyto running
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buffer containing 1 p~g/ml tetracycline. After obtaining steady state ECAR, the following
conditions were imposed:
1. Induced Autocrine cells: No tetracycline
2. Induced Autocrine cells: No tetracycline + 1 gg / ml blocking antibody 225
3. Uninduced Autocrine cells: 1 glg / ml tetracycline
4. Uninduced Autocrine cells: 1 pLg / ml tetracycline + 1 gg / ml blocking antibody 225.
These experiments were run seven - eight hours, allowing TGFa expression into
extracellular medium and binding to EGFR. Each cell chamber's ECAR was recorded at seven
hours and normalized to uninduced autocrine cells with 1 gg / ml blocking antibody 225. This
baseline was chosen as it has smallest ECAR reading due to little ligand expression and receptor
- ligand complex formation was inhibited. A typical TGF( induction experiment with autocrine
B82 R+ / TGFc cells is shown in Figure 6.16. As seen, induced cells' metabolic rate start
increasing after about 5 to 6 hours, corresponding to the average time it takes for a cell to
transcribe DNA to RNA, translation RNA to protein and secrete that protein in the extracellular
medium (Bringman et al. 1987). After this initial ECAR increase, cells establish a new
metabolic equilibrium.
The difference in ECAR response to TGFx induction and receptor / ligand complex
inhibition can be quantitated more clearly in Figure 6.17. Induced autocrine cells' ECAR
readings increased 16% compared to uninduced autocrine cells with blocking antibody. The
induction is also significant between uninduced cells and induced cells (one standard deviation)
and addition of blocking antibodies significantly reduced induced cells' ECAR levels by
inhibiting TGFc from binding EGFR. Thus, this experiment showed that measurements of
autocrine TGFa expression induction and inhibition autocrine signalling by blocking antibodies
can be measured on the Cytosensor.
6.6 Tetracycline Gradient on Autocrine B82R÷/TGFo Cells
One reason for using the tetracycline - controlled, two plasmid expression system is the
ability to control TGFc expression levels between "off' and "on" by adjusting tetracycline
concentrations in the medium. This induction "gradient" for TGFox expression was analyzed in
section 3.5 by measuring extracellular ligand concentrations as a function of tetracycline
concentrations. However, the Cytosensor provides an ability to measure receptor complex
levels as a function of ligand expression. Briefly, uninduced autocrine cells were plated into
Cytosensor transwells and allowed to attach overnight. A tetracycline gradient was added to
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induce TGFx expression overnight and achieve steady state ligand expression for the
experiment. Two transwells were designated as uninduced cells containing 1 gg / ml
tetracycline to its medium. One transwell was designated as semi-induced cells by addition of 5
ng / ml tetracycline to its medium (200 fold less tetracycline) and the last well designated as fully
induced autocrine cells tetracycline - free medium.
A representative graph of these experiments is plotted in Figure 6.18a. Upon addition
of 10 ng / ml EGF to each of the equilibrated autocrine cells, a difference in ECAR response can
be observed. There was a slight decrease (5% difference) in peak ECARs between uninduced
cells and semi-induced cells upon addition of EGF. A significant change in ECAR response
occurs when induced autocrine cells received EGF, giving a 35% decrease compared to
uninduced autocrine cells. This ECAR response differential between semi-induced and fully
induced autocrine cells compared to uninduced autocrine cells highlights the receptor
desensitization which occurs upon ligand induction. As seen in section 6.4a, autocrine cell
receptor numbers were fairly similar between the two ligand expression levels (16% decrease),
thus, at least half of the changes in ECAR must be due to desensitization of the EGF receptor.
Uninduced autocrine cells have very few receptor - ligand complexes compared to fully
induced autocrine cells as uninduced cells produce little to no TGFo ligand. Thus, upon
addition of high blocking antibody concentrations, one would expect a drop in ECAR
corresponding to initial complex levels. As seen in Figure 6.18b, fully induced autocrine cells'
ECAR dropped the most, due to the increased number of initial signalling complexes present
compared to uninduced autocrine cells upon antibody addition. Since semi-induced autocrine
cells' initial complex levels were in-between induced and uninduced cells, its ECAR drop
naturally falls between fully induced and uninduced autocrine cell's ECAR in the presence of
antibody. Thus, this experiment demonstrates receptor desensitization and initial receptor -
ligand complex levels can be quantified on the Cytosensor.
6.7 Antibody Inhibition of Receptor / Ligand Complex on B82R'/TGFca
The next experiment tests the central hypothesis of this thesis that blocking antibodies
are superior inhibitors of receptor / ligand complexes compared to decoy antibodies. Computer
modelling indicates that blocking antibodies inhibit receptor / ligand complex formation at much
lower antibody concentrations. One reason is unbound decoy antibody concentrations are
"diluted" by binding to extracellular bulk ligand, decreasing the antibodies' effective diffusion
gradient to the cell surface where it competes directly against EGFR for TGFa.
Briefly, uninduced autocrine B82R ÷ / TGFuc cells were plated in Cytosensor transwells
overnight to allow cell attachment. TGFoa expression was induced overnight to obtain steady
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state ligand expression by removal of tetracycline from the medium. The induced autocrine cells
were equilibrated on the Cytosensor in normal DV/cyto running buffer without tetracycline until
their ECAR reached a steady state. Ten ng / ml mouse EGF was added to each lane and peak
ECAR observed to ensure all cell lanes behaved similarly. Immediately upon reaching peak
ECAR, EGF was removed from the cells and their ECAR allowed to re-adjust back to baseline.
Upon establishing a baseline, varying concentrations of blocking antibody 225, decoy anti-
TGFox antibody, or neutral rabbit IgG were added to each cell lane and decreases in ECAR
measured for at least 30 minutes. An typical experiment is shown in Figure 6.19.
Shown in Figure 6.20 is a compilation of all antibody experiments on autocrine B82R' /
TGFca cells. Blocking antibody concentrations were varied over five orders of magnitude
resulting in no effect to total receptor / ligand binding inhibition. Inhibition of autocrine B82R+ /
TGFct binding was achieved at 1 nM blocking antibody, corresponding to predicted
concentration in the mathematical model. Also predicted by the model was blocking antibody's
superiority over decoy antibodies. Addition of high decoy antibody concentrations, around 900
nM, only slightly affected autocrine signalling, meaning nearly 7000 times more decoy antibody
was required to achieved the same inhibition as blocking antibodies. Both antibodies have a K d
equal to EGF / EGFR's Kd of 1 nM (Mendelsohn et al. 1987; Technical Support 1995).
Several control experiments were performed to ensure these antibody effects were
specific to receptor / ligand complex inhibition and not nonspecific events. Addition of
nonspecific rabbit IgG at 100 gg / ml did not affect cells' metabolic rate, indicating that
reduction in ECAR upon addition of blocking antibodies is specific to the inhibition of autocrine
receptor / ligand complex formation and not a random antibody effect. Another control
experiment ensured that addition of blocking antibody 225 did not stimulate or inhibit cell
signalling in control B82 R' or autocrine B82R+ / TGFc cells. The experiment is shown in
Figure 6.21. Antibody 225 was added to cells which did and did not receive a prior dosage of
EGF. Antibody 225 did not stimulate cell metabolic rates through receptor binding and no
decrease in ECAR occurred upon addition of blocking antibody after an EGF challenge. The
second part of the experiment proved that the decrease in ECAR upon addition of antibody was
not due blocking previously added exogenously bounded EGF (these complexes already
disappeared), but by preventing autocrine ligand TGFu binding.
One possible explanation for experimental decoy antibody's inability to successfully
inhibit receptor - ligand complex formation is the antibody could recognize and bind TGFo• but
not prevent it from binding to EGFR. In other words, it would be a recognition antibody, but
not a neutralizing antibody. Two large molecules (170 kDa - receptor and 150 kDa - antibody)
could successfully bind a small protein (5.5 kDa), the premise of sandwich ELISAs. Thus, an
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experiment was performed to prove anti-TGFco decoy antibody was a neutralizing antibody.
One Cytosensor transwell was plated with B82R' and three transwells were plated with induced
autocrine B82R' / TGFuo cells and allowed to attach overnight. The following day, ten gg / ml
TGFuo was added to each equilibrated cell lane and maximum ECARs recorded. Immediately,
after obtaining peak ECAR, TGFo was removed and ECARs returned back to baseline. Next,
the following conditions were applied:
1. B82R+ - 10 tg / ml decoy antibody + 10 ng / ml TGF(
2. Induced Autocrine - 50 gg / ml decoy antibody
3. Induced Autocrine - 50 gg / ml blocking antibody
4. Induced Autocrine - blank
As seen in Figure 6.22b, addition of blocking antibody inhibited autocrine receptor /
ligand binding while addition of decoy antibody did not. Addition of TGFa alone to B82R'
cells increased ECAR (Figure 6.22a - triangles), however, complete inhibition of signalling was
achieved upon addition of TGFx and decoy antibody (Figure 6.22b - triangles), proving that
the decoy antibody is a neutralizing antibody.
A more nuanced comparison between experimental (Figure 6.20) and mathematical data
(Figure 2.3) reveals a difference in initial receptor / ligand levels. Receptor / ligand complex
levels are predicted to be around 6%, however, experimental calculations determined receptor
complex levels are closer to 60%. A few potential explanations can be offered. First, one
assumption when correlating receptor / ligand levels for autocrine cells is a one to one
relationship exists between increasing ECAR upon addition of EGF and decreasing ECAR upon
addition of competing antibodies. Since both proteins affect signalling pathway at the same
point (receptor), the relationship should hold. If not, the data would suggest a 10 fold
difference exists between signal induction and degradation.
A secondary possibility is cell density affecting receptor complex levels during the
correlation experiments. During these experiments, cell density was around 350,000 cells / 35
mm dish for the 1125 EGF binding experiment and an estimated 400,000 cells / 12 mm transwell
for the Cytosensor experiment. The difference is cell coverage is nearly an order of magnitude
(-3 % and -30%, 1l25 and Cytosensor, respectively). At a higher cell density, receptor number
could be further down-regulated and desensitized on the Cytosensor compared to I125 cells.
This desensitization would change the slope of ECAR versus complexes curve lower, meaning
more complexes are required to achieve similar ECAR. However, there is an argument against
this possibility upon analysis of uninduced and induced autocrine Cytosensor data (Figure 6.1 1
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and 6.12). Assuming a ten fold increase in density was similar to a ten fold increase in ligand
expression or at worst case nonlinear and greater, the autocrine ligand induction was 200 fold,
yet the maximum ECAR only decreased by half upon ligand induction and receptor
desensitization, not a 10 fold discrepancy.
A third, and more likely, reason for the difference between experimental data and
computer predictions is a subtle difference between EGF and TGFu proteins. Autocrine
computer modelling assumes all receptor / ligand complexes are internalized and degraded in the
lysosome. This is a valid assumption for EGF. But, while both proteins have similar KdS at
physiological pH, TGFct is more pH sensitive and dissociates from its receptor as pH decreases
(TGFx - 6 nM to 400 nM and EGF - 3 nM to 80 nM as pH goes from 7.4 to 6.0). Thus, at
endosomal pH, TGFca is mostly unbound, allowing receptor recycling back to the cell surface
(Engler et al. 1988; French et al. 1995). Once, the receptors are back on the cell surface, they
can quickly rebind ligand forming new signalling complexes. This recycling means less EGFR
downregulation, faster recovery of binding following endocytosis, and therefore, increased
receptor / ligand complex number along with enhanced mitogenic potency (Engler et al. 1988;
Reddy et al. 1996). In addition, more ligand may be recycled as well at lower intercellular
complex levels. Differences between EGF and TGFa's endosomal trafficking could help
explain why both bulk ligand concentrations and receptor / ligand complexes are higher than
predicted by computer modelling.
6.8 Blocking Antibody Inhibition of Receptor Complexes on B82R'/sEGF
Autocrine B82R ÷ / TGFo's ligand is synthesized as a 25 kDa transmembrane precursor
and expressed to the cell surface before the extracellular mature protein (5.5 kDa) is
enzymatically cleaved into the medium. Autocrine B82R' / sEGF, constructed by Dr. Birgit
Will-Simmons, is synthesized as a mature 6 kDa protein and secreted directly out to the
medium. Studies in Dr. Steve Wiley's lab (University of Utah, Salt Lake City, Utah) and Dr.
Jeff Morgan's lab (Shriner's Burn Institute, Cambridge, MA) indicate the inability of blocking
antibodies to inhibit cell growth and migration in HMEC 184 and human keratinocytes cells
upon transfection of sEGF into these EGFR positive cell lines (personal communications). It is
hypothesized that sEGF and EGFR are secreted to the cell's surface in the same secretion
vesicles and able to bind together before reaching the cell surface. To maintain normal receptor
membrane turnover (0.03 min. -') for 100,000 receptor would require synthesizing 3,000 new
receptor / cell-minute. Both induced B82R' / TGFcx and B82R' / sEGF autocrine clones can
secrete over 6,000 ligand molecules / cell-minute. Thus, all of the receptors could be bound,
signalling and immediately internalized upon reaching the cell's surface with an autocrine B82R'
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/ sEGF cell. As transmembrane TGFx is bound to the secretory vesicle's surface and has a
precursor NH, end, it would be sterically hindered from binding EGFR present in the secretory
vesicles of autocrine B82R+ / TGFac cells.
The inability of blocking antibody 225 to inhibit autocrine B82R' / sEGF receptor -
ligand signalling is shown in Figure 6.23. Addition of 300 glg / ml blocking antibody 225 to
autocrine B82R' / TGFo cells would ensure complete and total inhibition of signalling;
however, when added to autocrine B82R' / sEGF cells resulted in only a 4% change from
baseline, similar to inhibition achieved with 0.02 gLg / ml (15,000 times less antibody) on
autocrine B82R' / TGFoa cells. Since both ligands bind similarly to EGFR, the difference
would appear to be sEGF's ability to intracellular bind EGFR before cell surface expression,
thus preventing blocking antibody from binding extracellularly.
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Figure 6.1: Experimental raw and rate data. Equilibrated B82R + were exposed to 20 ng /
ml mEGF (circles / cbtted line) or not (squares, solid line) for 8 minutes at 6. Graph A. Raw
data readings used to determine ECAR in graph B between points a and P. Graph B. Rate
data for B82R + cells.
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Figure 6.2: B82R+ control cells - Cytosensor EGF response curve.
Equilibrated B82R+ cells were exposed to a gradient of mEGF on Molecular
Devices Cytosensor. Data plotted as log in the figure and linear in the insert.
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Figure 6.3: Cytosensor measurement - B82R + with EGF and mAb225.
B82R+ cells were equilibrated in the presence of 0 (squares), 0.01 (cross), 0.1 (circle),
and 1 (triangle) gtg / ml anti-EGFR antibody 225. Upon equilibration, the cells were
exposed to indicated EGF gradient.
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Figure 6.4: Overview ECAR to Complex
1125 mEGF Gradient binding experiment.
- B82R + / 1st plasmid. Graph A.
Graph B. mEGF Gradient on
Cytosensor. Graph C. Correlation of ECAR to Complexes.
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Figure 6.5: Overview ECAR to Complex - uninducedB82R+ / TGFoa. Graph A.
1125 mEGF Gradient binding experiment. Graph B. mEGF Gradient on Cytosensor.
Graph C. Correlation of ECAR to Complexes.
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Figure 6.6: Overview ECAR to Complex - Induced B82R + / TGFoc. Graph
A. 1125 mEGF Gradient binding experiment. Graph B. mEGF Gradient on
Cytosensor. Graph C. Correlation of ECAR to Complexes.
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1125 Binding - B82R + / 1st plasmid. After incubating cells with D/H/B
media for 3 hours, cell were incubated with 1125 EGF for 10 minutes. Media was
removed and cpm counts defined as free ligand. Cells were lysed with 1 M NaOH and
cpm counts defined as bound ligand.
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Figure 6.8: 1125 Binding - Uninduced B82R+ / TGFc. Autocrine clone #1's
TGFct expression was repressed by 1 jgg / ml tetracycline containing media. After
incubating cells with D/H/B media for 3 hours, cell were incubated with 1125 EGF for
10 minutes. Media was removed and cpm counts defined as free ligand. Cells were
lysed with 1 M NaOH and cpm counts defined as bound ligand.
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Figure 6.9: 1125 Binding - Induced B82R + / TGFax. Autocrine clone #1's TGF(c
expression was induced overnight by removal of tetracycline. After incubating cells
with D/H/B media for 3 hours, cell were incubated with 1125 EGF for 10 minutes.
Media was removed and cpm counts defined as free ligand. Cells were lysed with 1 M
NaOH and cpm counts defined as bound ligand.
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Figure 6.10: Cytosensor - B82R + / 1st plasmid. After equilibrating cells on the
Cytosensor in DV / cyto running buffer for about 3 hours, cells were sequentially
exposed to increasing concentration of a mEGF gradient.
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Figure 6.11: Cytosensor - Uninduced B82R+ / TGFa. Autocrine clone #1's
TGFoa expression was repressed by 1 jgg / ml tetracycline containing media. After
equilibrating cells on the Cytosensor in DV / cyto running buffer for about 3 hours,
cells were sequentially exposed to increasing concentration of a mEGF gradient.
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Figure 6.12: Cytosensor - Induced B82R + / TGFa. Autocrine clone #1's TGFo
expression was induced overnight by removal of tetracycline. After equilibrating
cells on the Cytosensor in DV / cyto running buffer for about 3 hours, cells were
sequentially exposed to increasing concentration of a mEGF gradient.
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Figure 6.13: ECAR to Complex Correlation - B82R+ / 1st plasmid. Correlation of
B82R+ / 1st plasmid cell data and equation plotted together. Line plot is obtained by
combining best fit equations from Figures 6.7 and 6.10. Data obtained from same plots,
free ligand concentration was converted into predicted ECAR or complexes and plotted
against corresponding experimental ECAR or complexes.
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Figure 6.14: ECAR to Complex Correlation. - Uninduced B82R + / TGFo.
Correlation of uninduced autocrine clone #1 data and equation plotted together.
Line plot is obtained by combining best fit equations from Figures 6.8 and 6.11.
Data obtained from same plots, free ligand concentration was converted into
predicted ECAR or complexes and plotted against corresponding experimental
ECAR or complexes.
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Figure 6.15: ECAR to Complex Correlation - Induced B82R + / TGFa cells.
Correlation of induced autocrine clone #1 data and equation plotted together. Line
plot is obtained by combining best fit equations from Figures 6.9 and 6.12. Data
obtained from same plots, free ligand concentration was converted into predicted
ECAR or complexes and plotted against corresponding experimental ECAR or
complexes.
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Figure 6.16: Induction of autocrine B82R + / TGFoc cells on Cytosensor.
Equilibrated autocrine clone #1 cells were induced (circle) or remained uninduced
(squares) at time equal zero. Cells were also in the presence (open) or absence
(solid) of 1 gg / ml anti-EGFR 225 during the experiment. Only every 10 minute
data point is plotted for clarity.
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Figure 6.17: B82R+ / TGFa induction measured on Cytosensor.
Uninduced B82R+ / TGFct autocrine clone #1 cells were equilibrated on the
Cytosensor before beginning experiment. Above indicated conditions were imposed on
each cell lane and Cytosensor run for seven hours. ECAR readings at seven hours are
recorded and shown. Data for each run is normalized to uninduced autocrine cell lane
with blocking antibody. Anti-EGFR 225 blocking monoclonal antibody concentration
was I tg / ml.
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Figure 6.18: Tetracycline gradient affects on B82R + / TGFx cell ECAR.
Autocrine B82R+ / TGFca clone #1 cells were plated onto Cytosensor transwells at
varying tetracycline concentrations (ligand expression). Uninduced cells were at I [tg
/ ml tetracycline (squares and diamonds). Semi-induced cells were at 5 ng / ml
tetracycline (circle) and fully induced tetracycline free (triangles). One uninduced
cell line was control cells receiving no additions (squares). Graph A. Addition of 10
ng / ml mEGF. Graph B. Addition of 10 ýtg / ml monoclonal anti-EGFR blocking
antibody 225.
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Figure 6.19: Representative Cytosensor run - induced autocrine B82R + / TGFuc
with blocking antibodies. Equilibrated autocrine clone #1 cells were exposed to 10
ng / ml mEGF for 10 minutes. After re-equilibration, the cells were challenged with
0.0 (squares), 0.02 (diamonds), 0.1 (circles), and 20 (triangles) jtg / ml anti-EGFR
blocking antibody 225. For clarity, a 30 minute span during re-equilibration was
omitted (*) and only every 2 minute Cytosensor data point is plotted.
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Figure 6.20: Compilation of B82R + / TGFcx competing antibody additions.
Equilibrated autocrine clone #1 cells were challenged by the addition of varying
concentrations of anti-EGFR blocking antibody 225 (squares), anti-TGFR decoy
antibody (diamonds), and non-specific rabbit IgG ("x"). Cytosensor ECAR was
converted to complex number using correlation equation from Figure 6.15.
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Figure 6.21: Control experiment - mAb225 and cell stimulation.
Equilibrated B82R+ / 1st plasmid (circle) and B82R + / TGFo (square) autocrine
clone #1 cells were challenged with 10 gg / ml anti-EGFR blocking antibody 225
after addition of 10 ng / ml mEGF (clear). One set of each cell type did not
receive mEGF (solid).
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Control experiment - TGFcc neutralization
I I I I I
TGFa antibody. B82R + (triangle) and autocrine B82R+ / TGFc cells (square,
circle, diamond) equilibrated on the Cytosensor. Graph A. All cells were exposed
to 10 ng / ml TGFa. Graph B. 50 Rlg / ml decoy antibody anti-TGFaC was added
to one autocrine cell lane (circle). 50 jLg / ml decoy antibody was also added in
combination with 10 ng / ml TGFo to B82R+ . 50 jlg / ml blocking monoclonal
anti-EGFR antibody was added to one autocrine cell lane (diamond).
autocrine received no additions (squares).
Control
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Figure 6.23: Comparison of autocrine cell systems - TGFo vs. sEGF.
Autocrine cells B82R+ / TGFct (squares) and B82R+ / sEGF (circles)
equilibrated in the Cytosensor were challenged with a blocking anti-receptor
antibody 225 concentration gradient.
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Chapter 7: Discussion and Future Study
7.1 Overview
The purpose of this thesis was to gain a quantitative understanding of receptor - ligand
complex inhibition as a function of key cellular parameters in autocrine cells by addition of
competing antibodies. This objective was accomplished by developing a B82R' & - / TGFca
expression cell system, characterizing the TGFc expression system, and validating model
predictions on extracellular ligand concentration and receptor / ligand complex numbers. To
this end, the bioengineering autocrine EGFR / TGFc cell provided a 100 fold induction range
(tens to thousands molecules / cell minute) via tetracycline control with constitutive EGFR
expression. Testing of model predictions prove the importance of creating a protocol standard
in the literature for measuring ligand secretion rates at one cell density in the presence of
competing antibody. At high cell densities, it was found that addition of antibody was
important at low ligand secretion rate, while less important at higher cell secretion rates.
Measurement of receptor / ligand complexes using Molecular Devices Cytosensor showed
blocking antibodies could inhibit receptor / ligand complexes at a thousand (1000x) fold less
concentration than decoy antibodies. Finally, usage of Cytosensor indicated the possible
existence of an intracrine signalling pathway in autocrine EGFR / sEGF cells as blocking
antibodies were unable to inhibit receptor / ligand formation.
7.2 Summary of Results
Using a TGFx plasmid from Derynck (University of San Francisco) and the
tetracycline-controlled two plasmid system (pUHD 15.1 and pUHD10.3) from Gossen and
Bujard (University of Heidelberg), an inducible TGFc plasmid (pUHD10.3 / TGFa) was
constructed. The TGFu second plasmid was transfected into B82 receptor positive and
negative cells already containing pUHD 15.1. Under histidinol selection, clones were isolated
and examined for TGFL protein secretion. Several clones were discovered to produce TGFa,
resulting in the successful development of an inducible autocrine and paracrine TGFoa cell
system. The autocrine clones are composed of B82R' (pXER) / pUHD15.1 / (pR8) -
pUHD10.3 TGFc( wt, while the paracrine clones are B82R- / pUHD15.1 / (pR8) - pUHD10.3
TGFox wt (Figure 1.22). Autocrine clone #1 and paracrine clone #22 were chosen for further
characterization as initial results indicated that these two cell lines had high TGFu expression.
These two clones were found to have a broad protein expression range upon induction. The
suppression of TGFox synthesis is obtained with the addition of tetracycline, a bacterial
antibiotic, at low concentrations. Varying tetracycline concentration in the medium results in a
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corresponding adjustment in TGFx secretory rates. TGFct protein expression was induced 4
(paracrine) to 100+ (autocrine) times higher than basal levels upon removal of tetracycline.
Using high and low TGFcx expressing clones and varying tetracycline controlled TGFcX
expression, an expression system spanning several orders of magnitude is attainable (Figure
4.2, 4.5 and 4.6). The ability to adjust TGFcx levels enables one to determine the effect of
ligand secretion rates on receptor complexes as modeled in Figure 2.2 and experimentally
shown in Figure 6.18.
An experiment was done to verify the correct processing of TGFca. Paracrine medium
was run over a Sephadex G-50 column and the fully processed, 5.5 kDa, mature TGFcx protein
was eluted from the column (Figure 4.3). This result indicates that the B82 cells have the
elastase-like enzyme necessary for cleaving the mature TGFo from the transmembrane protein
(Pandiella et al. 1992). Investigations revealed that 99% of TGFcx is secreted into the medium,
suggesting that the protein is correctly folded and processed through the ER and Golgi to the
cell surface (Table 4.2). The experiment also shows that protein cleavage from the cell surface
does not seem to be a rate-limiting step. TGFcx accumulation rapidly increased in extracellular
medium upon the removal of tetracycline (Figure 4.4). However, the slow inhibition of TGFx
expression upon reintroduction of tetracycline indicates the presence of very stable messenger
RNA, meaning that cells must be continuously grown in tetracycline containing medium to
insure uninduced TGFa expression is truly repressed during experiments.
After characterizing TGFoa expression in B82R' " / TGFx cells, mathematical model
predictions as to the effect of ligand secretion rates, cell density, and antibody additions on
extracellular ligand concentrations were tested. Seen both experimentally and modeled (Figures
4.7 and 2.4), high ligand secretion rates renders extracellular ligand concentrations independent
of cell density and blocking antibodies. The amount of ligand secreted overwhelms receptor-
mediated uptake as ligand uptake is insignificant to the total amount secreted into the medium.
However, at lower secretion rates, receptor-mediated ligand uptake becomes significant,
resulting in large ligand loss from the medium. This data indicates the importance of measuring
and reporting not only the "observed" ligand secretion rate, but important parameters such as
cell density, plate size, and blocking antibody usage.
Original modelling predictions were done on receptor / ligand complexes as a function of
several different autocrine parameters including ligand / receptor affinity, ligand secretion rates,
and decoy anti-ligand antibodies versus blocking anti-receptor antibodies. Upon demonstrating
that the bioengineered B82R' / TGFcx autocrine cell system could test model predictions on
ligand concentrations, the next step was to experimentally test receptor / ligand complex
predictions. The first problem was how to measure complex levels. Prior methods involved
135
lysed cells, several days of preparation, and westerns or ELISAs to detect phosphotyrosine
levels as an indicator of activated receptor / ligand complexes. A problem with this approach
was high noise to signal ratios, not real time, and cell lyzing altering cell environment and
protein interactions. Thus, it was hypothesized that Molecular Devices Cytosensor
measurements of cell metabolic rates could be correlated to receptor / ligand complex levels. As
shown in Figures 6.4, 6.5, and 6.6, both 1125 EGF binding experiments and Cytosensor
response experiments had a dose dependent response to the addition of free EGF. Thus, a
correlation could be made equating ECAR to complexes.
Next experiments dealt with Cytosensor sensitivity measurements - could the
Cytosensor quantify antibody inhibition of receptor ligand complexes, measuring cellular
response to addition of antibody and induction of TGFx expression? The experiment depicted
in Figure 6.3 shows that addition of blocking antibody 225 shifted B82R 's EGF ECAR
response rightward. Induction of TGFt expression is a long term event usually requiring long
accumulation times before ligand detection. However, the Cytosensor works by continuously
flowing medium over cells, washing away accumulation of metabolites and protein. Could the
Cytosensor detect TGF( secretion? Uninduced autocrine clone #1 cells were placed on the
Cytosensor and induced. After 7 seven hours, a clear difference could be discerned between
uninduced and induced cells along with differences upon addition of antibody (Figures 6.16 and
6.17). This experiment was carried one step farther by measuring differences in receptor /
ligand complex levels and receptor desensitization as a function of ligand secretion rates (Figure
6.18). Addition of exogenous EGF to cells expressing varying TGFc secretion levels shows
that receptor desensitization occurs as receptor downregulation does not account for all of the
decrease in receptor signalling (Figure 6.8 and 6.9).
The central tenet of this thesis was that decoy antibodies could not inhibit receptor /
ligand complexes as well as blocking antibodies. This hypothesis was tested in Figure 6.20.
Induced autocrine clone #1 cells were placed on the Cytosensor and varying concentrations of
antibody added. As shown, blocking antibody inhibited receptor / ligand complexes at the
expected concentration (1 nM) and inhibited these complexes over a thousand (1000x) times
better than decoy antibodies. Proving that these results are not artifacts: addition of IgG did not
affect complex levels, addition of antibody 225 does not receptor signalling in B82R' cells
(Figure 6.21) and the decoy antibody is a neutralizing antibody (Figure 6.22).
Other researchers observed that blocking antibodies were unable to inhibit cell migration
and proliferation upon transfection of sEGF into EGFR positive cells. It was hypothesized that
sEGF could intracellularly bind EGFR whereas transmembrane TGFa could not. Thus, in
sEGF cells, receptors were secreted as ligand / receptor complexes whereas TGFac positive cells
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had to first cleaved the protein before it diffused to EGFR and bound, allowing inhibition by
addition of blocking antibodies. This hypothesis was tested by addition of blocking antibody
225 to B82R' / sEGF cells placed on the Cytosensor. As expected, inhibition of signalling in
autocrine sEGF cells was not achieved. In fact, it took about ten thousand (10,000x) times
more antibody to achieve the same, barely perceptible, decrease in signalling compared to
B82R' / TGFxo cells (Figure 6.23).
7.3 Discussion
Our artificial, bioengineered autocrine cell system has been developed, characterized,
and used to test several modelling predictions. Important advances from this research have
come from three key findings.
The first finding is the necessity for quantitative standards in ligand characterization.
When a ligand is found to be expressed in an autocrine fashion, its extracellular concentration is
normally reported qualitative as a Western gel band. Further characterization of the autocrine
system and ligand expression may quantify that expression by reporting extracellular ligand
concentration. However, this experiment is not performed in a standard manner and all of the
crucial information not reported in the literature. Variance in protocol usually include large or
small volumes, one or several day incubation of conditioned medium, with or without
competing antibodies, sub-confluent or over-confluent cells. As predicted by computer
modelling and shown experimentally, all of these parameters have important ramifications on
extracellular bulk ligand concentrations. Measuring conditioned medium, incubated over cells
for several days, leads to the question: what cell density does one use to equate ligand
expression on a per cell basis? low or high density? Figures 2.4 and 4.7 proved the necessity
of adding competing antibodies to prevent receptor-mediated ligand uptake, especially for a low
expressing autocrine cell at high cell density. A second question is: at what plate coverage does
cell density become important? At a cell density greater than 100,000 cells / 60 mm dish or a
less than 1% cell plate coverage, ligand concentration begins to decrease even in the presence of
competing antibodies. A reason for this phenomenon is cells are becoming close enough to
interaction with each other and begin to uptake ligand secreted by other cells before the ligand
can escape to the extracellular bulk medium. This nonlinearity at which small surface coverage
substantial changes global variables has been found before. A cell with 10,000 receptors
reaches half maximum ligand diffusive flux at a surface coverage of 0.02% (Lauffenburger and
Cozens 1989). Half-maximal probability of autocrine ligand capture occurs at a receptor surface
coverage of 0.2%, assuming a 1 nm protein diameter (Forsten and Lauffenburger 1994b).
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The second finding is the substantial disparity in effectiveness of blocking versus decoy
antibodies on autocrine complexes. Figure 2.3 and 6.20 reveals that decoy antibodies do not
inhibit receptor / ligand complexes as effectively as blocking antibodies. It was determined that
a thousand times more decoy antibody was required. As monoclonal antibody can cost a dollar
/ microgram and dosing patients for anti-cancer therapy requires milligrams, a thousand fold
increased antibody requirement is significant. For example, three clinical trials have been
initiated for anti-tumor therapy, two using antibodies against the receptor (Divgi et al. 1991;
Modjtahedi and Dean 1994) and one using an antibody against the ligand (Mulshine et al.
1992). A technological advance with this research indicates the futile and prohibitive costs in
anti-ligand decoy antibody therapy and should not continue without extreme extenuating
circumstances.
The third finding is the possibility of an intracrine pathway, which appears to exist in
autocrine B82R' / sEGF cells, but not in autocrine B82R' / TGFx cells. The occurrence of the
intracrine signalling pathway is likely due to the lack of a transmembrane tail in sEGF cells
which if present would prevent ligand / receptor binding by spatial and steric separation. The
intracrine pathway has been proposed and seen experimentally before (Bejcek et al. 1989;
Dunbar et al. 1989; Keating and William 1988). These studies modified endogenous cytokines
such as IL-3 and PDGF by adding the endosomal retention signal, KDEL, to the C-terminus.
Thus, the protein was unable to be secreted to the extracellular medium and the cells retained
high biologic activity in the presence of antibodies. Additional studies in Dr. Wiley's lab
(University of Utah) show EGFR positive cells can proliferate and migrate in the presence of
blocking antibodies upon transfection of sEGF (personal communications). These cytokines
are important cellular regulators of cell pathology and attempts to inhibit receptor / ligand
complexes via competing antibodies is useless if intracrine signalling pathway exists.
Thus, it is hoped that elucidating autocrine receptor / ligand interactions with itself and
cellular environment by understanding what cellular parameters are important in autocrine ligand
/ receptor regulation in this and future research will lead to increased understanding in cellular
signalling, proliferation and migration regulation in wound healing and cancer therapy.
7.4 Future Work
How autocrine cells relate to its environment and what signals cells provide to its
neighbors is the next logical and important question to ask. An autocrine cell can secrete several
different ligands into its extracellular medium, i.e. there are five (5) different ligands in the EGF
family which can bind to the same receptor. How does a cell recognize the different ligands and
the signal it might represent? EGF and TGFuo are enzymatic cleaved into the medium and binds
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its receptor (neighbor or same cell) without extracellular matrix interaction. HB-EGF and
amphiregulin can interact with and become entrapped in the extracellular matrix before diffusing
and binding to its receptor. Plus, HB-EGF remains mostly cell-associated until PKC activation
(receptor / ligand binding) promotes enzymatic cleavage (Goishi et al. 1995). A further
question is: does receptor affinity, down-regulation and / or desensitization play a role in a
cell's interaction with its environment? For example, increased A431 cell - cell contact upon
formation of multicellular spheroids resulted in decreased receptor levels and activity compared
to subconfluent monolayers (Mansbridge et al. 1992).
To answer these questions in a systematic and quantitative fashion, there are several
existing and potential cell systems and assays available. There are over a hundred different
mutated EGFR positive B82 cells created by Dr. Gordon Gill (University of San Diego) which
have altered receptor trafficking and ligand affinity parameters. Table 4.3 shows a select list of
mutated receptors. A comparison of results obtained with A654 and M721 cells would indicate
internalization importance to receptor / cell interaction with its environment, while performing
the experiment in the absence or presence of phorbol esters would indicate receptor / ligand
affinities importance. Dr. Steve Wiley (University of Utah) has constructed several chimera
proteins composed from mature EGF with EGF COOH tail, EGF NH 2, and HB-EGF ends.
These chimeras would indicate how a ligand interactions with its receptor in the absence and
presence of competing extracellular matrix. Another level of complexity is incurred by the
intermixing of mutated receptors, chimera ligands and "traditional" EGF ligand family, some of
which has already been created and listed in Table 4.4.
Several different assays exist to measure how an autocrine cell interactions with its
environment. Mixed cell populations of receiver (receptor only positive) cells and donor cells
(receptor positive or negative with ligand expression) can be tested on the Cytosensor with or
without extracellular matrix. Using these mixed cell populations, differences in ligand capture /
escape between paracrine and autocrine cells could be analyzed as a function of receptor
trafficking, ligand / receptor affinity, ligand expression, and ligand / extracellular matrix
binding. Another readout system is 32D (Pierce et al., 1988) or EP170.7 (Higashiyama et al.
1992) which are EGF dependent cells in the absence of IL-3. These cells would function as the
receiver cell, plated with mixed autocrine or paracrine cell populations expressing the desired
receptor / ligand construction discussed earlier. Increased receptor phosphorylation or 'H
thymidine uptake would indicated amount of ligand escaping from extracellular matrix and / or
autocrine receptor to the extracellular medium.
Utilization of these receptor / ligand constructions with Cytosensor or receiver cells
would further elucidate what information does an autocrine cell's ligand or ligands / receptor
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system provide to that cell and its neighbors about their environment. By increasing our
understanding of how this information is presented, recorded, and acted upon by autocrine cells
strengthen our ability to design better wound healing and anti-cancer therapies.
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Dulbecco's Modification of Eagles's Media (DMEM)
Amino Acid Stock-lOOX
L-arginine (HCL)
L-glutamine
Glycine
L-isoleucine
L-leucine
L-Lysine.HC1
L-phenylalanine
L-serine
L-threonine
L-tryptophan
L-tyrosine
L-valine
mg/L media
73.00
584
30.0
104.8
104.8
146.2
66.00
42.00
95.2
16.00
71
93.6
g/L stock
0.73
5.84
0.30
1.05
1.05
1.46
0.66
0.42
0.95
0.16
0.71
0.94
CM Stock--100X mg/L media g/500 ml stock
L-Cystine 48.00 0.48
L-methionine 30.00 0.60
Vitamin Stock--100X mg/L media g/100 ml stock
D-Ca pantothenate
Choline chloride
Folic acid
i-Inositol
Nicotinamide
Pyridoxal.HCI
Riboflavin
Thiamin.HCI
Ca.Fe.Mg Stock--10X mg/L
CaC12 .H,O
FeC13
MgSO 4 .7H20
media
264.9
0.25 umol
200.0
g/2L stock
5.30
5 umol
4.00
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4.00
4.00
4.00
7.00
4.00
4.00
0.40
4.00
0.080
0.080
0.080
0.140
0.080
0.080
0.008
0.080
Main Salt Stock-10X
KCI
NaCI
NaHCO 3
NaHPO 4 .2H 20
D-glucose
Phenol Red Sodium Salt
Sodium pyruvate
mg/L media
400.0
6400
3700
141.3
4500
15.00
110.0
DMEM His minus
Main Salt Stock
CaFeMg Stock
Amino Acid Stock
CM Stock
Vitamin Stock
Serum
Penicillin/Streptomycin Stock
Glutamine Stock
Water or Other Additions
Total
Other Additions:
Tetracycline Stock
Histidinol Stock
G418 Stock
Stock
500 gg/ml
3 mM
60 mg/ml
Addition/500 ml
1 mli
133 gl
5 mls
Final Conc.
1 jIg/ml
800 giMol
600 jgg/ml
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stockg/2L
8.00
128
74
2.83
90
0.30
2.2
50 mls
50 mls
50 mls
25 mls
5 mls
50 mls
5ml
5ml
260 mls
500 mls
Appendix B
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Comparison of Cytosensor EGF to secreted TGFa
Cytosensor EGF:
Flow chamber volume:
Flowrate:
Cell density:
Transwell diameter:
Transwell area:
Spacer diameter:
Transwell area:
Cell # in spacer:
10 ng / ml
2.8 gI (100 gm high, 6 mm ID spacer)
100 gls / minute
500,000 # / transwell (seeded at 250,000)
12 mm
113 mm 2
6mm
28.3 mm 2
(28.3 / 113) * 500,000 = 125,000 cells
(10 ng / ml) * (100 gl / min) * (nMol / 6045 ng) * (ml / 1000 gl) * (mole / le9 nmole)
* (6.02e23 molecules / mole) * (1 / 125,000 cells) equals
800,000 molecules / cell minute
Autocrine cell at 50 ng / million cells - 24 hours:
(50 ng / le6 cells - 24 hours) * (hr / 60 minutes) * (nMol / 6045 ng) * (mole / le9 nmole)
* (6.02e23 molecules / mole) equals
3,500 molecules / cell - minute
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c Main.f Program for Plated Cells - Blocker Model
c
implicit real*8 (a-h,o-z)
parameter (nvar=10,iliw=20+nvar,ilrw=22+9*nvar+nvar**2)
dimension iwork(iliw),rwork(ilrw),x(nvar)
character* 1 tab
common/bunny/del,gam,sig,chi,alp,z 1,z2,theta,theta2
common/bunny/ome,beta,xmu,eps,phi,xnu,epsint
external fex,jex
tab = CHAR(9)
sexp = 2.0d0
do 15, k = 1,35
sexp = sexp + 0.5d0
x(1) = 1.0dO
x(2) = O.OdO
x(3) = O.OdO
x(4) = 1.0dO
x(5) = 0.OdO
x(6) = 1.0d0
x(7) = 0.OdO
x(8) = O.OdO
x(9) = 0.OdO
x(10) = 1.0d0
! Step Function for Antibody Conc.
! Do Loop for Antibody Conc. Grad. around LSODE
Receptor, r
Receptor-Ligand Complex, c
Secretion Layer Ligand Conc., Istar
Secretion Layer Antibody Conc., bstar
Bulk Volume Ligand Conc., lbulk
Bulk Volumn Antibody Conc., bbulk
Bound Antibody-Receptor #1, sri
Bound Receptor-Antibody-Receptor #2, sr2
Intermed. Ligand Layer, lint
Intermed. Antibody Layer, bint
initialize Isode parameters
itol = 1
rtol = le-6
atol = le-6
itask = 1
istate = 1
iopt = 0
Irw = ilrw
liw = iliw
mf = 21
tstart = 0.0
tend = 1440.0
tstep = 3.0
xkt = .03d0
Start 0 minutes
End 24 hours
Time interval - minutes
! Constitutive Internalization Rate Constant
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value for EGF
xkt = .0046d0
value for 1L2
minA^-
xkoff = 1.4d-2
value for IL2
min^ - 1
xkoff = .34d0
value for EGF kr
xkoff = .85d0
value for koff EGF based on
tstart = tstart*xkoff
tend = tend *xkoff
tstep = tstep *xkoff
c
c --- set parameter values
pi = 3.141592653589793d0
! EGF / EGFR Disassoc. Rate Constant
intrinsic kon and KD
! Dimensionalize Time
xke = .3d0 ! Receptor-Ligand Induced Int
value for EGF
xke = .0462d0
value for IL2
minA^ -
xkon = 1.2d-13 ! EGF/EGFR Association Rat
cmA3/site*min
7.2d7 (value for kf EGF from Cindy) MA- 1 min^ - 1)
xkon = 3.0d-13
cmA3/site*min
value for kon intrinsic for EGF
xkon = 3.09d- 12
cmA3/site*min
value for IL2 (1
xkd = xkoff/xkon
sites/ml
c
a = 5.0d-4
c cm
xfu = 5.0d-6
c cm
xfuint = 25.0d-4
c cm
prad = 3.0dO
c cm
plvol = 5.0dO
c cm^3
parea = pi*prad**2
c cm^2
xheight = plvol / parea
ernaliz. Rate Constant
e Constant
.86d9 M^- 1 minA^- 1)
! Receptor-Ligand Equil. Constant
! Cell Radius
! Cell Boundary Layer =(4*pi*aA2/N)A.5
! Intermed. Layer
! 60 mm cell dish radius
! Volume of Media added to plate
! cell plate/dish surface area
! Determine Media height in a plate
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c cm
sa = 4.0d0*pi*a*a
avago = 6.02d23
c sites/mol
ro = 100000.0d0
site/cell
value for B82 cells in paper
dens = 1.0d5
--11 1--1 •A.
etalp/llec
vr = xkt*ro
* __1 e _
teis /cell min
q = 5000.0d0
* 1
teis /cell min
c
dl = 9.0d-5
c cmA2/min
dist = (prad**2 / dens)**0.5
c cm
c
spacer = pi*dist*dist
c cm^2 / cell
vcell = 4.0d0*pi*a**3/3.0d0
c cmA3/cell
vstar = 4.0d0*pi*((a+xfu)**3
c cmA3/cell
vi = spacer * xfuint - vstar - v(
c cmA3/cell
vb = spacer * (xheight - xfuinl
c cm^3/cell
! Cell Surface Area
! Avago. #
! Initial # of Receptors
! Cell Density
! Receptor Synthesis - Based on Receptor Intern.
! Ligand Secretion Rate
! Ligand Media Diffusion Rate
! 1/2 dist. btwn cells
! area for dist calc.
! Cell Volume
)/3.0d0 - vcell ! Cell Secr. Layer Vol.
cell ! Intermed. Volume
t) ! Bulk Media Vol.
c --- Properties of IgG
db = 2.28d-5
cmA2/min
(3.8d-7 cmA2/s)
! Antibody Media Diffusion Rate
c -- assume same koffa and kona as cellular receptor
xkoffa = 0.34d0
minA^-
xkoffa = xkoff
min^-1
xkona = 1.2d-13
cmA3/site*min
xkona = xkon
xkda = xkoffa/xkona
! Antibody-Receptor Dissoc. Rate Constant
! Antibody-Receptor Assoc. Rate Constant
! Antibody-Receptor Equil. Constant
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xkl = xkt ! Ab-Receptor Internalization Rate Const.
c rate of single bound antibody-receptor [srl]
c
xk2 = xke ! Recept-Ab-Recept Internal. Rate Const.
c rate of double bound antibody-receptor [sr2]
c
xkc = 480d-10 ! Recept. Cell Diffusion for Ab. Complex
c cm ^ 2/min*molecule
c
xkcoff = 60.0d0 ! Recept. Cell Diffusion for Ab. Complex
c min^-1
c
st = 10.d0**sexp ! Ab Conc. Added to Media (Sexp=Step fct)
c site/cm^3 cell
c (this corresponds with a vb of 9.9d-5 cmA3/cell)
c (corresponds with Id9site/cell (200d-6g/ml))
c
c --- Dedimensionaled Variables
c
del = ro*xkc/(sa*xkcoff)
c
gam = xkt/xkoff
c
sig = q/(vstar*xkd*xkoff)
c
chi = st/xkda
c
alp = xkona/xkon
c
zl = xkl/xkt
c
z2 = xk2/xkt
c
theta = 2.0d0*pi*(a+xfu)*dl/(xkoff*vstar) ! 2 for plated cells, norm=4
c
theta2 = dl*spacer / (xfuint*xkoff*vstar)
c
ome = xke/xkoff
c
beta = xkoffa/xkoff
c
xmu = ro/(vstar*xkd)
c
eps = vstar/vb
c
epsint = vstar/vi
c
phi = db/dl
c
xnu = xkcoff/xkoff
c
c --- Dedimensionalized Variables
150
cC
c
C
C
C
C
C
c
c
CC
c ---
c
1
eta = x(1)
rho = x(2)
us = x(3)
xlams = x(4)
u = x(5)
xlam = x(6)
psis = x(7)
psi = x(8)
uint = x(9)
xlamint = x(1O)
Dimen. Receptor
Dimen. Recep.-Ligand Complex
Dimen. Secretion Layer Ligand Conc
Dimen. Secr. Layer Ab Conc.
Dimen. Bulk Media Ligand Conc.
Dimen. Bulk Media Ab Conc.
Dimen. Bound R/Ab #1
Dimen. Bound R/Ab/R #2
Dimen. Intermed. Ligand
Dimen. Intermed. Ab.
time = alpha/xkoff
write(94,21) time,tab,x(1 ),tab,x(2),tab,x(3),tab,x(4),tab,
1 x(5),tab,x(6),tab,x(7),tab,x(8),tab,x(9),tab,x(10)
21 format(10(e 14.6,al),e 14.6)
if(istate .It. 0) then
print *,'istate = ',istate
stop
end if
4 continue
sexpm = sexp -20.2d0 ! Initial Ab Conc. (log)
c moles/liter
write(93,20) sexpm,tab,x(1),tab,x(2),tab,x(3),tab,x(4),tab,
1 x(5),tab,x(6),tab,x(7),tab,x(8),tab,x(9),tab,x(10)
20 format(10(e 14.6,al),e 14.6)
print *, iwork(l 11),iwork(12),iwork(13)
15 continue
end
151
eta = r/ro
rho = c/ro
us = lstar/xkd
xlams = bstar/st
u = lbulk/xkd
xlam = bstar/st
psis = [srl]/ro
psi = [sr2]/ro
uint = lint/xkd
xlamint = bint/st
begin integration
do 4, alpha=tstart,tend+1 .d-5,tstep
call Isode(fex,nvar,x,tstart,alpha,itol,rtol,atol,itask,istate,
iopt,rwork,lrw,iwork,liw,jex,mf)
15 
continue
end
c Func.f Program for Plated Cells - Blocker Model
c
subroutine fex(nvar,t,x,f)
c
implicit real*8 (a-h,o-z)
common/bunny/del,gam,sig,chi,alp,z 1 ,z2,theta,theta2
common/bunny/ome,beta,xmu,eps,phi,xnu,epsint
c
dimension x(nvar),f(nvar)
c
c --- calculate function residuals
c
eta = x(1)
rho = x(2)
us = x(3)
xlams = x(4)
u = x(5)
xlam = x(6)
psis = x(7)
psi = x(8)
uint = x(9)
xlamint = x(10)
c
c The actual functions
c
f(1) = -us*eta + rho -eta*gam -2.0d0*beta*chi*xlams*eta
1 +beta*(psis+2.0d0*psi) - xnu*del*eta*psis + gam
c
f(2) = us*eta -rho*(ome+1.0d0)
c
f(3) = -xmu*us*eta + xmu*rho +theta*(uint-us) +sig
c
f(4) = -2.0d0*alp*xmu*xlams*eta
1 + xmu*alp*psis*(1.OdO/chi)
1 + phi*theta*(xlamint-xlams)
c
f(5) = -theta2*eps*(u-uint)
c
f(6) = -theta2 *eps*phi*(xlam-xlamint)
c
f(7) = 2.0d0*beta*chi*xlams*eta -beta*psis +2.0d0*xnu*psi
1 -gam*z *psis -xnu*del*eta*psis
c
f(8) = xnu*del*psis*eta - psi*(2.0d0*xnu + z2*gam)
c
f(9) = -theta*epsint*(uint-us)+theta2*epsint*(u-uint)
c
f(10) = -theta*phi*epsint*(xlamint-xlams)
1 +theta2*phi*epsint*(xlam-xlamint)
c
return
end
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c Jacob.f Program for Plated Cells - Blocker Model
c
subroutine jex(nvar,t,x,ml,mu,dfdx,nrpd)
implicit real*8 (a-h,o-z)
common/bunny/del,gam,sig,chi,alp,z 1,z2,theta,theta2
common/bunny/ome,beta,xmu,eps,phi,xnu,epsint
dimension x(nvar),dfdx(nvar,nvar),dgdx( 10,10),f(10),g(10)
c
c --- calculate the Ox10 jacobian
eta = x(1)
rho = x(2)
us = x(3)
xlams = x(4)
u = x(5)
xlam = x(6)
psis = x(7)
psi = x(8)
uint = x(9)
xlamint = x(10)
dfdx(1,1) = -us -gam -2.
dfdx(1,2) = 1.OdO
dfdx(1,3) = - eta
dfdx(1,4) = - 2.0dO*bet
dfdx(1,5) = O.OdO
dfdx(1,6) = O.OdO
dfdx(1,7) = beta - xnu*c
dfdx(1,8) = 2.0dO*beta
dfdx(1,9) = O.OdO
dfdx(1,10) = O.OdO
.OdO*beta*chi*xlams -xnu*del*psis
a*chi*eta
lel*eta
dfdx(2,1) = us
dfdx(2,2) = -(ome + 1.OdO)
dfdx(2,3) = eta
dfdx(2,4) = O.OdO
dfdx(2,5) = O.OdO
dfdx(2,6) = O.OdO
dfdx(2,7) = O.OdO
dfdx(2,8) = O.OdO
dfdx(2,9) = O.OdO
dfdx(2,10) = O.OdO
dfdx(3,1) = -xmu*us
dfdx(3,2) = xmu
dfdx(3,3) = -xmu*eta - theta
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dfdx(3,4) = O.OdO
dfdx(3,5) = O.OdO
dfdx(3,6) = O.OdO
dfdx(3,7) = O.OdO
dfdx(3,8) = O.OdO
dfdx(3,9) = theta
dfdx(3,10) = O.OdO
c
dfdx(4,1) = -2.0dO*alp*xmu*xlams
dfdx(4,2) = O.OdO
dfdx(4,3) = O.OdO
dfdx(4,4) = -2.0dO*alp*xmu*eta -phi*theta
dfdx(4,5) = O.OdO
dfdx(4,6) = O.OdO
dfdx(4,7) = xmu*alp/chi
dfdx(4,8) = O.OdO
dfdx(4,9) = O.OdO
dfdx(4,10) = phi*theta
c
dfdx(5,1) = O.OdO
dfdx(5,2) = O.OdO
dfdx(5,3) = O.OdO
dfdx(5,4) = O.OdO
dfdx(5,5) = -theta2*eps
dfdx(5,6) = O.OdO
dfdx(5,7) = O.OdO
dfdx(5,8) = O.OdO
dfdx(5,9) = theta2*eps
dfdx(5,10) = O.OdO
c
dfdx(6,1) = O.OdO
dfdx(6,2) = O.OdO
dfdx(6,3) = O.OdO
dfdx(6,4) = O.OdO
dfdx(6,5) = O.OdO
dfdx(6,6) = -theta2*eps*phi
dfdx(6,7) = O.OdO
dfdx(6,8) = O.OdO
dfdx(6,9) = O.OdO
dfdx(6,10) = theta2*eps*phi
c
dfdx(7,1) = 2.0dO*beta*chi*xlams - xnu*del*psis
dfdx(7,2) = O.OdO
dfdx(7,3) = O.OdO
dfdx(7,4) = 2.0dO*beta*chi*eta
dfdx(7,5) = O.OdO
dfdx(7,6) = O.OdO
dfdx(7,7) = -beta -gam*z1 - xnu*del*eta
dfdx(7,8) = 2.0dO*xnu
dfdx(7,9) = O.OdO
dfdx(7,10) = O.OdO
c
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dfdx(8,1) = xnu*del*psis
dfdx(8,2) = O.OdO
dfdx(8,3) = O.OdO
dfdx(8,4) = O.OdO
dfdx(8,5) = O.OdO
dfdx(8,6) = O.OdO
dfdx(8,7) = xnu*del*eta
dfdx(8,8) = -2.0dO*xnu -z2*gam
dfdx(8,9) = O.OdO
dfdx(8,10) = O.OdO
c
dfdx(9,1) = O.OdO
dfdx(9,2) = O.OdO
dfdx(9,3) = theta*epsint
dfdx(9,4) = O.OdO
dfdx(9,5) = theta2*epsint
dfdx(9,6) = O.OdO
dfdx(9,7) = O.OdO
dfdx(9,8) = O.OdO
dfdx(9,9) = -theta*epsint-theta2*epsint
dfdx(9,10) = O.OdO
c
dfdx(10,1) = O.OdO
dfdx(10,2) = O.OdO
dfdx(10,3) = O.OdO
dfdx(10,4) = theta*phi*epsint
dfdx(10,5) = O.OdO
dfdx(10,6) = theta2*phi*epsint
dfdx(10,7) = O.OdO
dfdx(10,8) = O.OdO
dfdx(10,9) = O.OdO
dfdx( 10,10) = -theta*phi*epsint-theta2*phi*epsint
c
c - calculate the jacobian
c
c dx = 1.d-06
c zero = 1.Od-06
c
c call fex(nvar,t,x,f)
c
c do 2, j= 1,nvar
c
c if (abs(x(j)).lt.zero) then
c dxx = dx
c else
c dxx = dx*x(j)
c endif
c
c x(j) = x(j) + dxx
c
c call fex(nvar,t,x,g)
c
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c x(j)=x(j) -dxx
C
c do 1, i = 1,nvar
c dgdx(i,j) = (g(i)-f(i))/dxx
c 1 continue
c 2 continue
C
c
c do 4, i=l,nvar
c write(8,*) (dfdx(i,j), j=l,nvar)
c write(8,*) (dgdx(i,j), j=l,nvar)
c
c write(8,*)
c 4 continue
C
return
end
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Appendix D
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c Main.f Program for Plated Cells - Decoy Model
implicit real*8 (a-h,o-z)
parameter (nvar= 13,iliw=20+nvar,ilrw=22+9*nvar+nvar**2)
dimension iwork(iliw),rwork(ilrw),x(nvar)
character*1 tab
common/bunny/gam,sig,chi,alp,z,theta,ome,beta,xmu,eps
common/bunny/theta2, epsint
external fex,jex
tab = CHAR(9)
sexp = 2.0d0
do 15, k = 1,35
sexp = sexp + 0.5d0
x(1) = 1.OdO
x(2) = 0.OdO
x(3) = 0.OdO
x(4) = 1.0d0
x(5) = O.OdO
x(6) = 0.OdO
x(7) = O.OdO
x(8) = 1.Od0
x(9) = O.OdO
x(10) = O.OdO
x(1) = 1.0d0
x(12) = 0.OdO
x(13) = O.OdO
! Step Function for Antibody Conc.
! Do Loop for Antibody Conc. Grad. around LSODE
Receptor, r
Receptor-Ligand Complex, c
Secretion Layer Ligand Conc., lstar
Secretion Layer Antibody Conc., sstar
Secretion Layer Lig / Ab, ystar
Secretion Layer Lig / Ab / Lig, xstar
Bulk Layer Ligand Conc., lbulk
Bulk Layer Antibody Conc., sb
Bulk Layer Lig / Ab, yb
Int. Layer Lig Conc., lint
Int. Layer Antibody Conc., sint
Int. Layer Lig / Ab, yint
Int. Layer Lig / Ab / Lig, xint
Bulk Layer Lig / Ab / Lig, xb
initialize Isode parameters
itol = 1
rtol = le-6
atol = le-6
itask = 1
istate = 1
iopt = 0
Irw = ilrw
liw = iliw
mf = 21
tstart = 0.0
tend= 1440.0
! Start 0 minutes
! End 24 hours
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! Time interval - minutes
xkt = .03d0 ! Constitutive Internalization Rate Constant
value for EGF
xkt = .0046d0
value for IL2
minA- 1
xkoff = 1.4d-2 ! EGF / EGFR Disassoc. Rate Constant
value for IL2
minA^-
xkoff = .34d0
value for EGF kr
xkoff = .85d0
value for koff EGF based on intrinsic kon and KD
tstart = tstart*xkoff ! Dimensionalize Time
tend = tend *xkoff
tstep = tstep *xkoff
c --- set parameter values
pi = 3.141592653589793d0
xke = .3d0
value for EGF
minA^ - 1
! Receptor-Ligand Induced Internaliz. Rate Constant
xkon = 1.2d-13
^
cm3"./sitemnun
value for EGF
xkd = xkoff/xkon
siLes/L1ll
a = 5.0d-4
c cm
xfu = 5.0d-6
c cm
xfuint = 25.0d-4
c cm
c
prad = 3.060
cm
plvol = 5.0d0
A•
cm .5/plate
parea = pi*prad**2
A
! EGF / EGFR Association Rate Constant
! Receptor-Ligand Equil. Constant
! Cell Radius
! Cell Boundary Layer = (4*pi*aA2/N)A.5
! Intermed. Layer Height
! 60 mm cell dish radius
! Volume of media added to plate
! Cell dish surface area
cm2/plate
159
tstep = 1.0
xheight = plvol / parea ! Determine media height in a plate
cm
ro = 100000.OdO
site/cell
value for EGf
dens = 1.0d7
cell/plate
q = 5000.0d0
site/cell*min
dc = 9.0d-5
cm^2/min
! initial # of Receptors
! Cell Density
! Ligand Synthesis Rate
! Ligand Media Diffusion Rate
sa = pi*a*a ! projected cell surface area
cm^2/cell
dist = (prad**2 / dens)**0.5 ! 1/2 dist. btwn cells
cm
spacer = pi*dist*dist ! area of dist.
cmA2/cell
vcell = 4.0d0*pi*a**3 / 3.0d0 ! Cell Volume
cmA3/cell
vstar = 4.0d0*pi*((a+xfu)**3)/3.0d0 - vcell
cmA3/cell ! Cell Secr. Layer Volume
vi = spacer * xfuint - vstar - vcell
cmA3/cell
vb = spacer * (xheight - xfuint)
cmA3/cell ! C
c
c --- Properties of IgG
ds = 2.28d-5
cm^2/min
(3.8d-7 cmA2/s)
! Intermed. Volume
ell Bulk Volume
! Antibody Media Diffusion Rate
c -- assume same koffa and kona as cellular receptor
xkoffa = .34d0
min^A-
xkoffa = xkoff
min^ - 1
xkona = 1.2d- 13
cm^3/site*min
! Antibody-Ligand Dissoc. Rate Constant
! Antibody-Ligand Assoc. Rate Constant
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xkona = xkon
c
xkda = xkoffa/xkona ! Antibody-Ligand Equil. Constant
c
st = 10.dO**sexp ! Ab Conc. Added to Media (Sexp=Step fct)
c site/cm^3 cell
c (this corresponds with a vb of 9.9d-5 cmA3/cell)
c (corresponds with 1d9site/cell (200d-6g/ml))
c
c --- Dedimensionaled Variables
c
gam = xkt/xkoff
c
sig = q/(vstar*xkd*xkoff)
C
chi = st/xkda
c
alp = xkona/xkon
c
z = ds/dc
c
theta = 2.0d0*pi*(a+xfu)*dc/(xkoff*vstar)
c
theta2 = dc*spacer / (xfuint*xkoff*vstar)
C
ome = xke/xkoff
c
beta = xkoffa/xkoff
c
xmu = ro/(vstar*xkd)
c
eps = vstar/vb
c
epsint = vstar / vi
c
c --- Dedimensionalized Variables
c
c eta = r/ro
c rho = c/ro
c us = lstar/xkd
c xlams = sstar/st
c phis = ystar/st
c psis = xstar/st
c u = lbulk/xkd
c xlam = sb/st
c phi = yb/st
c psi = xb/st
c uint = lint/xkd
c xlamint = sint/st
c phint = yint/st
c psint = xint/st
c
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- begin integration
do 4, r=tstart,tend+1.d-5,tstep
call Isode(fex,nvar,x,tstart,r,itol,rtol,atol,itask,istate,
1 iopt,rwork,lrw,iwork,liw,jex,mf)
eta =
rho =
us =
xlams =
phis =
psis =
U =
xlam =
phi =
uint =
xlamint=
phint =
psint =
x(1)
x(2)
x(3)
x(4)
x(5)
x(6)
x(7)
x(8)
x(9)
x(10)
x(ll1)
x(12)
x(13)
psi = eps+ 1.0dO+eps/epsint-eps*(xlams+psis+phis)-eps/epsint
*(xlamint+psint+phint) - (xlam+phi)
time = r/xkoff
write(94,21) time,tab,x(1),tab,x(2),tab,x(3),tab,x(4),tab,
1 x(5),tab,x(6),tab,x(7),tab,x(8)
format(8(e 14.6,al ),e 14.6)
if(istate .It. 0) then
print *,'istate = ',istate
stop
end if
c
4 continue
c
sexpm = sexp -20.2d0
c moles/liter
write(93,20) sexpm,tab,x(1),tab,x(2),tab,x(3),tab,x(4),tab,
1 x(5),tab,x(6),tab,x(7),tab,x(8),tab,x(9),tab,
1 psi
20 format(10O(e 14.6,al),e14.6)
c
c
c print *, iwork(11),iwork(12),iwork(13)
c
c --- format statements
c
c
15 continue
end
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c
c
c21
c
c Func.f Program for Plated Cells - Decoy Model
c
subroutine fex(nvar,t,x,f)
c
implicit real*8 (a-h,o-z)
c
common/bunny/gam,sig,chi,alp,z,theta,ome,beta,xmu,eps
common/bunny/theta2,epsint
c
dimension x(nvar),f(nvar)
c
c --- calculate function residuals
c
eta = x(1)
rho = x(2)
us = x(3)
xlams = x(4)
phis = x(5)
psis = x(6)
u = x(7)
xlam = x(8)
phi = x(9)
uint = x(10)
xlamint= x(11)
phint = x(12)
psint =x(13)
c
psi = eps+ 1.OdO+eps/epsint-eps*(xlams+psis+phis)-eps/epsint
1 *(xlamint+psint+phint) - (xlam+phi)
c
c The actual functions
c
f(l) = -us*eta + rho -gam*eta + gam
c
f(2) = us*eta -rho*(ome+1.0d0)
c
f(3) = -xmu*us*eta + xmu*rho +2.0d0*chi*beta*beta*psis/alp
1 -2.0dO*chi*beta*us*xlams - beta*chi*phis*us
1 +chi*beta*beta*phis/alp + theta*(uint-us) +sig
c
f(4) = -2.0d0*alp*xlams*us +beta*phis +z*theta*(xlamint-xlams)
c
f(5) = 2.0d0*alp*xlams*us - beta*phis -alp*phis*us
1 +2.0d0*beta*psis +z*theta*(phint-phis)
c
f(6) = alp*phis*us-2.0d0*beta*psis +z*theta*(psint-psis)
c
f(7) = -2.0d0*beta*chi*xlam*u + beta*chi*beta*phi/alp
1 +2.0d0*beta*beta*chi*psi/alp-beta*chi*phi*u
1 -theta2*eps*(u-uint)
c
f(8) = -2.0dO*alp*xlam*u +beta*phi -z*eps*theta2*
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(xlam -xlamint)
c
f(9) = 2.0dO*alp*xlam*u - beta*phi -alp*phi*u
1 + 2.0dO*beta*psi-z*eps*theta2*(phi-phint)
c
f(10) = 2.0dO*beta*chi*beta*psint/alp - 2.0dO*uint*xlamint
1 *beta*chi-uint*phint*beta*chi+beta*chi*beta*phint/alp
1 - theta*epsint*(uint-us) + theta2*epsint*(u-uint)
c
f( 11) = -2.0d0*alp*uint*xlamint + beta*phint - epsint*theta
1 *z*(xlamint-xlams) + epsint*theta2*z*(xlam-xlamint)
c
f(12) = 2.0dO*alp*uint*xlamint - beta*phint - alp*phint*uint
1 + 2.0dO*beta*psint - theta*epsint*z*(phint-phis)
1 + theta2*epsint*z*(phi-phint)
c
f(13) = alp*uint*phint - 2.0dO*beta*psint - theta*epsint*z
1 *(psint-psis) + theta2*epsint*z*(psi-psint)
c
c
return
end
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c Jacob.f Program for Plated Cells - Decoy Model
c
subroutine jex(nvar,t,x,ml,mu,dfdx,nrpd)
c
implicit real*8 (a-h,o-z)
c
common/bunny/gam,sig,chi,alp,z,theta,ome,beta,xmu,eps
common/bunny/theta2, epsint
c
dimension x(nvar),dfdx(nvar,nvar),dgdx(13,13),f(13),g(13)
c
c --- calculate the 13x13 jacobian
c
eta = x(1)
rho = x(2)
us = x(3)
xlams = x(4)
phis = x(5)
psis = x(6)
u = x(7)
xlam = x(8)
phi = x(9)
uint = x(10)
xlamint= x(1 1)
phint = x(12)
psint = x(13)
c
psi = eps+ 1.OdO+eps/epsint-eps*(xlams+psis+phis)-eps/epsint
c 1 *(xlamint+psint+phint) - (xlam+phi)
c
c
dfdx(1,1) = -us -gam
dfdx(1,2) = 1.OdO
dfdx(1,3) = - eta
dfdx(1,4) = O.OdO
dfdx(1,5) = O.OdO
dfdx(1,6) = O.OdO
dfdx(1,7) = O.OdO
dfdx(1,8) = O.OdO
dfdx(1,9) = O.OdO
dfdx(1,10)= O.OdO
dfdx(l,l11)= O.OdO
dfdx(l,12)= O.OdO
dfdx(l,13)= O.OdO
c
dfdx(2,1) = us
dfdx(2,2) = -ome - 1.OdO
dfdx(2,3) = eta
dfdx(2,4) = O.OdO
dfdx(2,5) = O.OdO
dfdx(2,6) = O.OdO
dfdx(2,7) = O.OdO
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dfdx(2,8) = O.OdO
dfdx(2,9) = O.OdO
dfdx(2,10)= O.OdO
dfdx(2,11)= O.OdO
dfdx(2,12)= O.OdO
dfdx(2,13)= O.OdO
c
dfdx(3,1)= -xmu*us
dfdx(3,2) = xmu
dfdx(3,3) = -xmu*eta-2.0dO*chi*beta*xlams-theta-beta*chi*phis
dfdx(3,4) = -2.0dO*chi*beta*us
dfdx(3,5) = -beta*chi*us +chi*beta*beta/alp
dfdx(3,6) = 2.0dO*chi*beta*beta/alp
dfdx(3,7) = O.OdO
dfdx(3,8) = O.OdO
dfdx(3,9) = O.OdO
dfdx(3,10)= theta
dfdx(3,11)= O.OdO
dfdx(3,12)= O.OdO
dfdx(3,13)= O.OdO
c
dfdx(4,1) = O.OdO
dfdx(4,2) = O.OdO
dfdx(4,3) = -2.0dO*alp*xlams
dfdx(4,4) = -2.0dO*alp*us - z*theta
dfdx(4,5) = beta
dfdx(4,6) = O.OdO
dfdx(4,7) = O.OdO
dfdx(4,8) = O.OdO
dfdx(4,9) = O.OdO
dfdx(4,10)= O.OdO
dfdx(4,11)= z*theta
dfdx(4,12)= O.OdO
dfdx(4,13)= O.OdO
C
dfdx(5,1) = O.OdO
dfdx(5,2) = O.OdO
dfdx(5,3) = 2.0dO*alp*xlams - alp*phis
dfdx(5,4) = 2.0dO*alp*us
dfdx(5,5) = -beta -alp*us -z*theta
dfdx(5,6) = 2.0dO*beta
dfdx(5,7) = O.OdO
dfdx(5,8) = O.OdO
dfdx(5,9) = O.OdO
dfdx(5,10)= O.OdO
dfdx(5,11)= O.OdO
dfdx(5,12)= z*theta
dfdx(5,13)= O.OdO
c
dfdx(6,1) = O.OdO
dfdx(6,2) = O.OdO
dfdx(6,3) = alp*phis
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dfdx(6,4) = O.OdO
dfdx(6,5) = alp*us
dfdx(6,6) = -2.0dO*beta - z*theta
dfdx(6,7) = O.OdO
dfdx(6,8) = O.OdO
dfdx(6,9) = O.OdO
dfdx(6,10)= O.OdO
dfdx(6,11)= O.OdO
dfdx(6,12)= O.OdO
dfdx(6,13)= z*theta
c
dfdx(7,1) = O.OdO
dfdx(7,2) = O.OdO
dfdx(7,3) = O.OdO
dfdx(7,4) = -eps*2.0dO*beta*beta*chi/alp
dfdx(7,5)= -eps*2.0dO*beta*beta*chi/alp
dfdx(7,6)= -eps*2.0dO*beta*beta*chi/alp
dfdx(7,7) = -2.0dO*beta*chi*xlam - beta*chi*phi-theta2*eps
dfdx(7,8) = -2.0dO*beta*chi*u-2.OdO*beta*chi*beta/alp
dfdx(7,9) = -1.OdO*beta*chi*beta/alp -beta*chi*u
dfdx(7,10)= theta2*eps
dfdx(7,11 )= -2.0dO*eps*beta*beta*chi/(alp*epsint)
dfdx(7,12)= -2.0dO*eps*beta*beta*chi/(alp*epsint)
dfdx(7,13)= -2.0dO*eps*beta*beta*chi/(alp*epsint)
c
dfdx(8,1) = O.OdO
dfdx(8,2) = O.OdO
dfdx(8,3) = O.OdO
dfdx(8,4) = O.OdO
dfdx(8,5) = O.OdO
dfdx(8,6) = O.OdO
dfdx(8,7) = -2.0dO*alp*xlam
dfdx(8,8) = -2.0dO*alp*u -z*eps*theta2
dfdx(8,9) = beta
dfdx(8,10)= O.OdO
dfdx(8,11)= z*eps*theta2
dfdx(8,12)= O.OdO
dfdx(8,13)= O.OdO
c
dfdx(9,1) = O.OdO
dfdx(9,2) = O.OdO
dfdx(9,3) = O.OdO
dfdx(9,4) = -2.0dO*beta*eps
dfdx(9,5) = -2.0dO*beta*eps
dfdx(9,6) = -2.0dO*beta*eps
dfdx(9,7) = 2.0dO*alp*xlam - alp*phi
dfdx(9,8) = 2.0dO*alp*u - 2.0dO*beta
dfdx(9,9) = -beta -alp*u -2.0dO*beta -z*eps*theta2
dfdx(9,10)= O.OdO
dfdx(9, 11)= -2.0dO*beta*eps/epsint
dfdx(9,12)= z*eps*theta2 - 2*beta*eps/epsint
dfdx(9,13)= -2.0dO* beta*eps/epsint
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dfdx(10,1) = O.OdO
dfdx(10,2) = O.OdO
dfdx(10,3) = theta*epsint
dfdx(10,4) = O.OdO
dfdx(10,5) = O.OdO
dfdx(10,6) = O.OdO
dfdx(10,7) = theta2*epsint
dfdx(10,8) = O.OdO
dfdx(10,9) = O.OdO
dfdx(1 0,10) = -theta*epsint - theta2*epsint-2*xlamint*beta*chi-phint*beta*chi
dfdx(10,11) = -2.0d0*uint*beta*chi
dfdx(10,12) = -uint*beta*chi + beta*chi*beta/alp
dfdx( 0,13) = 2.0dO*beta*chi*beta/alp
dfdx(11,1) = O.OdO
dfdx(11,2) = O.OdO
dfdx(11,3) = O.OdO
dfdx(11,4) = epsint*theta*z
dfdx(11,5) = O.OdO
dfdx(11,6) = O.OdO
dfdx(11,7) = O.OdO
dfdx(11,8) = epsint*theta2*z
dfdx(11,9) = O.OdO
dfdx(11,10) = -2.0d0*alp*xlamint
dfdx( 11,11) = -2.0d0*alp*uint -epsint*theta*z -epsint*theta2*z
dfdx(11,12) = beta
dfdx(11,13) = O.OdO
dfdx(12,1) = O.OdO
dfdx(12,2) = O.OdO
dfdx(12,3) = O.OdO
dfdx(12,4) = O.OdO
dfdx(12,5) = theta*epsint*z
dfdx(12,6) = O.OdO
dfdx(12,7) = O.OdO
dfdx(12,8) = O.OdO
dfdx(12,9) = theta2*epsint*z
dfdx(12,10) = 2.0dO*alp*xlamint - alp*phint
dfdx(12,1 1) = 2.0dO*alp*uint
dfdx(12,12) = -beta - alp*uint-theta*epsint*z-theta2*epsint*z
dfdx(12,13) = 2.0d0*beta
dfdx(13,1)
dfdx(13,2)
dfdx(13,3)
dfdx(13,4)
dfdx(13,5)
dfdx(13,6)
dfdx(13,7)
dfdx(13,8)
dfdx(13,9)
= O.OdO
= O.OdO
= O.OdO
= -theta2*epsint*z*eps
= -theta2*epsint*z*eps
= -theta2*epsint*z*eps + theta*epsint*z
= O.OdO
= -theta2*epsint*z
= -theta2*epsint*z
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dfdx(13,10) = alp*phint
dfdx(13,11) = -eps*theta2*z*epsintlepsint
dfdx(13,12) = alp*uint - eps*theta2*epsint*z/epsint
dfdx(13,13) = -2.0dO*beta-theta*epsint*z-theta2*epsint*z
1 -eps*theta2*epsint*z/epsint
c
c - calculate the jacobian
c
c dx = 1.d-06
c zero = 1.0d-06
c
c call fex(nvar,t,x,f)
c
c do 2, j= 1,nvar
c
c if (abs(x(j)).lt.zero) then
c dxx = dx
c else
c dxx = dx*x(j)
c endif
c
c x(j) = x(j) + dxx
c
c call fex(nvar,t,x,g)
c
c x(j)=x(j) -dxx
c
c do 1, i = l,nvar
c dgdx(i,j) = (g(i)-f(i))/dxx
c 1 continue
c 2 continue
c
c
c do 4, i=l,nvar
c write(8,*) (dfdx(i,j), j=l,nvar)
c write(8,*) (dgdx(i,j), j=l,nvar)
c
c write(8,*) ' '
c 4 continue
c
return
end
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